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1
Calcium Phosphate Ceramics for Bone Tissue 
Engineering. 
 
P.Q. Ruhé1, J.G.C. Wolke1, P.H.M. Spauwen2, J.A. Jansen1
1   Department of Biomaterials, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2   Department of Plastic and Recontructive Surgery, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands
In press: CRC Biomedical Engineering Handbook 2005, Section Tissue Engineering 
1. Background
In reconstructive surgery, repair and regeneration of large bone defects is a major 
challenge. The use of autologous bone is still the gold standard, although concomitant 
problems as donor site morbidity and limited supply have resulted in worldwide endeav-
ors for the development of bone graft substitutes. Each potential substitute, including 
tissue engineering approaches with delivery of osteogenic cells and/or osteoinductive 
macromolecules, is based on an appropriate scaffold biomaterial that is biocompatible, 
allows bone ingrowth and shows subsequent degradation of the material. In view of 
this, a biomaterial used for tissue replacement shows by preference a resemblance with 
the inorganic and/or organic components of the tissue to be substituted.
Bone tissue is a living organ composed of an organic and an inorganic component. 
The organic substance (approx. ¼ to ⅓ of total dry bone weight) consists for more 
than 90% of collagen and only for a small fraction of cells (2%) and noncollagenous 
proteins (5%). The inorganic bone mineral (approx. ⅔ to ¾ of total dry bone weight) 
is composed of speciﬁc phases of calcium phosphate (Ca-P), especially carbonate rich 
hydroxyapatite (HA). In biologically carbonated HA, PO4 is substituted by CO3 (so-
called type B carbonation). Biological HA also contains other impurity ions as Cl, Mg, 
Na, K and F and trace elements like Sr and Zn.1 The apatite in bone mineral is composed 
of small platelet-like crystals of just 2-4 nm in thickness, 25 nm in width and 50 nm in 
length.2 
Together with the -organic- collagenous materials, Ca-P materials are among the 
few biomaterials that show high similarity to natural tissue. Ca-P biomaterials resemble 
the mineral phase of bone to a higher or lesser extent, depending on their stoichiometry 
and crystallinity (Fig. 1.1). In general, Ca-P biomaterials are crystalline ceramics charac-
terized by a high biocompatibility, the ability of direct bone bonding and osteoconduc-
tion, and a variable resorbability. Since the early seventies, Ca-P ceramics are clinically 
used in dentistry, followed by surgical specialties in the eighties. The various available 
Ca-P materials differ in their origin (naturally derived or synthetic), chemico-physical 
composition (calcium to phosphate ratio, crystallinity, (micro)porosity) and prepara-
tion process (prefabricated blocks and granules, coatings on other biomaterials, self set-
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Figure 1.1: X-ray diffraction (XRD) 
pattern of bone, hydroxyapatite 
and ß-tricalcium phosphate, clearly 
indicating the similarity between HA 
and bone.
ting cements and composite materials). In this review, the essential Ca-P characteristics, 
differences between various Ca-P biomaterials, and developments in Ca-P ceramic bone 
tissue engineering research will be discussed. 
2.  Chemico-physical properties of  
Calcium Phosphate ceramics
Calcium phosphate (Ca-P) compounds exist in several phases. Discern can be 
made regarding: 1. the crystallinity of various compounds (amorphous versus various 
crystalline Ca-P phases), 2. eventual heat treatment of the materials (sintering), and 3. 
the calcium to phosphate ratio.
2.1 Crystallinity
Amorphous Ca-P (ACP) is the ﬁrst solid phase to appear in solution containing high 
concentrations of calcium and phosphate. ACP lacks the orderly internal structure of 
crystalline Ca-P compounds and typically has a spherical morphology.3 Chemically, it 
has a Ca:P ratio of around 1.5 and is characterized by the absence of diffraction peaks on 
X-ray diffraction (XRD) patterns. ACP is unstable in aqueous ﬂuids and transforms into 
crystalline phases such as octacalciumphosphate (OCP) and apatite. Heating of ACP also 
results into conversion to poorly crystallized apatite (600°C), ß-TCP (800°C, dry heat) 
or HA (800°C, humid heat).4 Therefore, ACP should be considered as a precursor for 
crystalline Ca-P compounds. There has been, and still is, considerable debate whether 
or not ACP is substantially present in skeletal tissue. For example, TEM analysis has 
never revealed conclusive evidence for the presence of ACP in bone mineral.3 
Other phases of Ca-P than ACP reveal a crystalline structure with characteristic 
peaks on XRD analysis. There is a broad range in crystal morphology depending on 
composition and preparation characteristics such as temperature, pH, impurity, and the 
presence of macromolecules. Impurities, as commonly occur in bone mineral, greatly 
inﬂuence crystallinity (reﬂecting crystal size and crystal strain) but depend on the type 
of substitution. For example, type B carbonated apatite (CO3 for PO4 substitution) has 
a lower crystallinity and increased solubility, whereas F substitution (F for OH) results 
the opposite effects due to a better ﬁt of the F- ion in the apatite crystal structure.
2.2 Sintering
Sintering is the key step in processing of the majority of ceramic materials and 
conventionally consists of two separate phases: compacting the initial powder and 
heating the compacted powder up to temperatures only a little lower than their melting 
points. Thereby, atoms and molecules are set in rapid motion, and the particles coalesce. 
Fusion of the crystals reduces the porosity and increases the strength and density of 
the ﬁnal ceramic product. Currently, several sintering techniques are available, such 
as continuous hot pressing, microwave sintering, pressureless sintering and plasma 
9
sintering. Obviously, chemical composition of initial powders as well as variation of 
pressure and temperature inﬂuence ﬁnal structure and composition of the sintered 
product. 
2.3 Stoichiometry
The quantitative relationship (stoichiometry) of calcium to phosphate in Ca-P 
salts is essential for several material characteristics as strength, solubility and crystal 
structure. Table 1.1 lists the main Ca-P compounds for biomedical applications. From 
a crystallographic point of view, the most stable form of Ca-P has a Ca:P ratio of 1.67 
(hydroxyapatite). With a decrease of the Ca to P ratio, other Ca-deﬁcient phases occur 
like tricalcium phosphate (TCP, Ca:P ratio 1.50), octacalcium phosphate (OCP, Ca:P 
ratio 1.33), dicalcium phosphate anhydrous (DCPA or Monetite, Ca:P ratio 1.00) and 
dicalcium phosphate dihydrate (DCPD or Brushite, Ca:P ratio 1.00). Most of these 
calcium deﬁcient compounds are used as raw material for sintering procedures for 
ceramics, or as ingredients for e.g. Ca-P cements. TCP and HA will be discussed more in 
detail, since these materials are most used for biomedical applications.
 
2.3.1 TCP (Ca3(PO4)2)
Tricalcium phosphate (TCP) has a Ca:P ratio of 1.5, similar to the amorphous biologic 
precursors of bone.5 It can be prepared by sintering Ca deﬁcient apatite (Ca:P ratio 1.5). 
TCP is a polymorph ceramic and exhibits two phases (α- and ß-whitlockite), known 
as α- and ß-TCP. Variation in sintering temperature and humidity determine, which 
phase is being formed; α-TCP occurs at dry heat > 1300°C and subsequent quenching 
in water.4 Solubility and resorbability of both forms is much higher compared to HA. 
However, α-TCP is unstable in water and reacts to produce HA. α-TCP is used mainly as 
a compound of some Ca-P cements. ß-TCP is less soluble and less reactive than α-TCP. 
It is used pure as bone substitute, and in combination with HA (biphasic Ca-P ceramic). 
Due to its solubility, dissolution and reprecipitation occurs in vivo. This results in 
Ca/P Formula Name / Mineral Abbreviation
0.5 Ca(H2PO4)2.H2O Monocalcium Phosphate Monohydrate MCPM
1.0 CaHPO4.2H2O Hydrated Calcium Phosphate / Brushite DCP
1.0 CaHPO4 Anhydrous Calcium Phosphate / Monetite ADCP
1.33 Ca8H2(PO4)6.5H2O Octacalcium Phosphate OCP
1.5 Ca3(PO4)2 Tricalcium Phosphate / Whitlockite TCP
1.67 Ca10(PO4)6(F)2 Fluorapatite FA
1.67 Ca10(PO4)6(OH)2 Hydroxyapatite HA
2.0 CaO.Ca3(PO4)2 Tetracalcium Phospate / Hilgenstockite TTCP
Table 1.1: Ca-P compounds, names, formulas, and Ca:P ratios
10
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gradual phase transition into carbonated apatite, and resorption by macrophages, giant 
cells and osteoclasts. 
2.3.2 Hydroxyapatite (Ca10(PO4)6(OH)2)
Hydroxyapatite (HA) is the term commonly used for calcium hydroxylapatite 
Ca10(PO4)6(OH)2, the most stable form of Ca-P under physiological pH and body 
temperature. With ﬂuorapatite and chlorapatite, hydroxyapatite forms the group of 
apatite minerals, that share a similar hexagonal monoclinic crystal structure and the 
general formula A10(PO4)6(OH,F,Cl)2. The A cation can be several metal ions besides 
calcium, such as barium, strontium and magnesium. The phosphate anion can be 
substituted by a carbonate anion to a limited extent. 
HA has a Ca:P ratio of 1.67 which is similar to bone mineral. It can be prepared 
by sintering of precipitated Ca-P salts in a Ca:P ratio of 1.67 at temperatures above 
1000°C. Pure HA is hardly soluble under physiological conditions. Impurities like 
substitution of Ca2+ by other metal ions cause variation in solubility and crystal size 
due to the differences in ionic radius. With respect to mechanical strength, pure HA 
materials are superior to other Ca-P materials. In vivo, however, pure HA hardly shows 
any cellular resorption by macrophages, giant cells or osteoclasts unless the particle size 
is small enough for phagocytosis. As a consequence, HA should be considered as non-
resorbable whereas other compositions such as ß-TCP show substantial dissolution and 
resorption. 
2.4 Strength
Biomechanical properties are a considerable concern in the use of Ca-P ceramics. 
Compressive strength of cortical and trabecular bone varies, depending on the bone 
density, from 130-180 MPa and 5-50 MPa respectively. For tensile strength these values 
ﬂuctuate from 60-160 MPa and 3-15 MPa respectively. Dense sintered Ca-P ceramics 
may reach compressive strengths much higher than cortical bone (300-900MPa), 
whereas tensile strengths similar and higher than cortical bone (40-300MPa) have been 
reported.6 Problem, however, is that ceramics do not exhibit substantial elastic or plastic 
deformation before fracturing. Due to the lack of ductility, virtually all Ca-P ceramics are 
brittle. The brittleness can be explained by the atomic structure of ceramics. Elasticity 
is manifested as small reversible changes in the interatomic spacing and stretching of 
interatomic bonds. Plastic deformation corresponds to breaking of existing bonds and 
reforming of bonds with new neighboring atoms. In crystalline materials, this occurs in 
planes by means of atomic slip. As a consequence of the electrically charged nature of 
the ions, both elastic and plastic deformations in ceramics are limited. The brittleness 
of ceramics is further enhanced by very small and omnipresent ﬂaws in the material. 
These microcracks result in local ampliﬁcation of applied tensile stresses and cause a 
relatively low fracture strength. 
Due to the inferior biomechanical properties, Ca-P ceramics are less suitable for 
clinical application under weight-bearing conditions compared to for example metallic 
or polymeric biomaterials. Obviously, mechanical properties of porous ceramics 
11
deteriorate even further with an increasing porosity. Nevertheless, compressive 
strengths similar to trabecular bone have been reported.7 
2.5 Porosity
Cortical bone has pores ranging from 1 to 100 µm (volumetric porosity 5-10%), 
whereas trabecular bone has pores of 200 to 400 µm (volumetric porosity 70-90%). 
Porosity in bone provides space for nutrients supply in cortical bone and marrow cavity 
in trabecular bone. As mentioned in the previous paragraph, porosity is devastating for 
mechanical properties of Ca-P ceramics. On the other hand, it is known that porosity 
enhances degradation of Ca-P ceramics and determines the nature of ingrowing tissue. 
Consequently, this delicate equilibrium depends on more factors than mechanical 
material properties alone, i.e. application site (vascularization, weight loading, defect 
dimensions), biological material properties (biocompatibility, osteoconductivity and 
degradation) and other aspects as pore geometry and the use of tissue engineering 
strategies (addition of osteogenic cells or bioactive factors). Therefore, no general 
optimal pore size and architecture for all applications and biomaterials can be given. 
2.5.1 Microporosity
Microporosity covers pores sizes smaller than an -arbitrary- 5 µm: too small for 
penetration an ingrowth of cells, but sufﬁcient for penetration of ﬂuids. Crystalline 
Ca-P materials intrinsically exhibit, depending on crystal size and structure, a nano- 
or microporous structure. However, microporosity of ceramics is highly decreased or 
virtually absent due to high pressure compaction and (partial) fusion of crystals after 
sintering. Microporous Ca-P structures have an increased surface area which inﬂuences 
the biological behavior and the Ca-P dissolution/precipitation characteristics. It 
has even been reported that microstructure plays a crucial role in osteoinductive 
properties of ceramics. Yuan et al. observed heterotopic bone formation in macro- and 
microporous ceramics implanted in the dorsal muscle in dogs, whereas similar implants 
without microporous structure did not reveal bone formation.8 They suggested that 
the increased surface area, resultant of the microporous structure, could have caused 
accumulation of adsorbed proteinswhich could have triggered osteogenesis. 
2.5.2 Macroporosity
Pores larger than 10 µm can be considered as macropores. Various methods can 
be used to induce macroporosity in Ca-P material. For example, porous ceramics can 
be obtained by merging the Ca-P slurry with a polymer sponge-like mold or polymer 
beads before sintering. During the sintering, the polymer is completely burnt out which 
results in a porous ceramic structure. In this way, architecture of porous ceramics can 
be controlled and a completely interconnected structure with any desirable pore size 
and pore geometry is feasible. Obviously, interconnection of pores is essential for tissue 
growth throughout the scaffold. Tsuruga and Kuboki have investigated the inﬂuences 
of pore size and geometry in induced bone formation in ceramics. They reported 
that for porous sintered HA blocks with pore sizes ranging from 106-212 µm to 
12
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500-600 µm, the highest amount of bone was produced in implants with pore sizes 
of 300-400 µm.9 In another study, Kuboki et al. observed that an optimal vascular 
ingrowth was achieved in pores with a diameter of 350 µm, and claimed that this was 
the key factor for effective bone formation.10 Macroporous dimensions are also reported 
to play a role in osteoinductive behavior of Ca-P ceramics. In a series of experiments 
in primates, Ripamonti et al. reported that implant geometry is of critical importance 
for cell shape, cell locomotion and cell differentiation.11,12 They hypothesized that 
concavities in sintered HA mediate intrinsic osteoinduction. 
3. Ca-P products
Numerous Ca-P products are currently marketed for bone regenerative purposes. 
Most frequently used Ca-P products in dentistry and surgery are Ca-P coatings 
applied to prostheses. Several techniques, such as plasma spraying and RF magnetron 
sputtering can provide a thin bioactive Ca-P coating on the inert metal prosthesis 
surface.13 Consequently, the superior mechanical metal properties can be combined 
with favorable bone bonding Ca-P properties. Coatings applied usually consist of HA to 
prevent resorption of the coating in time. 
Other Ca-P products are marketed as bone ﬁller and are available in various forms 
as granules, blocks and injectable cements. Both granules and blocks are available with 
a dense or porous structure and several resorption rates. Most synthetic products 
are composed of ß-TCP, HA or a combination of both (so called bi-phasic ceramics 
[Fig. 1.2]. Besides synthetic ceramics, several naturally derived ceramics are commercially 
available. These and injectable Ca-P cements are being discussed in detail in the next 
paragraphs.
Figure 1.2: MicroCT representation of a 
highly porous biphasic ceramic implant 
material (Camceram®, Cam Implants, 
Leiden, The Netherlands) with a HA:TCP 
ratio of 60:40, porosity of 90% and  
macropores ranging from 300-500 µm.  
Bar represents 1 mm.
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3.1 Natural Ca-P ceramics
Natural Ca-P biomaterials can be prepared from the inorganic bone mineral matrix of 
bone. Chemical and/or high temperature heat treatment eliminate organic substances 
responsible for immunologic response and potential disease transmission (e.g. prions). 
Chemically treated materials derived from human spongiosa (Puros Tutoplast®, 
Zimmer Dental, Carslbad, CA, USA) or bovine spongiosa (Ortoss® and Bio-oss®, 
Geistlich Biomaterials, Geistlich, Switzerland), maintain the macroporous structure of 
spongious bone as well as the natural small carbonatehydroxyapatite crystal structure. 
Sintered bovine spongious bone products, such as Osteograf®-N (Dentsply Ceramed, 
Denver, Co, USA) and Endobon® (Biomet Merck, Darmstadt, Germany) also maintain 
its macroporous structure, but due to the high sintering temperatures (>1100°C) the 
natural carbonate HA crystals convert into larger HA crystals without CO3, resembling 
synthetic HA. 
Besides bovine origin, natural Ca-P biomaterials can also be derived from special 
species of coral (genus Porites and Goniopora). Hydrothermal ‘replamiform’ treat-
ment (260°C; 15.000PSI) of the calcium carbonate (calcite) exoskeletal microstructure 
of these corals results in conversion into hydroxyapatite.14 Like natural bone, this hy-
droxyapatite contains minor elements of Mg, Sr, F and CO3. The porous coralline hy-
droxyapatite is completely interconnected and available in various porosities (Interpo-
reTM, Pro OsteonTM, Interpore Cross International Inc, Irvine, CA, USA). Different hy-
drothermal treatment of coral used for Pro Osteon-R results in only partial conversion 
of the calcium carbonate to HA.5,15 As a result, the composite of HA/CaCO3 is being re-
sorbed faster than pure HA. Another coral derived bone substitute, which has not been 
converted into HA at all and therefore can not be considered as a Ca-P ceramic, shows 
even faster degradation. This CaCO3 material (Biocoral
®, Inoteb, St. Gonnery, France) 
currently does not have FDA approval, but is available for clinical use in Europe.
3.2 Injectable Ca-P cements
Difﬁculties with the clinical applicability of preformed ceramic blocks and gran-
ules have led to the development of injectable ceramic bone graft substitutes. In the 
early eighties, Brown and Chow were the ﬁrst to describe the principles of a self setting 
Ca-P paste.16,17 Currently, several different Ca-P cements are commercially available 
like BoneSource® (Stryker Leibinger, Kalamazoo, MI, USA), Norian® (Synthes, Ober-
dorf, Switzerland), α-BSM/Biobon® (Etex Corporation, Cambridge, MA, USA), and 
Calcibon® (Biomet Merck, Darmstadt, Germany). Each cement has a (slightly) differ-
ent chemical composition, which results in differences in handling properties, setting 
time, strength and resorbability.18 The major advantage of Ca-P cements is the inject-
ability of the cement paste. Obviously, this results in favorable moldability of the bone 
graft, but also it results in immediate, seamless contact of cement to the surrounding 
bone.19 Moreover, Ca-P cements have been found to exhibit excellent bone biocompat-
ibility.20,21
14
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Roughly, the different Ca-P cements can be divided into four distinct groups:17 
1. Cements composed of a solid Ca-P powder compound with an aqueous liquid 
component with or without Ca or P ions. After mixing, hardening of the cement is 
the result of the formation of one or more Ca-P compounds. 
2. Cements with a powder component similar to those in 1), but an organic acid as 
liquid component. Hardening of the cement is the result of complex formation of 
calcium and the organic acid. 
3. Cements similar to those in 2), except that the liquid component is a polymer 
solution. Cement hardening can be as described in 1) and/or complex formation of 
calcium and the polymer solution.
4. Cement composites on a polymer basis. Hardening of the cement is based on 
polymerization of the monomers. The Ca-P compounds present in these materials act 
as ﬁllers and do not play a signiﬁcant role in the mechanism of cement hardening. 
In this review, we will focus only on the ﬁrst group, as these cements currently play 
the most important role in research and clinical applications. The chemico-physical 
reaction that occurs during and after mixing of the powder and the liquid components 
is complex. After mixing, soluble compounds dissolve in the aqueous environment and 
subsequently precipitate, which results in formation and growth of different forms of 
Ca-P crystals. This crystallization ﬁnally results in entanglement of the insoluble Ca-P 
compounds and hardening of the cement. The setting time and phase transformation 
depend on the solubility of the various solid compounds, as well as of external factors 
as pH and temperature.22 The setting reaction can be accelerated when the liquid phase 
contains phosphate ions. Therefore, setting time is different for each Ca-P cement 
formulation and may vary from minutes to hours. After setting, Ca-P cements may have 
an amorphous appearance under low magniﬁcation, but high magniﬁcation (100.000x) 
reveals extremely small crystals. Crystal size and interparticle micropores were observed 
to grow in time.17 The ﬁnal result is a microporous structure of nanometer sized crystals 
composed of more or less apatitic compounds, resembling the small crystal size of 
biological apatite. 
After setting of the cement, gradual phase transformation of the Ca-P compounds 
occurs into more apatitic phases. Due to the non-sintered nature and the higher surface 
area of Ca-P cements, dissolution of calcium and phosphate ions in physiological condi-
tions occurs to a higher extent than in sintered ceramics. However, the relatively large 
surface area in combination with supersaturated body ﬂuids also results in high Ca-P 
precipitation. Ishikawa et al. reported that the total precipitation of (B-type) carbonate 
HA at the surface of Ca-P cement increased the total surface dissolution in simulated 
blood plasma in vitro for a period of 20 weeks.23 In vivo, formation of carbonated HA 
on cement surface has been reported to occur within 12 hours of implantation.24 This 
phenomenon could be one of the essential aspects of the exceptionally positive osteo-
conductive behavior of Ca-P cements.
15
4. In vivo interactions and osteoinductivity
In general, Ca-P compounds are found to be biocompatible and favorable for the ﬁnal 
bone response.4 The ability of Ca-P ceramics to bond to bone is a rather unique property. 
For example, it has been a consistent ﬁnding that the larger the ceramic solubility rate, 
the more pronounced bone ingrowth is observed.25 Ducheyne et al. hypothesized, that 
the dissolution of Ca-P and precipitation of a carbonated HA layer is essential in the 
bioactive behavior of ceramics. On the other hand, Davies claimed that microtopography 
played a crucial role as bone formation at the implant surface was achieved by micro-
mechanical interdigitation of the cement line with the material surface.26 
Protein- biomaterial interactions also play a key role in the biomaterial behavior in 
vivo. Directly after implantation, the surface of a biomaterial is being covered by serum 
proteins, which determine crucial reactions such as complement activation, thrombo-
genicity, and cell adhesion. Protein binding capacity depends on the speciﬁc ceramic 
characteristics as well as on the protein involved.27,28 Ceramic materials exhibit a high 
binding afﬁnity for proteins. Interestingly, several authors report that the combina-
tion of a material with high protein afﬁnity and an appropriate (micro)architecture, can 
exhibit intrinsic osteoinductive behavior.8,11,12 In a study in dogs, Yuan et al. observed 
ectopic bone formation after 3 and 6 months in micro- and macroporous HA whereas 
macroporous HA without microporous structure did not reveal bone formation. It was 
hypothesized that due to the microporosity, total surface area and subsequent protein 
adsorption was increased, which could have induced bone formation. On the other hand, 
Ripamonti et al. hypothesized that concave macroporosity was the driving force for in-
trinsic osteoinduction in ceramics. The ﬁndings of intrinsic osteoinductive behavior in 
ceramic are interesting. However, it must be emphasized that regarding the numerous 
studies using similar porous ceramics without evidence for intrinsic osteoinduction, 
these observations are exceptional and require conﬁrmation of reproducibility.
Protein adsorption on ceramics not only plays an important role in biological pro-
cesses, it also inﬂuences the ceramic itself with respect to dissolution and precipitation 
of calcium and phosphate ions. Radin et al. reported that in an in vitro environment, 
serum proteins slowed down the dissolution (OHA and ß-TCP) and precipitation (car-
bonated HA) of crystals at the surface of a crystalline multiphasic ceramic coating.29 
A similar observation was done by Ong et al., who reported an initial decrease in dissolu-
tion of phosphate molecules from Ca-P coatings in the presence of proteins with a high 
binding afﬁnity.30 Combes et al. investigated the interference of protein adsorption and 
HA maturation in detail and found that, depending on the concentration, serum albu-
min can exhibit a dual role and acts as a promotor or inhibitor of nucleation and growth 
of (octa)Ca-P crystals.31 The energy needed for the ﬁrst step in the precipitation process, 
nucleation, was lower when adsorbing molecules were present. Therefore, multiplica-
tion of nuclei occurred as a consequence of protein adsorption. The subsequent steps, 
growth to critical nuclei and formation of Ca-P crystals, were slowed down by a protein 
coating. However, at low serum albumin concentrations, the mineral surface could not 
be efﬁciently coated and crystal growth occurred faster than in the absence of albumin 
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Figure 1.3: Bone formation in rat bone marrow 
stromal cell loaded porous HA/TCP implants  
(Camceram®), implanted in muscular ﬂaps in rats 
for 8 weeks. Direct apposition of bone on the ceramic 
surface and bone marrow formation in the remaning 
porosity is observed. OC= osteocyte, BM= bone mar-
row. Bar represents 100 µm. Light microscopical  
undecalciﬁed section stained with methylene blue 
and basic fuchsin (original magniﬁcation 10x). 
Printed with permission from Hartman et al.38 
due to the larger number of nuclei and their greater reactivity. At high -physiological- 
serum albumin concentration, the mineral surface was efﬁciently coated slowing down 
the ionic diffusion to the crystal surface and inhibiting crystal growth.31 
5.  Calcium Phosphate ceramics 
for bone tissue engineering
For reconstruction of large bone defects, implantation of osteoconductive porous 
scaffold materials alone is not sufﬁcient for complete bone regeneration. Therefore, os-
teogenesis needs to be induced throughout the scaffold material. In the tissue engineer-
ing paradigm, osteogenic cells and/or osteoinductive macromolecules are being deliv-
ered to a suitable scaffold material. Many prerequisites have been postulated for the ideal 
scaffold material but non of the current materials meets all the demands. Porous ceram-
ics are potential scaffold materials for bone tissue engineering due to their outstanding 
osteocompatible properties, especially with respect to osteoconduction and gradual 
resorption. In the recent years, a variety of researchers have investigated Ca-P ceramic 
scaffold materials for cellular- as well as growth factor based tissue engineering. 
5.1 Ca-P ceramics and osteogenic cells
In 1988, Maniatopoulos et al. published a study on harvesting and culturing of rat 
bone marrow stromal cells (BMSCs) in vitro.32 Through this method, the small number 
of undifferentiated progenitor cells present in bone marrow could be isolated, expanded 
and differentiated into the osteoblastic lineage. Currently, the essence of this technique 
is still in use to administer osteoprogenitor cells to various scaffold materials for cell-
based bone engineering. Many studies in rodent animal studies have shown the validity 
of this concept in conjunction with ceramic scaffold materials as coralline HA, porous 
HA, porous HA/ß-TCP and porous ß-TCP.33-38 (Fig. 1.3) 
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Less studies, however, have investigated the bone forming capacities of large BMSCs 
loaded ceramic implants in higher mammals. This is in particular challenging, as the living 
constructs are transposed from ideal cell culture conditions to an in vivo environment 
where oxygen supply prior to capillary ingrowth is only provided by (limited) diffusion. 
Vitality of the BMSCs within ceramic scaffold material was shown to be essential for 
osteogenicity.39 Despite the potential jeopardy of cell death, bone formation was observed 
in the studies investigating ectopic implants in dogs and goats,40,41 or critical size defects 
in dogs, goats and sheep.41-46 In most of these studies, bone formation was also observed 
in the center of the implants where the unloaded controls did not show osteogenesis. This 
indicates, that possibly even a small number of surviving progenitor cells may be sufﬁcient 
to result in signiﬁcant bone formation. Also, it emphasizes that future tissue engineering 
research should also focus on multicomponent constructs, in which BMSCs are being 
combined with bone- and angiogenic growth factors. 
Ca-P ceramics and osteoinductive growth factors
During the last decade, several strategies have been developed to deliver growth 
factors such as Bone Morphogenetic Proteins (BMP’s) to the desired site. Basically, 
the proteins can be delivered directly via a carrier/delivery vehicle, or by gene therapy 
techniques, in which a growth factor encoding gene is delivered to host cells via a viral 
factor or plasmid. Through this method, transfected cells secrete growth factor. Cells 
can be transfected in vitro, prior to transplantation to the desired site, or directly in 
vivo. In this review, only direct delivery of proteins will be discussed as this approach 
has developed furthest and recently acquired FDA approval for speciﬁc clinical 
applications.47
The growth factor loaded ceramic has a twofold function; ﬁrst, it serves as a scaffold 
material, which enables and stimulates bone and blood vessel ingrowth; second, it 
serves as a carrier or delivery vehicle for the inductive factor, which should result in 
most favorable biopresentation and optimal activity of the protein. The role of ceramics 
on the bioactivity of growth factors is not completely clear. The ceramic might potentiate 
the activity of BMP by binding the protein and presenting it to target cells in a “bound” 
form.48,49 On the other hand, the ceramic can act as vehicle for factor delivery to the 
surrounding tissues. Released protein may provide a supra-physiological concentration 
of free protein in the vicinity of the implant, which may attract target cells to the 
implant-site by chemotaxis.50 It is hypothesized that for optimal bioactivity, initial 
burst release chemotactically recruits osteoprogenitor cells, and following sustained 
release -or retained factor- differentiates these cells towards the desired phenotype.51 
To our judgment, however, no convincing evidence provides further speciﬁcation of 
this partition. Moreover, optimal pharmacokinetics are presumably speciﬁc for each 
surgical site. 
5.2.1 Growth factor release from Ca-P ceramics
The correlation between factor bioactivity and release or retention is a delicate issue. 
Since the protein needs to induce bone locally and not systemically, the released protein 
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only has a short time to attract cells before it is being cleared from the application site. 
For example, a depot of 5 µg rhBMP-2 injected subcutaneously in the back in rats is 
cleared from the application site for more than 80% within 24 hours. (Fig. 1.4) After 
clearance, the proteins are being metabolized by the body and excreted renally.52 The 
systemic exposure to released rhBMP-2 is reported to be neglectible.52 
The speciﬁc parameters resulting in protein release or retention are the driving 
factors behind the ﬁnal clinical efﬁcacy of a carrier system. Unfortunately, only few 
researchers have investigated these phenomena for ceramics. In a series of experiments 
in a rat ectopic model, Uludag et al. have shown that growth factor retention depend 
on carrier- as well as on factor characteristics.53,54 Proteins with a higher isoelectric 
point (pI) show higher implant retention and higher retention of BMP yields higher 
osteoinductive activity. Various rhBMP-2 loaded ceramic implants (TCP cylinders and 
coral derived HA cylinders) show initial burst release of approximately 70% within 
three hours after implantation, which is followed by a slower second phase release and 
a ﬁnal retention of approximately 6% of the initial dose after 14 days. In another study 
carried out by Louis-Ugbo et al., initial burst release from HA/TCP granules (60:40) 
was less than 20% within the ﬁrst day in a rabbit spinal fusion model.52 After two weeks 
27 ± 9% of rhBMP-2 was still retained in this model. Li et al. determined the release 
kinetics of rhBMP-2 mixed through Ca-P cement (α-BSM) and injected in a rabbit ulnar 
defect.55 Within the ﬁrst day, approximately 40% of the loaded factor was released. After 
14 days, 15 ± 7% of the loaded factor was still present in the cement. The differences in 
release and retention rates between these studies could be explained by variations in 
surgical site, dose, adsorption procedures, material surface area and chemico-physical 
interactions between material and growth factor. Overall, ceramics exhibit multiphasic 
release kinetics in vivo with a decrease of release in time and a certain retention for 
several weeks. It has been hypothesized, that ceramic surface area plays the key role in 
protein binding.56 
As previously mentioned, Ca-P ceramic materials show a high binding afﬁnity for 
proteins. Conformational changes of proteins upon adsorption on Ca-P surface have 
been observed.30 Protein conformation is of great importance for the accessibility of the 
speciﬁc binding sites and subsequent protein-cell interaction.57,58 As a result, protein-
biomaterial bonding may directly affect the protein’s intrinsic function due to orienta-
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Figure 1.4: Retention of 131I rhBMP-2  
injected subcutaneously in rats. Over 80% 
of rhBMP-2 was cleared from the applica-
tion site within 24 hours, underlining the 
short residence time of rhBMP-2 after  
release from a carrier material.  
Error bars represent means ± standard 
deviation for n=6.
tion or conformational changes. To evaluate the bioactivity of retained proteins, cells 
can be cultured on the surface of protein loaded ceramics in vitro.59 A complicating fac-
tor is that no material exhibits a 100% retention.54 For a true differentiation between 
activity expressed by retained protein versus released protein, control groups have to 
correct for the released fraction bioactivity. In an in vitro model, Santos et al. investi-
gated the bioactivity of rhBMP-2 adsorbed onto a Ca-P layer on bioactive glass-gel 
(Xerogel S70) in comparison with the activity of “free” rhBMP-2 present in cell culture 
medium.59 The osteogenic response of osteoblast like cells seeded on the Ca-P surface 
was found signiﬁcantly higher in the adsorbed rhBMP-2 group. The authors suggested 
that the biomaterial could generate, maintain or even concentrate an effective level of 
growth factor. 
5.2.2 Growth factor loading in Ca-P ceramics 
In view of the previous paragraph, discern has to be made between proteins/growth 
factors adsorbed at the ceramic surface and proteins/growth factors mixed through the 
material during preparation. For sintered ceramic materials, the latter is impossible as 
sintering temperatures would result in complete protein destruction. For the self setting 
Ca-P cements, mixing of proteins during setting reaction has been described though.60-
62 By physical entrapment by cement particles, the majority of the protein binding sites 
will be unavailable until the protein is released from the cement. This situation is quite 
similar to bioactive macromolecules entrapped in polymeric drug delivery vehicles, 
where protein release is the main focus.63-68 However, a frequently neglected issue is 
that mixing of proteins through ceramics can inﬂuence the crystallization process 
during the setting reaction. This can modify the in vivo dissolution and/or degradation 
properties of the formed material.
For the growth factors entrapped within a Ca-P ceramic material, bioactivity is 
likewise only expected after release from its carrier. Bioactivity of released protein can 
be demonstrated through in vitro models where sensible cells are being exposed to 
the released protein.55,64,68 To evaluate loss of activity, the induced biological response 
should be compared to the response to similar protein directly suspended in the culture 
medium.55 In vivo, however, this comparison is difﬁcult and most authors just examine 
whether or not the protein expresses (part of its) bioactivity.
5.2.3 Osteoinductive capacity of growth factor loaded Ca-P ceramics
Osteogenic differentiation induced by BMPs is dependent on the regulating growth 
factor as well as on the carrier speciﬁcations. Murata et al. observed that in a synthetic 
HA carrier, BMP induced ossiﬁcation was predominantly intramembranous, whereas 
enchondral bone formation was observed in a non-ceramic carrier.69 Direct bone 
formation on BMP loaded Ca-P ceramics was also observed by others.70-73 
However, the osteogenic behavior of growth factor loaded Ca-P ceramics is not as 
straightforward as suggested, because a wide variety of material compositions, animal 
models, surgical sites and factor dosage have been used in the various studies. Another 
complicating factor is that physiological bone regeneration is induced by a cascade of 
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growth factors, whereas most tissue engineered concepts investigate osteoinduction 
by single factors only. Consequently, most research in the recent years has focused on 
BMPs like rhBMP-2 and rhBMP-7 (OP-1). Due to the numerous parameters, there is 
no such thing as one ideal dosage or scaffold composition. Most animal studies inves-
tigating growth factor loaded ceramics have been carried out in smaller animals like 
rats9,10,53,54,69,70,72,74-78 and rabbits,52,55,73,79-85  (Fig. 1.5) whereas only few studies were per-
formed in larger animals as minipigs,86,87 dogs71,88,89 and primates.90-92 Generally speak-
ing for all carrier materials, the relative dosage of growth factor needed for bone induc-
tion increases with the animal size.51 However, the dosages applied to ceramics vary 
substantially within similar animal models as well as between different species. For 
rhBMP-2, dosages applied for effective osteoinduction varied from 0.03 – 0.46 mg/ml 
implant in rats9,54,75 to 0.004 – 2.1 mg/ml implant in rabbits,55,73,80,81,83,85 whereas in 
canine and primate models dosages have been used from 0.15 – 1.2 mg/ml71 and 1.35 
– 2.7 mg/ml92 respectively. A dose-response relation for BMP loaded ceramics has been 
reported in some studies in rodents,75,80,83 but was absent or even reciprocal in studies 
with larger animal models.71,91,92 Yet, it seems likely that in the dose-response relation, 
there ﬁrst is a certain threshold dosage to achieve consistent results,92 followed by a lin-
ear dose-response interval and ﬁnally a saturation effect occurs.
Besides BMPs, other growth factors like transforming growth factor-ß (TGF-ß) and 
insulin-like growth factor-I (IGF-I) have been investigated. TGF-ß may potentiate the 
osteoinductivity of BMPs, but its overall osteoinductive capacity when applied alone 
is weak compared to BMPs.93 IGF-I has also been applied to TCP ceramic carriers, which 
resulted in increased osteogenesis in an orthotopic implantation site four weeks after 
implantation.94 Similarly, Damien et al. reported that IGF-I loaded porous hydroxyapatite 
accelerated orthotopic bone ingrowth during an implantation period up to three weeks.95 
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Figure 1.5: Bone formation in rhBMP-2 loaded 
porous Ca-P cement implants, implanted subcuta-
neously in rabbits for 10 weeks. Macroporosity in 
the cement (Calcibon®, Biomet Merck, Darmstadt, 
Germany) was induced by formation of CO2 during 
setting of the cement, after which a dosage of 10 µg 
rhBMP-2 was applied. OB= osteoblasts, BM= bone 
marrow, BV= blood vessel. Bar represents 100 µm. 
Light microscopical undecalciﬁed section stained 
with methylene blue and basic fuchsin (original 
magniﬁcation 10x). 
The synergism of various growth factors, as present in the physiological bone 
regeneration cascade, has only been investigated in few studies with Ca-P ceramics. 
Ono et al. investigated the role of prostaglandin E1 (PGE1) and basic ﬁbroblast growth 
factor (bFGF) loaded on porous hydroxyapatite and observed that PGE1 as well as bFGF 
acted synergistically with rhBMP-2.80,83,96 Meraw et al. prepared a true growth factor 
cocktail and reported that orthotopic bone formation in a canine model was enhanced 
by a combination of extremely low dosages of TGFß, bFGF, BMP-2, and PDGF mixed 
through a calcium phosphate cement.89 
6. Objectives of this Thesis
The general aim of the Bone Tissue Engineering research group, a collaboration of 
the department of Biomaterials and the department of Plastic and Reconstructive Sur-
gery, Radboud University Nijmegen Medical Centre, is the development of an osteo-
genic and/or osteoinductive bone graft substitute (BGS) for reconstruction of osseous 
defects. Such a BGS should be composed of an osteoconductive material and should 
possess a porous structure to enable tissue ingrowth, gradual resorption and substitu-
tion by autologous tissues. Reconstruction of the osseous defect could be either directly, 
which requires an injectable material for seamless ﬁtting into the defect and appropriate 
shaping of the construct, or indirectly by prefabrication at an ectopic location and sub-
sequent (micro)surgical transfer to the defect, which requires a moldable material for 
shaping the preset construct.
The investigations described in this thesis were part of this project. The aims of this 
thesis are:
1. Investigation of the suitability of preset porous calcium phosphate (Ca-P) cement as 
carrier material for recombinant human bone morphogenetic protein-2 (rhBMP-2) 
at orthotopic and ectopic locations.
2. Investigation of the feasibility of a composite material based on Ca-P cement and 
embedded poly(DL-lactic-co-glycolic acid) (PLGA) microparticles for delivery of 
rhBMP-2.
3. Investigation of the in vivo tissue response to PLGA/Ca-P cement composites.
4. Investigation of the in vivo tissue response to porous PLGA/Ca-P cement 
composites with CO2 induced porosity.
5. Investigation of the in vivo release of rhBMP-2 from porous Ca-P cement and 
development of a method to inﬂuence release kinetics without vital alterations in 
chemico-physical material properties.
6. Investigation of the in vivo release of rhBMP-2 from PLGA/Ca-P cement 
composites and development of composites with different release kinetics.
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1. Introduction
The use of autologous bone grafts is considered to be the gold standard for repair and 
reconstruction of bone. To overcome the disadvantages of this technique, such as (1) 
the low availability of transplantable tissue, (2) postoperative morbidity, and (3) lack 
of functional shape of the transplant, several alternatives to autologous bone have been 
investigated. One of these is tissue engineered synthetic bone graft substitute (BGS). 
In this concept, a BGS consists of an osteoconductive scaffold material combined with 
osteogenic cells and/or osteoinductive proteins. 
A lot of prerequisites have been postulated for the ideal scaffold material with 
regard to mechanical properties, biocompatibility, biodegradability, absence of allergic 
reactions, disease transmission, delivery of the osteoinductive factor, gross architecture, 
shaping, clinical handling, and regulatory issues. Nevertheless, none of the currently 
available scaffold materials meets all of the formulated demands.
Calcium phosphate (Ca-P) cements have been studied extensively.1-5 Besides the 
clinical advantage that this cement can be injected directly into a bone defect, it shows 
a fast deposition of new bone at the cement surface and is considered to be extremely 
biocompatible.6,7 To enhance tissue ingrowth and degradation rate of the cement, we 
have recently developed a method to increase the porosity of the cement by creating 
macropores.8 In an animal study in goats, the degradation rate was shown to increase 
up to 80% in ten weeks.9
Osteoinductive proteins play an important role in bone regeneration. These 
proteins belong to the Transforming Growth Factor (TGF)-ß super family. Currently 
ﬁfteen different Bone Morphogenetic Proteins (BMPs) have been identiﬁed.10 Various 
in vitro and in vivo (rodents, dogs, sheep, humans) studies have been done to establish 
the osteoinductive effect of BMP.11-18 Especially human BMP-2 has been investigated 
thoroughly for bone engineering purposes. This homodimeric protein can be produced 
by human recombinant technology since 1988 and consists of two polypeptide chains 
of more than 400 amino acids.16,19 A region with seven cystine amino acids located 
near the C-terminus plays a crucial role in the protein function.19 Recent investigations 
showed that the so-called cystine knot is located in the core of the complex three 
dimensional structure.20,21 More insights into the primary steps of BMP receptor 
activation have been provided with the characterization of two receptor binding 
epitopes for high afﬁnity BMP receptors.20,22 Binding of BMP to cell surface receptors on 
mesenchymal cells activates a BMP signaling cascade that results in gene expression and 
leads to differentiation of the mesenchymal cells into chondrocytes or osteoblasts.21 
The role of biomaterials on the osteoinductive activity of BMP is not completely clear. 
The biomaterial itself might directly inﬂuence cellular differentiation23 and it might 
potentiate the activity of BMP by binding the protein and presenting it to target cells in a 
“bound” form.24,25 On the other hand, slowly released BMP may provide a physiological 
concentration of free protein in the vicinity of the implant, what may attract target cells 
to the implant-site by chemotaxis.26 The ideal retention/release rates for growth factors 
have not been established yet. 
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Although in several studies the combination of growth factors with Ca-P ceramics, 
like hydroxyapatite and tricalciumphosphate, has been reported,18,27-33 to our knowl-
edge only a few studies have been carried out with Ca-P cement and osteoinductive 
proteins.34-38 The Ca-P cements used in these studies did not have a macroporous struc-
ture and growth factors were mostly added to the cement before setting. 
To our knowledge, this is the ﬁrst study with macroporous Ca-P cement and rhBMP-2. 
We hypothesize that: 1. Porous Ca-P cement is an appropriate candidate scaffold 
material for bone engineering purposes. 2. Bone formation in porous Ca-P cement can 
be enhanced by lyophilization of rhBMP-2 on the scaffold surface. 3. Porous rhBMP-2 
loaded Ca-P cement discs show degradation after implantation in cranial defects in 
rabbits for ten weeks.
2. Materials and methods
Porous calcium phosphate cement implants:
Thirty-six disc-shaped porous calcium phosphate (Ca-P) cement implants were 
prepared by a CO2 induction technique as previously described.
8  The discs were made 
out of Calcibon® (Biomet Merck, Darmstadt, Germany). This cement consists of a 
mixture of 62.5wt% tricalcium phosphate (α-TCP), 26.8wt% dicalcium phosphate 
anhydrous (DCPA), 8.9wt% calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite 
(HA). An aqueous solution of Na2HPO4 (2wt%) was used as the liquid component. 
To generate macroporosity of the scaffold, NaHCO3 was added for production of CO2 
gas in the cement. After mixing, the cement was immediately injected in a cylindrical 
mould of 2.7 mm height and 8.0 mm diameter. The discs were air dried in a furnace 
at 50oC for 1 hour. Thereafter, the surface of the discs was carefully ground with 
ﬁne sand-paper to ensure a standardized height of 2.7 mm. Finally, the discs were 
removed from the moulds and sterilized by autoclaving for 15 minutes at 121oC. 
Average weight was 108 ± 7 mg/disc. The total porosity of the discs was 75% as was 
calculated with the formula: porosity (%) = 100 * {1-(disc weight/ [cement density * 
disc volume])}. Histomorphometrical analysis of the discs before implantation revealed 
that the macroporosity was 36%. In a previously published paper, it was shown that the 
microporosity (pores < 1 µm) of this cement is 39%.8
Absorbable collagen sponge implants:
As positive reference material for administration of rhBMP-2, sterile absorbable 
collagen sponge (ACS) was used as provided by Dr. D.W.R. Hall (Yamanouchi Europe 
BV. Leiderdorp, The Netherlands). Under sterile conditions the ACS sheets (thickness 
3.5 mm) were moistened with H2O to induce the common shrinkage of the material 
and the sheets were lyophilized subsequently. Thereafter, discs were punched out of the 
lyophilized sheets with sterile 8 mm biopsy punches (Stiefel Laboratories BV, Veendam, 
The Netherlands) under sterile conditions. 
31
rhBMP-2 loading:
Eighteen porous Ca-P cement implants were loaded with rhBMP-2 (Yamanouchi 
Europe BV, Leiderdorp, The Netherlands) one day prior to implantation. Thereafter, the 
Ca-P discs were placed in a sterile Eppendorf® tube under sterile conditions and 25 µl 
of diluted rhBMP-2 (0.2 mg/ml PBS/BSA[0.1%]) was added to each side of the implant 
to achieve a total dose of 10 µg per implant. The specimens were lyophilized and stored 
at 4oC until implantation.
Eighteen ACS discs were loaded with rhBMP-2 on the day of implantation as 
prescribed by the provider. To achieve a total dose of 10 µg rhBMP-2 per implant with a 
soak-load of 30%, 50 µl of the diluted rhBMP-2 solution (0.2 mg/ml PBS/BSA[0.1%]) 
was pipetted carefully onto the discs of ACS. The ACS discs were allowed to soak-load 
for minimally 15 minutes before being inserted into the cranial defects. Care was taken 
not to squeeze the discs.
Surgical procedure for cranial implants:
Fifty-four healthy skeletally mature female New Zealand White rabbits with a weight 
between 2.8 - 3.2 kg were used as experimental animals. National guidelines for the care 
and use of laboratory animals were observed. 
Surgery was performed under general inhalation anesthesia. The anesthesia was in-
duced by an intravenous injection of Hypnorm® (0.315 mg/ml fentanyl citrate and 10 
mg/ml ﬂuanisone) and atropine, while maintained by a mixture of nitrous oxide, iso-
ﬂurane, and oxygen through a constant volume ventilator. To reduce the peri-operative 
infection risk, the rabbits received antibiotic prophylaxis [Baytril® 2.5% (Enroﬂoxacin), 
5-10 mg/kg].
For the insertion of the implants, the animals were immobilized in ventral posi-
tion. The skull was shaved, washed and disinfected with povidone-iodine. A longi-
tudinal incision was made down to the periosteum from the nasal bone to the occipi-
tal protuberance. Subsequently, a midline incision was made in the periosteum. The 
periosteum was undermined and lifted off the parietal skull. The defect was drilled in 
the parietal calvarial bone with a dental trephine burr (ACE Dental Implant System, 
Brockton, MA, USA) with an outer diameter of 8.0 mm and continuous internal and 
external cooling with physiologic saline. Care was taken to make a full thickness de-
fect without damaging the underlying dura. Following insertion of the implants (Fig. 
2.1A and 2.1B), the periosteum was closed using non-resorbable Prolene® 4-0 sutures. 
Finally, the skin was closed intracutaneously using resorbable Vicryl® 4-0 suture ma-
terial. Implantation periods were two and ten weeks. At the end of each implantation 
period, euthanasia was performed with an overdose of Nembutal® (pentobarbital). 
In this way, a total of ﬁfty-four implants were placed into the ﬁfty-four rabbit skulls: 
eighteen rhBMP-2 loaded Ca-P cement implants, eighteen unloaded Ca-P cement 
implants and eighteen rhBMP-2 loaded ACS implants (n=9 for each implant and time 
period). In the group of rabbits that received an unloaded Ca-P cement implant, an 
additional defect was drilled in the contralateral parietal bone, which was left open 
and served as control (empty defect). In this group, no rhBMP-2 was administered. 
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Therefore, there was no cross-over effect of rhBMP-2.
Sequential quadruple ﬂuorochrome labeling, i.e. tetracycline (yellow), alizerin-
complexon (red), calcein (green) and tetracycline (yellow), was performed in four 
rabbits of each group at respectively one, three, seven and nine weeks postoperatively. 
All labels were administered subcutaneously at 25 mg/kg body weight. Parallel to this 
study, a separate study was performed in the same animals where identical experimental 
groups were implanted subcutaneously.
Implant retrieval and histological preparations.
Directly after euthanasia, implants with the surrounding tissues were retrieved and 
ﬁxed in 4% phosphate-buffered formaldehyde solution (pH=7.4). Subsequently, the 
tissue blocks were dehydrated in ethanol and embedded in methylmethacrylate. Fol-
lowing polymerization undecalciﬁed 10-µm-thick sections were prepared in a trans-
verse direction to the implant’s axis using a modiﬁed sawing microtome technique.39 
At least three sections of each implant were stained with methylene blue/basic fuchsin 
and examined with a light microscope. Two additional unstained 30-µm-thick sections 
of the ﬂuorochrome-labeled specimens were prepared for reﬂectant ﬂuorescence mi-
croscopy.  
Histological and histomorphometrical evaluation
A light microscope (Leica Microsystems AG, Wetzlar, Germany) was used for his-
tological evaluation. This evaluation consisted of a morphological description of three 
sections per implant. 
Further, all sections that contained Ca-P cement implants were used for histomor-
phometrical evaluation using computer based image analysis techniques (Leica® Qwin 
Pro-image analysis system, Wetzlar, Germany). Digital analysis determined the follow-
ing parameters: 
Fig. 2.1A (left):  
rhBMP-2 loaded ACS 
implant inserted in  
cranial defect. 
Fig. 2.1B (right):  
Porous Ca-P cement 
implant inserted in  
cranial defect (left) and 
empty defect (right).
2.1A 2.1B
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1. The surface of the area within the defect edges and the thickness of the implant, 
which was called region of interest (ROI). 
2. Cement surface area [%], indicative for the macroporosity. 
3. Total bone area in Ca-P specimens [%], deﬁned as the index of the surface area of 
bone and the ROI. This parameter was subdivided in: A. Bone inside the cement 
(BIC), deﬁned as bone formed within the implant edges. B. Bone outside the cement 
(BOC) deﬁned as newly formed bone deposited outside the implant at either skin- 
or cerebral side.
4. Pore ﬁll [%], deﬁned as the index of BIC and the surface area of macropores. 
The results are based on the average of the separate measurements of three sections 
per implant. We have to emphasize that no histomorphometrical measurements were 
done for the ACS implants. A quantitative comparison of parameters for this group 
would be unreliable since no proper ROI, in terms of implant thickness and area, could 
be deﬁned for the spongy ACS. 
A reﬂectant ﬂuorescence microscope equipped with an excitation ﬁlter of 470-490 
nm (Leica Microsystems AG, Wetzlar, Germany) was used for ﬂuorescent microscopical 
assessment. 
Statistical analysis
All measurements of rhBMP-2 loaded and unloaded porous Ca-P cement implants 
were statistically evaluated with GraphPad® Instat 3.05 software (GraphPad Software 
Inc, San Diego, CA, USA), using an unpaired T-test with Welch correction. 
3. Results
 
Experimental animals
During the experiment, all ﬁfty-four rabbits remained in good health and did not 
show any wound complications. At the end of the two implantation periods, a total of 
ﬁfty-four implants and eighteen empty control defects could be retrieved. At retrieval, 
the implants were all covered by periosteum. No inﬂammatory signs or adverse tissue 
reaction could be observed. Bone formation could be seen macroscopically in most of 
the specimens.
Light microscopy
Light microscopic analysis of the sections revealed various amounts of bone forma-
tion between implants, groups and time periods. In all sections, the original defect edge 
was still visible. Little or no inﬂammatory multinucleated cells were observed on the 
cement surface. Representative sections are depicted in Figure 2.2.
Two weeks specimens
Two weeks postoperatively, none of the empty defects was closed completely. Pri-
mary bone ingrowth from the defect edge to the defect center covered about half of the 
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defect diameter. In the ACS group, all defects were completely closed after two weeks 
of implantation. The new-formed primary bone was characterized by the presence of 
osteoblasts, osteocytes and small blood vessels and had a structure, comparable with 
the new bone formation in the empty defects. Microscopically, no collagen left from 
the ACS material could be observed. The newly formed bone layer was thinner than 
the originally inserted ACS material and thinner than the surrounding skull bone in all 
sections. 
Light microscopy showed that the macropores in the Ca-P cement implants were 
irregularly formed and had a channel-like rather than a spherical structure. In three 
unloaded Ca-P cement implants, some fracturing of the scaffolds occurred. In these 
sections, fracture lines in the Ca-P cement and loose Ca-P fragments were observed. 
Fig. 2.2: Overview of representative sections of 
implants and empty defects after two and ten weeks. 
Original magniﬁcation 2.5x. Bar represents 1 mm.
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However, the outline of these discs was not affected. All other implants had maintained 
their integrity. Fibrous encapsulation of the Ca-P cement implants was not observed. 
Bone ingrowth from the skull bone into the macropores of the cement was present in 
all implants. Also, direct bone contact with the cement and layers of osteoblast-like cells 
were observed in all sections. At the interface, no inﬂammatory cells or ﬁbrous tissue 
were present between bone and cement. Further inside the implant, macropores were 
ﬁlled with loose connective tissue and blood vessels. Remarkably, all rhBMP-2 loaded 
Ca-P implants were surrounded by a thin layer of primary bone outside the cement at 
the cerebral side of the implant, the skin side or both sides. This callus-like tissue was 
characterized by the frequent absence of contact between bone and cement. In eight 
out of nine implants, the bone outside the cement covered the defect completely. A 
very limited formation of bone outside the cement was also observed in three of the 
unloaded Ca-P cement implants. 
Ten weeks specimens
Ten weeks postoperatively, average bone ingrowth in the empty defects covered 
about 75% of the defect diameter. One of the empty defects was closed completely 
by a thin layer of new trabecular bone. In the ACS group, all defects were completely 
closed. The primary bone of the two weeks ACS implants was now replaced by a more 
cortical-like structure. Occasionally, the newly formed bone was difﬁcult to discern 
from the original skull bone. Further, we noticed that in four of the nine specimens 
the newly deposited bone was not formed according the original skull contour and 
lacked the ﬁnally required shape. Microscopically, the ACS appeared to have degraded 
completely. 
All of the Ca-P cement scaffolds were intact and had maintained their integrity. 
Bone bridging between the Ca-P implant and skull occurred in all specimens. Bone 
ingrowth in both the rhBMP-2 loaded and unloaded Ca-P cement scaffolds had increased 
dramatically compared to the two weeks implants. Complete closure of the defect was 
observed in all rhBMP-2 loaded specimens and in seven unloaded specimens. The 
Fig. 2.3: Light microscopic aspect of bone formation in 
the center of a rhBMP-2 loaded Ca-P cement scaffold 
after ten weeks of implantation. Bone formation is 
characterized by the presence of osteocyte-like cells 
(OC) embedded in the matrix and the layer of cubical 
osteoblast-like cells (OB) at the matrix surface. Bone 
marrow-like tissue (BM) is observed in the macropores. 
Original magniﬁcation 10x. Bar represents 100 µm.
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deposited bone had a more lamellar appearance than after two weeks of implantation. 
Bone formation in the cement porosity was characterized by the presence of osteoblast- 
as well as osteocyte-like cells embedded in a mineralized matrix (Fig. 2.3). Also, bone 
remodeling and bone marrow-like tissue were observed. Osteoclast-like cells and 
foreign body giant cells were noticed occasionally. Formation of bone outside the Ca-P 
cement was present in eight of the nine rhBMP-2 loaded Ca-P scaffolds. Unlike the two 
weeks sections, the bone outside the cement was frequently in direct contact with the 
Ca-P cement. In the unloaded group, formation of bone outside the scaffold was very 
limited in four of the nine scaffolds. Here, direct bone- Ca-P cement contact existed 
also. Finally, in both the rhBMP-2 loaded and non-loaded Ca-P cements implants no 
clear indication for cement degradation was observed.
Fluorescence microscopy
Results of ﬂuorescence microscopy are depicted in Figure 2.4. Tetracycline labels, 
that were administered one and nine weeks post-operatively, were scarcely observed. 
Analysis of the ﬂuorescence labels revealed that formation of bone started at the cement 
surface and proceeded into the macropores.  
Histomorphometry
The results of the histomorphometrical analysis of the Ca-P specimens are shown 
in Figures 2.5 and 2.6.
Measurement of cement surface before implantation revealed a cement/ROI ratio of 
63.6 ± 0.3%, indicative for a macroporosity of the scaffold of 36.4 ± 0.3%. After two and 
ten weeks of implantation, the macroporosity was not signiﬁcantly changed (p>0.05). 
In the histomorphometrical analysis, we discerned total bone formation in bone 
inside the cement (BIC) and bone outside the cement (BOC). In the rhBMP-2 loaded 
group, total bone surface area increased from 8.9 ± 7.1% (BIC: 3.2 ± 1.9%; BOC: 5.7 
± 5.3%) after two weeks to 27.4 ± 6.2% (BIC: 19.5 ± 3.6%; BOC: 7.9 ± 3.3%) after ten 
weeks. In the unloaded group, total bone surface area increased from 3.2 ± 1.9% (BIC: 
Fig. 2.4: Fluorescence microscopy of bone formation 
in the center of a rhBMP-2 loaded Ca-P cement 
scaffold. Formation of bone started at the cement 
surface and proceeded into the macropore.  A= alizerine 
complexon label (red), administered after three weeks 
of implantation. C= calcein label (green), administered 
after seven weeks of implantation. T= tetracycline label 
(yellow), administered after nine weeks of implantation. 
Original magniﬁcation 20x. Bar represents 50 µm.
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2.4 ± 1.2%; BOC: 0.8 ± 1.1%) after two weeks to 16.6 ± 5.1% (BIC: 14.2 ± 4.4%; BOC: 
2.4 ± 1.6%) after ten weeks. Statistical testing revealed that these increases were sig-
niﬁcant (p< 0.0001) for both groups. Comparison between loaded and unloaded groups 
showed that total bone surface area was signiﬁcantly higher in the rhBMP-2 loaded 
group after two weeks (p< 0.05) and after ten weeks (p< 0.005). 
After two weeks of implantation, pore ﬁll in the rhBMP-2 group (9.3 ± 3.7%) was 
not signiﬁcantly different from the unloaded group (8.3 ± 4.0%). After ten weeks, pore 
ﬁll was signiﬁcantly higher (p< 0.05) in the rhBMP-2 group (53.0 ± 5.4 vs. 43.1 ± 10.4).
4. Discussion
This study focuses on the osteoinductive properties of rhBMP-2 loaded porous Ca-P 
cement in cranial defects in rabbits. The critical size of cranial defects in rabbits has been 
reported to measure 15 mm in diameter for implantation periods up to twenty-four 
weeks.40,41 This corroborates with our ﬁndings in previous research, which showed that 
7.3 mm cranial defects are non-critical size defects for implantation periods of eight 
weeks.42 In the current study, one open defect had closed completely after ten weeks and 
the remaining eight defects showed a tendency to complete closure. However, it should 
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Fig. 2.5: Total bone surface in porous 
Ca-P cement scaffolds, expressed as the 
index of the surface area occupied by 
bone and the region of interest (ROI). 
Total bone formation is subdivided in 
bone inside the Ca-P cement (BIC) and 
bone outside the Ca-P cement (BOC). 
Error bars represent means ± standard 
deviation for n=9.  
* = p< 0.05  ** = p< 0.005.
Fig. 2.6: Pore ﬁll percentage, 
expressed as the index of the surface 
area occupied by bone inside the Ca-P 
cement (BIC) and the pore surface 
area. Error bars represent means ± 
standard deviation for n=9.  
* = p< 0.05.
be noticed that we did not intend to create a critical size defect in the current study. Our 
aim was to investigate whether lyophilized rhBMP-2 on a porous Ca-P cement scaffold 
surface stimulated bone formation. 
rhBMP-2 loaded ACS was used in this study as positive reference material for 
rhBMP-2 bone induction. Unloaded ACS was not included since the carrier material was 
not under investigation in this study, and has been investigated thoroughly.35,43-46 The 
loaded ACS proved to be a powerful osteoinductive positive reference, as bone bridging 
was observed in all ACS ﬁlled defects after two weeks of implantation. Unfortunately, 
histomorphometrical comparison of ACS and Ca-P cement implants was impossible 
due to the indeﬁnable region of interest (ROI) in the ACS group. We underline the 
importance of the ROI for histomorphometry and we refrain from quantitative 
comparison if this parameter is insecure. However, the qualitative histological analysis 
revealed that in four of the ACS implants, the new deposited bone showed some variety 
in contour and did not match the desired shape. We presume that this is due to the 
ﬂaccid aspect of the collagen sponge. Despite the excellent osteoinductive properties, 
this lack of shape maintenance is a drawback of the rhBMP-2 loaded ACS as a scaffold 
material for bone engineering.
The complete closure of all defects ﬁlled with unloaded Ca-P cement indicates 
that porous Ca-P cement did not hamper the physiologic bone healing response. 
Biocompatibility of porous Ca-P cement was conﬁrmed by histological analysis of the 
sections. Formation of ﬁbrous capsule around the implant was observed in none of the 
sections. In agreement with previous studies, few multinucleated inﬂammatory cells 
were seen on the cement surface.9 Loose connective tissue and blood vessel ingrowth 
occurred in all macropores throughout the scaffolds. The macropores in this ceramic 
can thus be regarded as completely interconnected.
Fluorescence microscopy revealed that formation of bone started at the cement 
surface and proceeded into the macropores. This observation agrees with previously 
described bone deposition in porous ceramics47 and emphasizes again the beneﬁcial 
effect, which Ca-P ceramics of a speciﬁc geometry and composition can have on bone 
healing. 
The histomorphometrical analysis showed that after ten weeks of implantation pore 
ﬁll and total bone surface area were signiﬁcantly higher in the rhBMP-2 loaded Ca-P 
cement scaffolds than in the unloaded scaffolds. This conﬁrms that administration of 
rhBMP-2 can indeed enhance the formation of bone in porous Ca-P cement scaffolds. 
As the defects created in the current study were non-critical size and bone formation 
also occurred without administration of growth factor, we assume that the signiﬁcance 
of bone formation induced by rhBMP-2 will increase in clinically more relevant (critical 
size) defects. Nevertheless, we have to emphasize that the unloaded Ca-P cement 
scaffolds also supported a fair amount of bone formation inside the cement porosity. 
We suggest that this is due to the osteoconductive qualities of the macroporous Ca-P 
cement. 
Perhaps the most striking difference between the loaded and unloaded implants was 
the early callus-like bone formation outside the cement as occurred in all of the rhBMP-2 
39
loaded two weeks implants. To determine whether this bone formation was induced by 
a relatively high concentration of growth factor in the surrounding tissues, we assessed 
the in vitro rhBMP-2 release proﬁle from Ca-P cement with 125I labeled rhBMP-2 in an 
additional study according to previously described methods ( ﬁg. 2.7).48 The results 
showed that our Ca-P cement scaffolds showed no initial burst release. Instead, there 
was a very limited release of the loaded rhBMP-2 of accumulatively 9.7 ± 0.9% after 28 
days. In other studies, limited release of growth factors from Ca-P cement in vitro has 
been reported also.37,49 It is known from column chromatography separation techniques, 
that ceramics exhibit a high binding afﬁnity for proteins. However, the exact binding 
mechanism of rhBMP-2 on a ceramic surface is not known to our knowledge. Therefore, 
it remains unclear how the protein is attached to the ceramic surface, and whether the 
receptor binding epitopes maintain their accessibility. Binding of BMP on a biomaterial 
has even been suggested to potentiate the activity of the protein.24 Unfortunately, no 
data are available on the activity of “bound” rhBMP-2 on ceramic surface. Evidently, 
the limited release of rhBMP-2 in vitro does not explain the formation of bone outside 
the scaffold, unless the early physiologic callus formation is very sensitive to induction 
by rhBMP-2. On the other hand, we noticed that Li et al. reported slow release of 
rhBMP-2 from a Ca-P cement in vitro, whereas in vivo release was signiﬁcantly faster.37 
Therefore, the in vitro release proﬁle as determined in the current study can still be 
an underestimation of the in vivo release and the subsequent concentration of growth 
factor in the surrounding tissues.
In a previous study, we have demonstrated that degradation of porous Ca-P cement 
can reach up to 80% after ten weeks.9 In that study, a trabecular condylar defect in goats 
was ﬁlled with a Ca-P cylinder. In contrast, in the current animal model no degradation 
of the cement was observed after ten weeks of implantation. Initial bone-implant 
contact surface area was relatively large in the cylinder shaped defect in the goat study 
and relatively small in the current study. Therefore, in the current study there was less 
initial bone ingrowth and a longer time was needed before the cement was completely 
surrounded by bone. Consequently, the manifestation of osteoclasts and degradation 
of the Ca-P cement might occur later. This conﬁrms that the degradation rate of porous 
Ca-P cement is inﬂuenced by various factors such as species, implantation site and 
implant geometry.  
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Fig. 2.7: In vitro release proﬁle of 125I 
rhBMP-2 from porous Ca-P cement scaffolds. 
Iodination of rhBMP-2 and the release assay 
were carried out according to methods 
described in chapter four.48 Error bars 
represent means ± standard deviation for n=3  
5. Conclusions
We conclude that porous Ca-P cement is an appropriate candidate scaffold material 
for bone engineering purposes. This material reveals excellent osteoconductive 
properties and maintains its shape and stability during the formation of new bone. 
Bone formation in porous Ca-P cement scaffolds can be enhanced by lyophilization of 
rhBMP-2 on the scaffolds. Degradation of porous Ca-P cement is species-, implantation 
site- and implant dimension-speciﬁc.
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1. Introduction
Bone tissue is one of the most frequently used tissues for transplantation. The vast de-
mand for bone is due to various reasons, i.e. to ﬁll defects caused by trauma or tumor resec-
tion, reconstruction of congenital malformation and age related decrease of bone mass.
Autogenous bone is the treatment-of-choice to restore and augment osseous 
structures. Unfortunately, insufﬁcient autogenous bone is available for reconstruction 
in many cases. 
Furthermore, autografting is associated with donor-site morbidity. Many complica-
tions like infection, pain, loss of sensibility and hematoma have been described.1 There-
fore, several alternatives to autogenous bone have been investigated. One of these are 
the so called synthetic Bone Graft Substitutes (BGSs).2-5 A BGS could be engineered di-
rectly at the recipient site (orthotopically) or, depending on medical implications such 
as radiation therapy or unfavorable local physical conditions, it could be prefabricated 
ectopically in subcutaneous or intramuscular pockets before being transplanted to the 
recipient site. 
Calcium phosphate (Ca-P) cement is one of the materials currently under investi-
gation for its potential as BGS.6-9 An advantage of cement-like Ca-P materials is that 
they can be injected directly into a bone defect and can be shaped and molded to ﬁt 
the required shape. Further, Ca-P cements are considered to be extremely biocompati-
ble and show fast deposition of new bone at their surface.10,11 Recently, a method has 
been developed within our laboratory to increase the porosity of the cement by creating 
macropores.12 In this way, the degradation rate and tissue ingrowth of the cement were 
enhanced.13 
Besides the scaffold material, another important component in bone regeneration 
are osteoinductive factors like Bone Morphogenetic Protein (e.g. BMP-2). BMP’s play 
an important regulatory role in many steps in bone morphogenesis like chemotaxis, 
differentiation as well as mitosis of cartilage and bone producing cells.14 At this 
moment 15 different kinds of BMPs are known,15 which belong to the Transforming 
Growth Factor (TGF)-ß gene super family. Research especially focuses on the bone 
regenerating properties of  BMP-2 and BMP-7.14,16-19 Both factors are available in large 
quantities by human recombinant technology. BMP-2 also showed osteogenic activity 
at intramuscular20,21 and subcutaneous sites.22-24
Osteoinductive proteins require an appropriate carrier material as delivery 
vehicle.25 However, the role of biomaterials on the osteoinductive activity of BMP is not 
completely clear. A material itself might potentiate the activity of BMP by binding the 
protein and presenting it to target cells in a “bound” form.26,27 For several biomaterials, 
a correlation between growth factor retention and osteoinductivity has been reported.28 
On the other hand, slowly released BMP may provide a physiological concentration of 
free protein in the vicinity of the implant, what may attract target cells to the implant-
site by chemotaxis.29 The optimal retention/release rates for growth factors and their 
carriers have not been established yet. 
In the present study, we hypothesized that rhBMP-2 loaded porous Ca-P cement can 
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induce bone in an ectopic site. rhBMP-2 loaded as well as unloaded preset porous Ca-P 
cement discs were implanted subcutaneously in the rabbit model and compared with the 
current standard for rhBMP-2 delivery, absorbable collagen sponge (ACS). 
2. Materials and methods
Porous calcium phosphate cement implants
In total, 36 disc-shaped porous calcium phosphate (Ca-P) cement implants were 
created by the CO2 induction technique.
12 The implants were made out of Calcibon® 
(Biomet Merck, Darmstadt, Germany). This cement consists of a mixture of 62.5wt% 
tricalcium phosphate (α-TCP), 26.8wt% dicalcium phosphate anhydrous (DCPA), 
8.9wt% calcium carbonate (CaCO3 ) and 1.8wt% hydroxyapatite (HA). To generate 
macroporosity of the scaffold, NaHCO3 was added for production of CO2 gas in the 
cement.
Hundred-twenty µl of an aqueous Na2HPO4 (2% in weight) solution was added to 
the cement, which was placed in a syringe. The syringe was closed with an injection 
plunger and mixed in a mixing device (Silamat® Vivadent, Schaan, Liechtenstein) for 
30 seconds. Thereafter, 150µl NaH2PO4  (8%) was added and thoroughly mixed for 3 
seconds. The newly formed cement was injected immediately into a cylindrical mold 
to ensure a standardized shape of the implants (discs of 2.7 mm height and 8.0 mm 
diameter). The samples were placed into an oven at 50oC for one hour. Afterwards, the 
surface of the discs was sandpapered to ensure a standardized height of 2.7 mm. Finally, 
the discs were air dried and sterilized by autoclaving for 15 minutes at 121 oC. 
The average weight of the discs was 108 ± 7 mg.  Channel –like macropores varying 
from 100 µm to more than 1000 µm in length could be detected. Histomorphometrical 
analysis of the discs before implantation showed that the volumetric macroporosity 
was 36%. Previously, the microporosity (pores < 1 µm) of this cement was shown to 
be 39%.12
Absorbable Collagen Sponge (ACS) implants
Sterile Absorbable Collagen Sponge (ACS) loaded with rhBMP-2, was used as a ref-
erence material (provided by Yamanouchi Europe BV). Under sterile conditions, discs 
were punched out of lyophilized ACS sheets with 8 mm biopsy punches (Stiefel Labora-
tories BV, Veendam, The Netherlands). Prior to this procedure, the material was mois-
tened with H2O under sterile conditions to induce common shrinkage of the material. 
rhBMP-2 loading
The stock solutions of rhBMP-2 (1 mg/ml) were stored frozen at -20°C before use. 
This solution was thawed slowly to refrigeration temperature and was diluted with 
4000 µl buffer to give a total volume of 5000 µl (rhBMP-2 concentration 0.2 mg/ml). 
The dilution buffer (pH 7.2) for both the Ca-P implants and the ACS implants was PBS/ 
BSA [0.1%]. 
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One day before implantation, eighteen calcium phosphate implants were loaded 
with this rhBMP-2 concentration. Twenty-ﬁve µl of diluted rhBMP-2 (0.2 mg/ml) was 
administered to each side of the sterile porous Ca-P implants, which were placed in a 
sterile Eppendorf® tube. In this way, a total dose of 10 µg per implant was achieved. 
Thereafter, the specimens were lyophilized and stored at 4°C until surgery took place.
Fifty µl of the diluted rhBMP-2 solution (0.2 mg/ml) was pipetted carefully onto the 
8 mm diameter cylindrical pieces of the ACS. In this way, 10 µg of rhBMP was present 
per implant (30% soak-load). The ACS discs were allowed to soak-load for minimally 15 
minutes before they were implanted subcutaneously. Care was taken not to squeeze the 
discs to prevent the loss of growth factor.
Surgical procedure 
Fifty-four female New Zealand White rabbits, each weighing 2.8 –3.2 kg, were 
used (De Vaan, Bergharen, The Netherlands). National guidelines for the care and use 
of laboratory animals were observed.  The animals were divided into three groups of 18 
animals (Table 3.1). Each animal received one subcutaneous implant to prevent cross-
over effects of rhBMP-2.
Group No. of rabbits Implant Sacriﬁce of rabbits 
   2 weeks      10 weeks
I 18 Porous Ca-P cement  9  9
II 18 Porous Ca-P cement + rhBMP-2  9  9
III 18 ACS + rhBMP-2 9  9
Table 3.1: Implantation scheme
Surgery was performed under general inhalation anesthesia and sterile conditions. 
The rabbits received antibiotic prophylaxis [Baytril (2.5% Enroﬂoxacin), 5-10 mg/kg] 
before surgery. The anesthesia was initiated by an intramuscular injection of 0.5 ml/
kg Hypnorm® (0.315 mg/ml fentanyl citrate and 10 mg/ml ﬂuanisone) and 0.25 mg 
atropine. Thereafter, the rabbits were intubated and connected to an inhalation venti-
lator with a constant volume of a mixture of nitrous oxide, isoﬂurane, and oxygen.  
Before the insertion of the subcutaneous implants, each animal was immobilized in 
the ventral position and mid dorsum, the skin was shaved and marked with a small tattoo 
to indicate the implantation site. Subsequently, the skin was washed and disinfected 
with povidone-iodine. Paravertebral, at one side of the spinal column, a longitudinal 
incision of about 1.5 cm was made through the full thickness of the skin. Subsequently, 
a subcutaneous pocket towards the tattoo was created by blunt dissection with a pair 
of scissors. The implant then was inserted in this pocket close to the tattoo. Finally, the 
skin was closed intracutaneously using resorbable Vicryl® 4-0 suture material. A total 
of 54 implants were inserted this way.
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Two weeks after implantation, nine animals of each group were euthanized by an 
overdose of Nembutal®. The remaining nine rabbits were euthanized after ten weeks of 
implantation.
At the time of euthanasia the implants with surrounding tissue were retrieved for 
histological analysis. Parallel to this study, a separate study was performed in the same 
animals where identical experimental groups were implanted in the rabbit’s skull.
Fluorochrome labeling
Sequential quadruple ﬂuorochrome labeling, i.e. tetracycline (yellow), alizerin-
complexon (red), calcein (green) and tetracycline (yellow), was performed in four 
rabbits of each group at respectively one, three, seven and nine weeks postoperatively. 
All labels were administered subcutaneously at 25 mg/kg body weight. 
Histological preparations
Directly after retrieval, specimens were ﬁxed in 4% buffered formalin solution, 
dehydrated in a graded series of alcohol and embedded in methylmethacrylate (MMA). 
After polymerisation, non-decalciﬁed thin (10 µm) transverse sections of the implant 
were prepared (at least three of each implant) using a modiﬁed sawing microtome 
technique.30 Methylene blue and basic fuchsin were used for staining the sections. 
Two extra unstained slides (10 µm) were made of the specimens where ﬂuorochrome 
labeling analysis was indicated. 
Histological and histomorphometrical evaluation
The histological evaluation consisted of a concise description of the observed 
specimens and a histomorphometrical analysis of the tissue response using a light 
microscope (Leica Microsystems AG, Wetzlar, Germany). The Leica® Qwin Pro-image 
analysis system (Wetzlar, Germany) was used for the computer based image analysis 
techniques (histomorphometrical evaluation). A reﬂectant ﬂuorescence microscope 
equipped with an excitation ﬁlter of 470-490 nm (Leica Microsystems AG, Wetzlar, 
Germany) was used for the ﬂuorochrome labeling analysis.
All Ca-P cement scaffolds were digitally analyzed. The quantitative measurements 
were performed for all three digitalized sections per implant. Results were based on the 
average of these measurements. ACS implants were not evaluated with this method, 
because no ACS residue or subsequent bone formation could be retrieved after two and 
ten weeks of implantation (see also Results section). 
 
The following parameters were assessed for histomorphometrical analysis:
• The surface of the area where the implant is inserted, which is called the region of 
interest (ROI).
• The bone surface area and the cement surface area [expressed as a percentage of the 
ROI]. The cement surface area included microporosity of the cement, since pores 
smaller than 1 µm could not be distinguished histomorphometrically from cement 
particles.
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• The (macro)pore surface area [%], calculated from the ROI minus the cement surface 
area and bone surface area. 
• Pore ﬁll by bone [%], expressed as percentage of pore surface area occupied by bone.
Statistical analysis
Data for all parameters of the of rhBMP-2 loaded and unloaded porous Ca-P cement 
implants were compared among and within groups using an unpaired T-test with Welch 
correction. All statistical analyses were performed with GraphPad® Instat 3.05 software 
(GraphPad Software Inc, San Diego, CA, USA). Differences were considered signiﬁcant 
at p-values less than 0.05.
3. Results
Experimental animals
In this study, all 54 animals survived the procedure without any sign of disease 
or wound complications. Thirty-six porous Ca-P implants (group I and II) could be 
retrieved. At retrieval, no inﬂammatory signs or adverse tissue reaction could be 
observed. All implants were surrounded by a thin ﬁbrous capsule.
On the contrary, none of the ACS implants (group III) could be detected and even 
after microscopical evaluation of the area surrounding the tattoo, no ACS residue or 
signs of bone formation were observed. 
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Fig. 3.1: Overview of representative sections of 
subcutaneous Ca-P cement implants retrieved after  
two and ten weeks. Original magniﬁcation 2.5x.  
Bar represents 1 mm 
Light microscopy 
Two weeks specimens
Analysis revealed that all Ca-P cement implants had maintained their shape. A 
thin ﬁbrous capsule surrounded the implants. Ingrowth of blood vessels and loose 
connective tissue were present in all macropores throughout the scaffolds. Little or no 
inﬂammatory cells could be observed at the cement surface. None of the porous Ca-P 
implants (group I and II) showed bone or cartilage formation after two weeks (Fig. 3.1A 
and 3.1C).
Ten weeks specimens
Ten weeks postoperatively, all Ca-P implants had maintained their shape. The ﬁbrous 
capsule around the discs had a more mature appearance and blood vessel ingrowth was 
more prominent than in the two weeks sections. Bone formation was observed in all 
rhBMP-2 loaded Ca-P cement implants, but was absent in the unloaded Ca-P cement 
discs (Fig 3.1). Bone formation in the rhBMP-2 loaded specimens was characterized 
by the presence of osteoblasts and osteocyte-like cells embedded in the matrix 
(Fig. 3.2). The newly formed bone had a lamellar appearance. Bone remodeling was seen 
in some sections. Bone formation was diffusely spread throughout the macropores of 
the whole implant. Formation of cartilage or bone outside the cement was not observed 
in any of the Ca-P cement scaffolds. 
Fluorescence microscopy
The ﬁrst yellow Tetracycline label and the red Alizerin-Complexon label, admin-
istered after one and three weeks respectively, were not detected. On the other hand, 
the green Calceine label and the second yellow Tetracycline label, indicative for bone 
formation after seven and nine weeks, were clearly visible in the bone formation in the 
rhBMP-2 loaded Ca-P cement implants (Fig. 3.3). 
 
Fig. 3.2: Light microscopic aspect of bone 
formation in rhBMP-2 loaded porous 
Ca-P cement implants after ten weeks 
of implantation. OB= osteoblasts, BM= 
bone marrow, BV= blood vessel. Original 
magniﬁcation 10x. Bar represents 100 µm. 
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  Bone surface (% of ROI) Pore ﬁll (%)
Porous Ca-P  0 ± 0% 0 ± 0%
Porous Ca-P  + rhBMP-2 7 ± 3% ** 18 ± 6% **
Table 3.2: Histomorphometrical analysis of ectopic bone formation after  
ten weeks of implantation (means ± standard deviation for n=9 ** p<0.05). 
Histomorphometry
Histomorphometrical results are summarized in Table 3.2. As previously described, 
bone formation was only present in the ten weeks rhBMP-2 group. In this group, total 
bone surface was 7 ± 3% of the scaffold’s ROI. This resembled a pore ﬁll percentage of 18 
± 6%. After two and ten weeks of implantation, the macroporosity was not signiﬁcantly 
changed in both groups. 
4. Discussion
In this study, we investigated the osteoinductive characteristics of rhBMP-2 loaded 
and unloaded porous preset Ca-P cement discs at an ectopic site in rabbits. As reference 
material, rhBMP-2 loaded ACS discs were implanted similarly. 
After two and ten weeks, implants were retrieved from their subcutaneous pockets. 
All Ca-P discs had maintained their shape and stability. This observation suggests that 
the mechanical properties of this porous Ca-P cement are sufﬁcient to serve as scaffold 
material for subcutaneous bone engineering. On the contrary, none of the ACS discs 
could be retrieved. Despite widespread searching, no ACS residue or subcutaneous 
bone formation were observed. Bone formation in the vicinity of the tattoo could not be 
conﬁrmed histologically. Therefore, we conclude that the ACS has been degraded com- 
pletely within two weeks. This rapid degradation of the ACS sponge was also observed 
in the cranial defect study that was performed in the same rabbits.31 In contrast to 
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Fig. 3.3: Fluorescence microscopy image 
of rhBMP-2 loaded Ca-P cement implant 
after ten weeks of implantation. Formation 
of bone started at the cement surface and 
proceeded into the macropore. C=calceine 
label, administered after seven weeks 
of implantation (green). T=tetracycline 
label, administered after nine weeks 
of implantation (yellow). Original 
magniﬁcation 20x. Bar represents 50 µm.
studies dealing with rhBMP-2 loaded ACS in subcutaneous pockets in rats,28,32 ectopic 
bone formation was not observed in the rhBMP-2 loaded ACS implants. We assume 
that the absence of bone formation in the current study is due to the spongy nature of 
the ACS, which causes rapid dispersion of the rhBMP-2 directly after implantation. This 
explanation is supported by the ﬁndings of Friess et al., who reported that the fraction 
of rhBMP-2 retained in the ACS in subcutaneous sites is less than 10% after 10 days,33 
which is perhaps too low to induce bone formation. Further the implantation site could 
have an effect on ectopic bone formation. For example, Yoshida et al. described that 
subcutaneous implantation is less favorable for rhBMP-2 induced bone formation com-
pared to intramuscular or intermuscular implantation.24 This suggests that although rh-
BMP-2 loaded ACS is a powerful osteoinductive material in other locations,34,35 it could 
be less suitable for subcutaneous prefabrication of bone graft substitutes. 
Histomorphometrical analysis determined that bone formation in the rhBMP-2 
loaded porous Ca-P cement discs reached a pore ﬁll of 18 ± 6% after ten weeks of im-
plantation. As the two weeks light microscopical sections did not show bone deposi-
tion or cartilage formation, and the three weeks ﬂuorescent Alizerin-Complexon label 
was never observed, it could be supposed that direct bone formation started after three 
weeks of implantation. Some studies even suggested that calcium phosphate biomateri-
als show osteoinductive characteristics in soft tissues without administration of growth 
factors or osteoblastic cells.36,37 However, this suggestion could not be conﬁrmed by the 
present study because unloaded porous Ca-P cement discs did not show any bone for-
mation after subcutaneous implantation up to ten weeks. 
The sequence of the ﬂuorescent labels also conﬁrmed that bone formation started at 
the cement surface and subsequently proceeded into the center of the macropores. This 
observation agrees with previously reported bone deposition in porous ceramics31,38 and 
illustrates the osteocompatibility of porous Ca-P cement. Furthermore, it is opposite to 
bone formation in other scaffold materials like titanium ﬁber mesh, which is reported 
to start in the center of the pore.39,40
Finally, histomorphometrical analysis included quantiﬁcation of the cement surface 
as indicator of macroporosity and implant degradation. Degradation of the cement 
was not observed in this study. In previous studies, degradation of similar porous Ca-
P cement varied from none to 80% after ten weeks.13,31 It is known that the presence 
of bone -and thus osteoclasts- is essential for degradation of Ca-P material. Ideally, 
bone formation and scaffold degradation follow one another progressively until the 
biomaterial has been replaced completely by new bone. As long as bone formation is 
not extensive enough to supply mechanical strength, the scaffold material should not 
be degraded too quickly to assure stability of the construct. We think that the limited 
extent of bone formation in the rhBMP-2 loaded Ca-P cement discs after ten weeks does 
not justify signiﬁcant degradation of the Ca-P cement at this phase. Furthermore, in 
the orthotopic implants, no degradation of the porous Ca-P cement discs was observed 
either, while these implants showed an extensive bone ﬁll up to 53.0 ± 5.4%.31 This is 
in contrast to a previous study in goats, where porous Ca-P cement implants inserted in 
the femoral condyle showed 80% degradation within ten weeks.13 This illustrates that 
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degradation of Ca-P cement depends on various parameters such as implant dimension, 
species and implantation site. 
5. Conclusions
In summary, we conclude that porous Ca-P cement is a suitable carrier material for 
ectopic bone engineering. Although the amount of bone formation in this study was 
limited, porous Ca-P cement in combination with rhBMP2 revealed osteoinductive 
properties and maintained its shape and stability during subcutaneous implantation in 
New Zealand white rabbits for ten weeks. 
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1. Introduction
Porous biodegradable polymers and ceramics are frequently used as scaffold materi-
als in bone tissue engineering approaches. Among the various available biodegradable 
polymers, aliphatic polyesters of poly(lactic acid), poly(glycolic acid), and poly(DL-lac-
tic-co-glycolic acid) (PLGA) are popular because of the long clinical experience, favor-
able degradation characteristics and possibilities for sustained drug delivery. PLGA can 
be processed into spherical microparticles for delivery of bioactive molecules. In light 
of this, PLGA microparticles have been thoroughly investigated as delivery vehicles 
for transforming growth factor-ß1 (TGF-ß1), recombinant human bone morphoge-
netic protein-2  (rhBMP-2), and other molecules.1-6 Polymer degradation and drug re-
lease rates from these microparticles can be adjusted by altering the polymer molecular 
weight, copolymer ratio and the microparticle size and structure. These rates are also 
inﬂuenced by environmental factors such as pH which can decrease because of physi-
ological (inﬂammation phase of wound healing) or iatrogenic (PLGA degradation prod-
ucts) conditions.  
Calcium phosphate (Ca-P) materials are widely used as bone substitutes in ortho-
paedic, reconstructive, and oral surgery due to their beneﬁcial effect on bone healing. 
Manufacturing of Ca-P ceramics usually requires processing at elevated temperatures. 
Most Ca-P ceramics, therefore, are available for implantation only as granules or prefab-
ricated blocks. Unfortunately, granules can easily migrate into the surrounding tissue 
and prefabricated blocks are difﬁcult to shape and may result in incomplete ﬁlling of the 
bone defect. A solution for these processing and delivery problems can be found in an 
injectable Ca-P cement that can be shaped according to the defect dimensions. Although 
injectable Ca-P cement reveals excellent biocompatibility and osteoconductivity, in 
vivo resorption and tissue ingrowth is slow.7 These limitations may be overcome by the 
generation of a macroporous structure within a Ca-P implant.7 Compressive strength of 
a macroporous cement, however, is greatly decreased.8 
Growth factors have been added to injectable Ca-P ceramics either before setting of 
the cement9-11 or after complete setting.12,13 In these studies, a solution containing the 
growth factor was directly mixed with the Ca-P powder or absorbed onto the cement 
surface. When in vitro release was determined, it was shown to be rather slow (3-13% 
after two weeks).9,11,13 In case of a non-macroporous structure, prolonged retention of 
entrapped proteins might result in their loss of osteoinductive potential. Therefore, we 
presume that delivery of growth factors from injectable Ca-P cements can be optimized. 
We hypothesize that incorporation of rhBMP-2 loaded microparticles in Ca-P ce-
ment is feasible and will result in a sustained release of bioactive protein under various 
conditions. The aim of our research is to develop an injectable composite based on Ca-P 
cement with PLGA microparticles as the delivery vehicle for rhBMP-2. Controlled re-
lease of the growth factor from the microparticles should result in a continuous level of 
bioactive protein delivered in the surrounding tissues. Also, degradation of the PLGA 
microparticles should result in a macroporous Ca-P cement structure that allows for 
increased bone ingrowth. Additionally, the resulting macroporosity should expedite 
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the degradation of the Ca-P cement scaffold. In this study, we focus on the composite 
preparation and determination of the rhBMP-2 release kinetics. 
2. Materials and methods
Materials
RhBMP-2 was generously supplied by Yamanouchi Europe BV., Leiderdorp, The 
Netherlands. 125I (Amersham Pharmacia Biotech, Piscataway, NJ, USA) was used to 
label rhBMP-2 with the Iodo-Gen® tube according to the manufacturer’s instructions 
(Pierce, Rockford, IL, USA). Iodination was kindly done by Chrysalis Biotechnology 
Inc., Galveston TX, USA. Poly(DL-lactic-co-glycolic acid) (PLGA) with a 50:50 lactic to 
glycolic acid copolymer ratio (Medisorb®) was obtained from Alkermes, Cincinnati, OH, 
USA. The molecular weight (Mw) of PLGA was 47.6 ± 0.5 kDa and the polydispersity 
index (PI) was 1.73 ± 0.05 as determined by gel permeation chromatography. Ancillary 
chemicals for microparticle preparation were all of analytical grade and obtained as 
previously described.3 Ca-P cement (Calcibon®) was received from Biomet Merck, 
Darmstadt, Germany. The powder component of this material consisted of a mixture 
of 62.5 wt% tricalcium phosphate (α-TCP),  26.8 wt% dicalcium phosphate anhydrous 
(DCPA), 8.9 wt% calcium carbonate (CaCO3) and 1.8 wt% hydroxyapatite (HA). An 
aqueous solution of Na2HPO4 (2 wt%) was used as the liquid component. 
Preparation of 125I rhBMP-2 loaded PLGA  
microparticles 
The rhBMP-2 solution used in this study was produced by adding a trace amount 
of 125I labeled rhBMP-2 to an unlabeled rhBMP-2 solution (hot:cold rhBMP-2 = 1:100). 
The hot/cold rhBMP-2 solution was diluted in a buffer solution of phosphate buffered 
saline and bovine serum albumin (PBS/BSA[0.1%]) to a ﬁnal concentration of 1.6 mg/
ml. PLGA microparticles were prepared by a double-emulsion-solvent-extraction tech-
nique ([water-in-oil]-in-water) as previously described.3,6,14 The microparticles were 
produced by injecting 125 µl hot/cold solution (200 µg rhBMP-2) into a ﬂint glass tube 
containing a solution of 242.3 mg PLGA in 1 ml dichloromethane. This mixture was 
emulsiﬁed for 60 seconds on a vortexer (Vortex Genie 2, Scientiﬁc Industries, Bohemia, 
NY, USA). Subsequently, 1.5 ml 0.3% aqueous poly(vinyl alcohol) (PVA) solution was 
added and emulsiﬁed for 60 seconds on a vortexer to produce the second emulsion. The 
mixture was then added to 98.5 ml PVA solution and 100 ml of 0.2% aqueous isopro-
panol solution with rapid stirring for 1 hour. The extraction of the dichloromethane 
into the external aqueous phase resulted in the precipitation of the dissolved polymer 
and subsequent microparticle formation. The formed microparticles were collected, 
centrifuged at 1000 rpm for 2 minutes, lyophilized, weighted, and stored at –20°C 
until use. The entrapment efﬁciency of the protein was determined by normalizing the 
amount actually entrapped with the amount added to the fabrication process. A calibra-
tion curve was generated through serial dilutions of the 125I-rhBMP-2 stock solution 
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to determine the quantity of rhBMP-2 (µg/mg microparticle), using a gamma counter 
(Cobra II Autogamma, Packerd, Meridian, CT, USA). 
Preparation and characterization of blank PLGA  
microparticles 
Blank microparticles were prepared according to the previously described proto-
col, using PBS/BSA[0.1%] without rhBMP-2 as the ﬁrst aqueous phase. The size of the 
microparticles was measured with a Coulter Counter Multisizer (model 0646, Coulter 
Electronics, Hialeah, FL, USA). The morphology of the microparticles was evaluated 
by scanning electron microscopy (SEM) (Jeol JSM-5300 Scanning Microscope, Boston, 
MA, USA).
Preparation of 125I-rhBMP-2 PLGA/Ca-P cement  
composite
For the preparation of 125I-rhBMP-2 loaded PLGA/Ca-P cement discs, a mixture of 
blank PLGA microparticles and 125I-rhBMP-2 loaded PLGA microparticles (50:50 wt%) 
was used to achieve a rhBMP-2 dosage of approximately 5 µg per disc. This mixture of 
PLGA microparticles was added to the Ca-P cement powder in a PLGA:Ca-P weight ratio 
of 30:70. A 3 ml syringe (Becton Dickinson & Co, Franklin Lakes, NJ, USA) was closed 
at the tip with a plastic stopper and ﬁlled with  700 mg  of this PLGA/Ca-P mixture. 
After adding 300 µl of Na2HPO4 (2 wt%), the syringe was closed with the injection 
plunger and placed in a mixing apparatus (Silamat, Vivadent, Schaan, Lichtenstein). 
After mixing for 15 seconds, the stopper was removed and the composite was injected 
in Teﬂon molds (6.35 mm Ø * 2.4 mm). The discs were removed from the molds after 
setting of the cement at room temperature for one hour. Radioactivity in the discs was 
determined by a gamma counter (Cobra II Autogamma, Packerd, Meridian, CT, USA) to 
quantify the initial amount of rhBMP-2 per disc. 
Preparation and characterization of blank  
PLGA/Ca-P cement composite
Similar to preparation of the 125I-rhBMP-2 loaded PLGA/Ca-P cement discs, blank 
PLGA/Ca-P cement and control discs (Ca-P cement without PLGA microparticles) were 
prepared. The specimens were used for Ca-P cement cytotoxicity assessment, analysis 
by SEM and microcomputed tomography (µCT) (Scanco Medical, µCT 80, resolution 
10 µm, Bassersdorf, Switzerland) and mechanical testing (scaffold dimensions 6.0 mm 
Ø * 12.0 mm). Discs used for cytotoxicity assessment were sterilized by autoclaving for 
15 minutes at 121°C.
Mechanical testing of PLGA/Ca-P cement composites
For mechanical testing, ﬁve PLGA/Ca-P cement composite and ﬁve control cylinders 
were removed from the molds after one day of setting. Subsequently, the cylinders were 
soaked in Ringer solution (NPBI BV, Emmer-Compascuum, The Netherlands) for 3 days 
at 37°C. Samples were placed in a mechanical testing bench (Instron TT-CM, Instron 
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Corporation, Canton, MA, USA) and compressive strength was measured at a cross- 
head speed of 1 mm/minute. 
Cytotoxicity assay for Ca-P cement
For the in vitro cytotoxicity assay, the viability of pre-cultured cells was assessed 
after exposure to conditioned medium of different dilutions (1:1, 1:10, 1:50, 1:100). 
Three Ca-P cement discs were incubated in 1 ml culture medium (Dulbecco’s modiﬁed 
Eagle’s medium supplemented with 10% fetal bovine serum [FBS], 4% L-Glutamine 
and 0.5% gentamicin) at 37°C, 95% relative humidity and 5% CO2 in 24 well tissue 
culture plates. The conditioned medium was removed after 24 hours and diluted 0, 
10, 50 and 100 times with unconditioned medium. Meanwhile, W20 c17 cells (20th 
passage, ATCC, Manassas, VA, USA) were pre-cultured in culture medium on 96 well 
tissue culture plates at a density of 40.000 cells/cm2 (10.000 cells/well) at 37°C, 95% 
relative humidity and 5% CO2 for 24 hours. Then, the culture medium was removed 
and the cells were exposed to 100 µl of (diluted) conditioned medium at 37°C, 95% 
relative humidity and 5% CO2 for 24 hours. 
After 24 h, the conditioned medium was removed and the cells were rinsed with a 
PBS solution twice to remove any remaining conditioned medium. Then, 100 µl LIVE/
DEAD reagent (Molecular Probes Inc., Eugene, OR, USA) were added to each sample 
well and incubated in darkness for 30 minutes at room temperature. The resulting 
ﬂuorescence was measured using a ﬂuorescence microplate reader (FLx800, BIO-TEK 
Instrument, Winooski, VT, USA). Cells cultured without exposure to conditioned 
medium were used as positive control (live) and cells exposed to 70% methanol solution 
for 30 min served as negative control (dead).
In vitro 125I-rhBMP-2 release kinetics 
In vitro release kinetics of 125I-rhBMP-2 loaded PLGA microparticles (10 mg 
blank/loaded microparticle mixture [50:50 wt%] per sample) and 125I-rhBMP-2 
Fig. 4.1: Scanning electron 
micrograph of PLGA microparticles, 
showing the spherical shape of the 
microparticles.  
Bar represents 10 µm.
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loaded PLGA/Ca-P cement discs were evaluated. Release kinetics of rhBMP-2 were 
studied at physiologic pH 7.4 (PBS, Gibco, Grand Island, NY, USA) and acidic pH 4.0 
(B-79 certiﬁed buffer, Fisher Chemical, Fair Lawn, NJ, USA). Buffer solutions were 
supplemented with 100 µg/ml ampicillin as antibiotic prophylaxis. Samples (n=4 for 
each group) were incubated in glass vials containing 3 ml buffer solution at 37°C on a 
shaker table (70 rpm) for 28 days. At 1, 4, 7, 14, 21 and 28 days, the buffer solutions 
were carefully removed and stored at –20°C until analysis. Subsequently, the samples 
were resuspended in fresh buffer. All gamma emission measurements were corrected 
for radioactive decay by assuming 125I half-life of 59.4 days.
Statistical analysis
GraphPad® Instat 3.05 software (GraphPad Software Inc, San Diego, CA, USA) was 
used for statistical evaluation using an unpaired t-test with Welch correction for the 
mechanical testing and a one-way analysis of variance (ANOVA) with Dunnett multiple 
comparison post test for the cytotoxicity assay.
Fig. 4.2: Microcomputed 
tomography image of 30/70wt% 
PLGA/Ca-P cement composite.  
In the µCT reconstruction, PLGA 
microparticles appear as pores in 
the Ca-P cement.  
Bar represents 1 mm.
Fig. 4.3: Scanning electron 
micrography image of 30/70 
wt% PLGA/Ca-P cement 
composite. Several different sized 
microparticles surrounded by 
microporous Ca-P cement can be 
observed.  
Bar represents 20 µm.
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3. Results
 
Preparation and characterization of  
(125I rhBMP-2 loaded) PLGA microparticles 
PLGA microparticles were fabricated by a double-emulsion-solvent-extraction 
technique as previously described.3,6,14 The average size of the microparticles was 17.2 
± 1.3 µm. SEM analysis conﬁrmed the spherical shape and the size distribution of the 
microparticles (Fig. 4.1). Gamma counting revealed that entrapment efﬁciency of 125I 
rhBMP-2 was 79 ± 8%, resulting in a dosage of 0.72 µg rhBMP-2 per mg microparticle. 
Preparation and characterization of  
PLGA/Ca-P cement composite
125I-rhBMP-2 loaded PLGA/Ca-P cement discs were prepared according to the 
described protocol. Discs of 6.35 mm diameter and 2.4 mm thickness had an average 
weight of 76.1 ± 2.6 mg. 125I-rhBMP-2 loading was 5.0 ± 0.4 µg per disc as determined 
by gamma emissions after preparation of the discs. µCT analysis showed a homogeneous 
distribution of the microparticles throughout the scaffold (Fig. 4.2). SEM pictures 
showed that the microparticles maintained their integrity during incorporation into the 
Ca-P cement (Fig. 4.3).
Mechanical testing of PLGA/Ca-P cement composites
Five PLGA/Ca-P cement composite scaffolds and ﬁve Ca-P cement scaffolds 
(controls) were tested in a mechanical testing bench. Results of mechanical testing are 
depicted in Fig. 4.4. Compressive strength was signiﬁcantly lower for the PLGA/Ca-P 
cement composite scaffolds (6.4 ± 0.6 MPa) than for the control scaffolds (38.6 ± 2.6 
MPa). 
Cytotoxicity assay Ca-P cement
Results of the cytotoxicity assay are shown in Fig. 4.5. Exposure of conditioned 
medium to pre-cultured W20 c17 cells for 24 hours did not signiﬁcantly affect the 
viability of the cells compared to exposure of unconditioned medium. 
Fig. 4.4: Results of mechanical 
testing of Ca-P cement and PLGA/
Ca-P cement composite. Error bars 
represent the mean and standard 
deviation for n=5. The asterisk 
indicates a signiﬁcant difference 
between the groups (p<0.001).
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In vitro 125I-rhBMP-2 release kinetics 
In vitro release kinetics of rhBMP-2 for rhBMP-2 loaded PLGA microparticles 
(initial loading 3.6 ± 0.0 µg rhBMP-2/sample) and rhBMP-2 loaded PLGA/Ca-P cement 
discs (initial loading 5.0 ± 0.4 µg rhBMP-2/disc) were evaluated in two different buf-
fers over the course of 28 days (n=4 for each formulation). All discs maintained their 
integrity during this period. Normalized cumulative mass release from all samples is 
depicted in Fig. 4.6. None of the formulations displayed a substantial initial burst re-
lease. At physiological pH (7.4), the PLGA/Ca-P discs showed an initial release of 1.1 
± 0.1% after 24 hours, followed by a linear, but marginal release (0.1%/day) resulting 
in a total cumulative release of 3.1 ± 0.1% after 28 days. PLGA microparticles showed 
an initial release of 2.4 ± 0.3% after 24 hours, followed by a linear release  of 0.5% per 
day. By day 28, 18.0 ± 1.9% of the total actual loaded rhBMP-2 was released. In an acidic 
environment (pH 4.0), PLGA/Ca-P discs revealed a greater release of rhBMP-2 after 28 
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Fig. 4.5: Results of LIVE-DEAD 
cytotoxicity assay of Ca-P cement.  
Normalized viability, based on 
total ﬂuorescence, is displayed for 
cells exposed to unconditioned 
medium (control) and cells exposed 
to conditioned medium in different 
dilutions. Error bars represent the 
mean and standard deviation for n=3. 
Variation among LIVE bar means was 
not signiﬁcantly greater than expected 
by chance (p> 0.05).
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Fig. 4.6: In vitro release of rhBMP-
2 loaded PLGA microparticles and 
PLGA/Ca-P cement composite in pH 
7.4 and pH 4.0 under continuous 
shaking at 37°C, expressed as the  
ratio of total cumulative mass of 
rhBMP-2 released to total mass of 
rhBMP-2 entrapped. Error bars 
represent the mean and standard 
deviation for n=4. 
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days than PLGA microparticles alone (14.5 ± 6.3% vs. 5.4 ± 0.7%). PLGA microparti-
cles at pH 4.0 showed an initial release similar to the release of microparticles at pH 7.4 
(2.4 ± 0.5% vs. 2.4 ± 0.3% after 24 hours), but release after day 1 was minimal. In the 
composite group, an increase in the release of rhBMP-2 into the acidic environment 
was observed from day 21 to day 28. This phenomenon was not observed in the PLGA 
microparticle group at pH 4.0. 
4. Discussion
This study focused on the preparation of an injectable composite material of 
rhBMP-2 loaded PLGA microparticles and a Ca-P cement. We hypothesized that incor-
poration of rhBMP-2 loaded microparticles in a Ca-P cement would result in a sustained 
release of rhBMP-2 under neutral and acidic conditions. 
With some PLGA microparticles fabrication techniques, rhBMP-2 is absorbed on 
the surface after preparation of the microparticles.15-18 This method may be advanta-
geous with respect to entrapment efﬁciency because no proteins are lost during the fab-
rication process. On the other hand, it does not provide encapsulation of proteins, and 
therefore the possibilities of a controlled release. It seems less suitable for our PLGA/
Ca-P composite as the high protein concentration present at the outer surface of the 
microparticles might interfere with the setting reaction of the cement.19 Therefore, 
PLGA microparticles were produced and loaded with rhBMP-2 by an established tech-
nique which produced microparticles with similar dimensions as reported in previous 
papers.1,3,6,14
Pilot studies had conﬁrmed that microparticles can indeed be incorporated into a 
Ca-P cement at various PLGA/Ca-P ratios up to 50/50wt%. For this study, an inter-
mediate PLGA/Ca-P ratio of 30/70wt% was chosen. Mechanical testing of this for-
mulation showed that this composite was signiﬁcantly weaker than Ca-P cement with-
out PLGA microparticles, but stronger than previously described macroporous Ca-P 
cement.7 Whereas the cytotoxicity of PLGA has already been investigated thoroughly, 
this study demonstrated that the Ca-P cement exhibits no cytotoxic effects.  
A dosage of 5 µg rhBMP-2 per 75 mm3 scaffold has been shown to be within the 
therapeutical range of this growth factor in rats and rabbits.12,13,20,21 We achieved this 
dosage with a 50/50wt% ratio of rhBMP-2 loaded/unloaded microparticles. Conse-
quently, the dosage of rhBMP-2 within the scaffold can be adjusted by altering the load-
ed to unloaded microparticle ratio without altering the composite properties.   
An entrapment efﬁciency of rhBMP-2 in PLGA microparticles was 79 ± 8% was 
achieved. This percentage is within the range of previously published studies that var-
ied in entrapment between 37% and 91%.2,3,6,22 It must be emphasized however, that 
drug properties, drug concentration, and polymer composition play an important role 
in entrapment efﬁciency.3,6 In the current study, the inﬂuence of these parameters upon 
the entrapment of rhBMP-2 into PLGA microparticles was not explored. The formula-
tion used was chosen based upon the results of previous studies. For example, in order 
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to minimize rhBMP-2 loss, poly(ethylene glycol) (PEG) was not added as it has been 
shown that the addition of PEG negatively inﬂuences the entrapment efﬁciency of TGF-
ß1 in PLGA microparticles fabricated with the same method.3 
The release kinetics of our composite in two buffer solutions i.e. neutral (pH 
7.4) and acidic (pH 4.0) were investigated. An acidic pH buffer was used to simulate 
inﬂammatory phase of wound healing and degradation of the polymer. In addition, 
the release kinetics of rhBMP-2 loaded PLGA microparticles alone was determined 
for use as a control. Release of rhBMP-2 was very limited for all formulations. In the 
PLGA microparticle control group, 18.0 ± 1.9% of the rhBMP-2 was released after 
28 days. This release is marginal compared to previous studies under similar, but in 
some possibly important respects, different conditions. For example, Lu et al. found 
a cumulative release from PLGA microparticles of 68% (loading density 6.0 ng TGF-
ß1/mg PLGA) after 28 days with the co-encapsulation of FITC-BSA (loading density 
4 µg/mg PLGA).3 Peter et al. determined a cumulative TGF-ß1 release of 33% (loading 
density 6.0 ng TGF-ß1/mg PLGA/PEG blend with 0.5% PEG) after 28 days under co-
encapsulation of FITC-dextran (loading density 10 µg/mg PLGA/PEG).6 Hedberg et al. 
showed a cumulative release of 62% (loading density 204 µg TP 508/mg PLGA) after 
28 days without co-encapsulation, but the bioactive molecule released was very small 
(23 amino acid peptide) compared to rhBMP-2 and TGF-ß1.1 In the current study, PBS/
BSA[0.1%] buffer was used as dilution agent for rhBMP-2 solution as recommended 
by the manufacturer of rhBMP-2. The amount of co-encapsulated BSA was minimal 
compared to the amount of co-encapsulated molecules in the studies of Lu et al. and 
Peter et al. Therefore, we hypothesize that the amount of co-encapsulated protein may 
inﬂuence the ﬁnal rhBMP-2 release proﬁle. 
The composite material revealed a release of 3.1 ± 0.1% after 28 days under neutral 
conditions. The difference with the PLGA microparticles control group (18.0 ± 1.9%) 
was signiﬁcant. The physical entrapment of microparticles within the nanoapatitic 
porous cement23 may have contributed to the limited release of rhBMP-2 from the 
PLGA/Ca-P composites. A high binding afﬁnity for proteins exhibited by ceramics9 may 
have diminished the amount of rhBMP-2 released from the composite. After release 
from the PLGA microparticles, rhBMP-2 may have bound to the Ca-P cement resulting 
in delayed release from the composite. Thus, the nanoporosity of the Ca-P cement not 
only did not facilitate the release of rhBMP-2 but may have further limited it due to the 
protein absorption on the ceramic.
An acidic environment increased the release of rhBMP-2 from the composite material. 
However, release in the PLGA microparticle control group was decreased compared to 
neutral conditions. Therefore, it appears unlikely that PLGA in the composite plays a 
role in the observed increase of release. On the contrary, it is known that Ca-P cement 
dissolves in an acidic environment. Consequently, Ca-P cement bound rhBMP-2 might 
be released after dissolving of the Ca-P cement. This phenomenon also supports our 
earlier suggestion that rhBMP-2 binds to the surrounding Ca-P immediately after 
release from the PLGA due to the high binding afﬁnity of proteins for Ca-P cement. 
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5. Conclusions
This study demonstrated the feasibility of fabrication of an injectable calcium 
phosphate cement embedded with biodegradable polymeric microparticles loaded 
with rhBMP-2.  The results show that the composite composition and nanostructure 
as well as the environmental pH inﬂuence rhBMP-2 release from the composites. The 
data further suggest that the afﬁnity of the protein to the ceramic carrier inﬂuences the 
amount of protein released and factors altering the dissolution of the ceramic carrier 
such as pH affect the release kinetics. Finally, this study demonstrates that the Ca-P 
cement exhibits no cytotoxic effects.  
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1.  Introduction
Calcium phosphate (Ca-P) ceramics are widely used as bone substitutes in dentistry, 
orthopedic and reconstructive surgery due to their biocompatibility and osteoconductiv-
ity. Production of these ceramics usually involves processing at high temperatures which 
results in highly crystalline materials, clinically available as either granules or prefabri-
cated (porous) blocks. Despite their favorable biological behavior, granules do not pro-
vide dimensional stability and can easily migrate or disperse into the surrounding tissue. 
Prefabricated blocks, on the other hand, are difﬁcult to shape, resulting in poor contour 
or incomplete ﬁlling of the bone defect. To overcome these disadvantages, injectable Ca-
P materials have been in development since the early 1980’s.1,2 Injectable Ca-P cements 
consist of a powder containing one or more solid compounds of calcium phosphate salts 
and an aqueous cement liquid. Mixed in an appropriate ratio, a paste is formed which 
sets at body temperature by entanglement of the crystals precipitating within the paste. 
Therefore, Ca-P cements can be shaped according to the defect dimension and set in situ. 
After setting, the Ca-P crystals typically form a microporous structure with pores smaller 
than 1 µm.3,4 Currently, several injectable Ca-P cements are marketed with slight differ-
ences in chemical composition, setting time, strength and resorbability.5-7 
In vivo resorption of Ca-P cements is mainly due to cellular activity. Small particles 
can be phagocytozed by multinucleated cells such as macrophages and foreign body giant 
cells.3 Resorption of larger volumes of material occurs by osteoclasts at the bone-cement 
surface. Currently marketed injectable Ca-P cements do not possess a macroporous 
structure which enables bone ingrowth. Consequently, the ratio of surface area to volume 
is low and the resorption rate is slow.8,9 
Considering the resorption pathway, we demonstrated that the resorption rate of Ca-
P cements can be improved by increasing the porosity of the material. In a recent study we 
increased the porosity of Ca-P cement by creation of gas bubbles during the fabrication 
process.4 An experimental animal study in goats demonstrated that such porous Ca-P 
cement was resorbed almost completely within ten weeks.10 
Another approach to induce macroporosity (pore size ≥ 15 µm) is the integration of 
degradable polymeric microparticles into the Ca-P cement. Poly(DL-lactic-co-glycolic 
acid) (PLGA) is a synthetic polymer that is known to degrade by non-enzymatical 
hydrolysis of its ester linkages.11 Incorporation of PLGA microparticles would therefore 
result in a macroporous Ca-P cement structure after PLGA hydrolysis. Additionally, the 
inclusion of degradable microparticles enables a method for sustained delivery of growth 
factors, as we demonstrated in a recent in vitro study.12 
The aim of this study was to investigate the in vivo tissue response to PLGA/Ca-P 
cement composites in both osseous and non-osseous sites. We hypothesized that 
incorporation of PLGA microparticles would result in a macroporous Ca-P scaffold after 
degradation of the PLGA. Additionally, we hypothesized that incorporation of PLGA 
microparticles would potentiate the ingrowth of bone and connective tissue and would 
accelerate degradation of the material. This ﬁrst in vivo study should be regarded as a proof 
70
B
io
co
m
p
at
ib
il
it
y 
an
d
 D
eg
ra
d
at
io
n
 o
f P
LG
A
/
C
a-
P 
C
em
en
t C
om
p
os
it
es
of concept for this novel composite material, investigating a range of compositions with a 
limited number of experimental animals. To assure sufﬁcient statistical power for testing 
of our hypotheses, this study was carried out using an animal model with several small 
implants per animal and evaluation at one relevant implantation time period only.
 
2. Materials and methods
 
2.1 Materials
Poly(DL-lactic-co-glycolic acid) (PLGA) with a 50:50 lactic to glycolic acid copoly-
mer ratio was obtained from Alkermes, Cincinnati, OH, USA. The molecular weight 
(Mw) of PLGA was 47.6 kDa and the polydispersity index (PI) was 1.73 as determined 
by gel permeation chromatography. Ancillary chemicals for microparticle preparation 
were all of analytical grade and obtained as previously described.12 The Ca-P cement 
(Calcibon®, Biomet Merck, Darmstadt, Germany) consisted of a mixture of 62.5wt% 
tricalcium phosphate (α-TCP),  26.8wt% dicalcium phosphate anhydrous (DCPA), 
8.9wt% calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite (HA). The particles 
demonstrated a crushed morphology with particle size ranging from 1-250 µm. A ster-
ile aqueous solution of Na2HPO4 (2wt%) was used as the liquid component. 
2.2 Preparation of PLGA microparticles 
PLGA microparticles were prepared by an established double-emulsion-solvent-
extraction technique ([water-in-oil]-in-water) as previously described.12-15 The micro-
particles were produced by injecting 125 µl PBS/BSA[0.1%] into a ﬂint glass tube 
containing a solution of 250 mg PLGA in 1 ml dichloromethane. This mixture was 
emulsiﬁed for 60 seconds on a vortexer (Vortex Genie 2, Scientiﬁc Industries, Bohemia, 
NY, USA). Subsequently, 1.5 ml 0.3% aqueous poly(vinyl alcohol) (PVA) solution was 
added and emulsiﬁed for 60 seconds on a vortexer to produce the second emulsion. This 
mixture was then added to 98.5 ml PVA solution and 100 ml of 0.2% aqueous isopropa-
nol solution with rapid stirring for 1 hour. The extraction of the dichloromethane into 
the external aqueous phase resulted in the precipitation of the dissolved polymer and 
subsequent microparticle formation. The formed microparticles were collected, cen-
trifuged at 1000 rpm for 2 minutes, lyophilized, and sterilized under UV light for 24 
hours. The morphology of the microparticles was evaluated by scanning electron mi-
croscopy (SEM) (Jeol JSM-6310 Scanning Microscope, Tokyo, Japan). Microparticle size 
distribution was assessed by morphometrical analysis using a light microscope (Leica 
Microsystems AG, Wetzlar, Germany) and computer based image analysis techniques 
(Leica® Qwin Pro-image analysis system, Wetzlar, Germany).
2.3 Preparation of PLGA/Ca-P cement composites
PLGA/Ca-P cement composites were prepared under sterile conditions in various 
formulations. The Ca-P cement powder was sterilized by ethylene oxide gas exposure 
(Anprolene Automatic Ventilated Sterilizer; Anderson Products, Chapel Hill, NC, USA). 
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Sterile PLGA microparticles were added to the Ca-P cement powder in PLGA/Ca-P 
weight ratios of 0/100 (control), 15/85, 30/70 and 50/50. A 3 ml syringe (Becton 
Dickinson & Co, Franklin Lakes, NJ, USA) was closed at the tip with a plastic stopper and 
ﬁ lled with 500 mg of PLGA/Ca-P mixture. Then, cement liquid (2 wt% aqueous solu-
tion of Na2HPO4) was added in a liquid/powder weight ratio of 0.5. Subsequently, the 
syringe was closed with the injection plunger and placed in a mixing apparatus (Silamat, 
Vivadent, Schaan, Lichtenstein). After mixing for 15 seconds, the stopper was removed 
and the composite was injected in PTFE molds (3.5 mm Ø * 2.0 mm). The discs were 
removed from the molds after setting of the cement at room temperature for one hour. 
In this way, 16 sterile discs of each formulation were made for cranial and subcutaneous 
implantation. Similarly, discs were prepared for SEM and microcomputed tomography 
(µCT) (SkyScan 1072, SkyScan, Aartselaar, Belgium). Size distribution of macropores 
(pore diameter ≥ 15 µm) was evaluated by morphometrical analysis of non-implanted 
composites. 
2.4 Surgical procedure
Sixteen healthy skeletally mature male Wistar rats (Harlan, Indianapolis, IN, USA) 
with an approximate weight of 250 g were used as experimental animals. National 
Institutes of Health guidelines for the care and use of laboratory animals were observed. 
The implants were inserted into cranial defects in the parietal bone and subcutaneously 
in the back of the rats. Preoperatively, all animals received a subcutaneous injection of 
buprenorphine (50 µg/kg; Henry Schein, Melville, NY, USA) for analgesia. Surgery 
was performed under general inhalation anaesthesia. The anaesthesia was induced with 
4% isoﬂ urane/O2 gas mixture and maintained with 2.5% isoﬂ urane/O2 gas mixture by 
a non-rebreather mask. After induction, the incision sites and surrounding areas were 
shaved and disinfected with povidine iodine. 
� �
Fig. 5.1: Schematic overview of histomorphometric 
parameters in cranial implant. Region of  interest 
(ROI) is determined by the boundaries of the 
implanted material within the defect edges as shown 
in Figure 5.1. Figure 5.1 shows the morphometrical 
differentiation made between the area ﬁ lled by bone or 
Ca-P cement (blue), and the remaining area (green).
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2.4.1 Cranial implantation
For the insertion of the cranial implants, a longitudinal incision was made down 
to the periosteum from the nasal bone to the occipital protuberance. Subsequently, a 
midline incision was made in the periosteum. The periosteum was undermined and 
lifted off the parietal skull. One defect was drilled in each parietal calvarial bone with a 
dental trephine burr (ACE Dental Implant System, Brockton, MA, USA) with an outer 
diameter of 3.5 mm and continuous internal and external cooling with saline. Care was 
taken to make a full thickness defect without damaging the underlying dura. Following 
insertion of the implants, the periosteum and skin were closed in separate layers using 
resorbable Vicryl® 5-0 suture material (Ethicon, Somerville, NJ, USA). 
2.4.2 Subcutaneous implantation
One longitudinal incision was made vertebrally through the full thickness of the 
skin. At both lateral sides of the incision, a subcutaneous pocket was created by blunt 
dissection with scissors. Subsequently, one PLGA/Ca-P cement implant was inserted 
in each pocket. Finally, the skin was closed with Vicryl® 5-0 suture material.
In this way, a total of thirty-two cranial implants and thirty-two subcutaneous 
implants were placed according to a randomization scheme (n=8 for each formulation 
and implantation site). After twelve weeks, all rats were sacriﬁced by CO2 suffocation. 
2.5  Implant retrieval and histological  
preparations.
Directly after euthanasia, implants with the surrounding tissues were retrieved and 
ﬁxed in 4% phosphate-buffered formaldehyde solution (pH=7.4). Subsequently, the 
Fig. 5.2: SEM image showing smooth, spherical PLGA 
microparticles with occasional pores and a broad 
range in size (average size 66 ± 25 µm). Original 
magniﬁcation 500x, bar represents 10 µm.
Fig. 5.3: SEM image of the inner surface of a broken 
30/70 PLGA/Ca-P cement composite disc, revealing 
intact PLGA microparticles (MP) embedded within 
the microporous Ca-P cement (Ca-P) and indentation 
(I) of  a detached micrparticle. Original magniﬁcation 
500x, bar represents 10 µm.
73
tissue blocks were dehydrated in ethanol and embedded in methylmethacrylate. Fol-
lowing polymerization, undecalciﬁed 10-µm-thick sections were prepared in a direc-
tion transverse to the implant’s axis using a modiﬁed sawing microtome technique.16 At 
least three sections of each implant were stained with methylene blue/basic fuchsin and 
examined with a light microscope (Leica Microsystems AG, Wetzlar, Germany).  
2.6  Histological and histomorphometrical  
evaluation
The histological evaluation consisted of a morphological description of three sec-
tions per implant. In sections made from subcutaneous implants, special attention was 
given to the soft tissue response, and soft tissue ingrowth into macropores formed by 
microparticle degradation. In sections made from cranial implants, bone-implant in-
terface and bone ingrowth into macropores formed by microparticle degradation were 
analyzed. Also, cranial sections were assessed for closure of the defect by new bone for-
mation within and around the implant (bone bridging). 
Further, all sections were used for morphometrical evaluation using computer based 
image analysis techniques (Leica® Qwin Pro-image analysis system, Wetzlar, Germany). 
Digital analysis determined the following parameters ( ﬁgures 1A and 1B): 
1. The region of interest (ROI): the surface area within the boundaries of the implanted 
composite.  
2. Pore surface area (% of ROI): the surface area ﬁlled by PLGA microparticles or ﬁbrous 
tissue. Indicative for the theoretical macroporosity, i.e. percentage of ROI occupied 
by microparticles before degradation of PLGA (non-implanted composites), Ca-P 
cement surface area, i.e. percentage of ROI occupied by Ca-P cement (non-implant-
ed and subcutaneous composites) and defect ﬁll, i.e. percentage of ROI occupied by 
cement and bone (cranial composites). 
2.7 Statistical analysis
All measurements were statistically evaluated with GraphPad® Instat 3.05 software 
(GraphPad Software Inc, San Diego, CA, USA), using an unpaired T-test with Welch 
correction. 
3. Results
3.1  Preparation and characterization of PLGA  
microparticles 
PLGA microparticles were fabricated by a double-emulsion-solvent-extraction 
technique as previously described.13-15  SEM analysis showed smooth, spherical shaped 
particles with occasionally pores (Fig. 5.2). The average size of the microparticles was 
66 ± 25 µm. 
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3.2  Preparation and characterization of  
PLGA/Ca-P cement composites
PLGA/Ca-P cement discs were prepared according to the described protocol. SEM 
of non-implanted discs visualized intact PLGA microparticles embedded within the 
Ca-P cement (Fig. 5.3). Microcomputed tomography and histological analysis could not 
visualize the PLGA microparticles, which appeared as empty spaces (macropores) in the 
Ca-P cement. Cross sections of both methods suggested a homogeneous distribution of 
microparticles throughout the scaffolds in all formulations ( ﬁgures 4, 6 and 7). Mor-
phometry of non-implanted composites revealed a theoretical volumetric macroporos-
ity, i.e. the volume occupied by PLGA microparticles, of 0 ± 0% for the control group 
(PLGA/Ca-P = 0/100 wt/wt%), 30 ± 1% for the 15/85 PLGA/Ca-P cement compos-
ites, 41 ± 3% for the 30/70 PLGA/Ca-P cement composites and 50 ± 6% for the 50/50 
PLGA/Ca-P cement composites. Average pore size was similar for all PLGA micropar-
ticle containing implants (73 ± 27 µm). Pore size distribution was similar to PLGA mic-
roparticle size distribution (Fig. 5.5). 
Fig. 5.4: Microcomputed tomography images of PLGA/Ca-P cement composites. PLGA microparticles appear 
as pores in the Ca-P cement. µCT reconstruction of segments of the various composites suggests a homogeneous 
distribution of microparticles throughout the scaffolds. Bar represents 1 mm.
Fig. 5.5: Pore size distribution in 
PLGA/Ca-P cement composites 
displayed adjacent to the microparticle 
size distribution. X-axis represents 
pore/microparticle diameter per 
10 µm range. Y-axis represents the 
fraction of total pore/microparticle 
number (n/ ∑n).
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3.3 Implant retrieval
All sixteen rats in this experiment remained in good health and did not show any 
wound complications. After twelve weeks, a total of sixty-four implants were retrieved. 
At retrieval, the cranial implants were all covered by periosteum, whereas all 
subcutaneous implants were surrounded by a thin ﬁbrous capsule. Macroscopically, 
implants with the highest PLGA/Ca-P cement ratio (50/50) showed considerable 
volumetric decrease and loss of structural integrity in both implantation sites. All 
other implants remained intact. No inﬂammatory signs or adverse tissue reaction were 
observed. 
3.4 Light microscopy 
3.4.1 Subcutaneous implants
Light microscopic analysis of the subcutaneous sections revealed a thin ﬁbrous cap-
sule of 5-10 cell layers around the implants (Fig. 5.6A-B). Inﬂammatory cells were ob-
served occasionally in all formulations. As with the sections of non-implanted compos-
ites, no remnants of PLGA microparticles could be observed histologically. However, 
complete ingrowth of ﬁbrous tissue and blood vessels into macropores conﬁrmed deg-
radation of the PLGA (Fig. 5.6C). In all PLGA containing formulations, tissue ingrowth 
was observed completely throughout the implants. On the other hand, ingrowth of 
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Fig. 5.6: Representative histological section 
of subcutaneous implant (15/85 PLGA/Ca-
P cement composite) after twelve weeks 
of implantation under low (A) and high 
magniﬁcation (B, C). Figure 5.6B shows the thin 
ﬁbrous capsule around the subcutaneous implant. 
In Figure 5.6C the central part of the composite is 
depicted. Connective tissue, blood vessel ingrowth 
and macropore interconnections are evident, 
whereas no remnants of PLGA are observed. 
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Fig. 5.7: Representative histological sections of cranial 
implants after twelve weeks of implantation. A-C: 
0/100 PLGA/CA-P cement composite (control). Bone 
formation can not proceed into the Ca-P cement except 
into small fractures in the cement (A, B). Bone forma-
tion has also been conducted at the cerebral (lower) 
side of the implant, resulting in complete bone bridging 
(A). Direct apposition of bone at the cement surface is 
evident at higher magniﬁcation (B, C). D-F: Ingrowth 
of bone and connective tissue into the 15/85 PLGA/Ca-
P cement composite. Bone bridging is present inside the 
composite as well as at the cerebral outside (D, E). 
Macropores without bone formation are ﬁlled with con-
nective tissue (F). G-I: 30/70 PLGA/Ca-P cement com-
posite showing some erosion at the implant boundaries 
(G). Abundant bone formation is observed throughout 
the composite. Pore interconnectivity (H) and a typical
osteon-like bone structure (I) can be observed at higher 
magniﬁcation. J-L Various 50/50 PLGA/Ca-P cement 
composites at low magniﬁcation. Bone formation shows 
wide variability in this formulation ranging from virtu-
ally none (J), partial (K) to complete bone bridging 
with original skull thickness (L). Degradation of the 
implant is evident in all sections.  
tissue was not observed within occasional air bubbles in the control implants (0/100 
PLGA/Ca-P cement). All discs except the 50/50 PLGA/Ca-P cement composites main-
tained their integrity. Implants from this group had degraded extensively and were 
recovered only partially. Phagocytozing multinucleated cells were not observed.
3.4.2 Cranial implants
In all cranial histological sections, the original defect edge was still visible. Little or 
no inﬂammatory cells were observed. Representative sections of the various formula-
tions are depicted in Figure 5.7. Variable amounts of new bone formation between im-
plants and formulations were observed. In the control implants (0/100 PLGA/Ca-P ce-
ment), a characteristic Ca-P cement bone response was observed; i.e. direct apposition 
of bone at the Ca-P cement surface (in seven out of eight implants) and ample osteocon-
duction. Four out of eight implants showed complete closure of the defect (bone bridg-
ing) along the cerebral side of the implant. The implants had maintained their integrity 
and did not exhibit signs of resorption. In the 15/85 PLGA/Ca-P cement composites, 
direct bone-cement contact occurred in all implants. Bone ingrowth into the macro-
pores of the scaffold occurred in all sections; in four out of eight composites, this bone 
ingrowth resulted in complete bridging of the defect within the composite. Moreover, 
all 15/85 composites revealed bone bridging along the outside of the implant. Similar 
to the other formulations, this occurred speciﬁcally along the cerebral side of the im-
plant. Connective tissue and blood vessels were observed in pores not ﬁlled by bone. 
All implants remained intact during the implantation period. In the 30/70 PLGA/Ca-P 
cement composites, direct apposition of bone also occurred in all implants. Seven out 
of eight composites showed complete bridging of the bone defect. However, only in 
one implant did bone bridging also occur along the outside of the implant. One implant 
appeared to have partially lost its integrity. The other implants remained intact, though 
their boundaries appeared to have eroded slightly (Fig. 5.7G). Pore interconnections 
were clearly observed in the histological sections, suggesting resorption of thin Ca-P 
cement walls between macropores (Fig. 5.7H). Bone formation appeared more abun-
dant and more consistent than in the 15/85 PLGA/Ca-P cement composites. The 
50/50 PLGA/Ca-P cement composites showed non-uniform results between im-
plants. In three defects, bone formation was limited and the defects were ﬁlled only 
with ﬁbrous tissue and remnants of partially degraded composite (Fig. 5.7J). Only in 
four out of eight implants did complete bone bridging within or around the implant 
occur. In two defects, the regenerated bone showed dimensions similar to the original 
skull (Fig. 5.7L). All eight implants had degraded to a large extent, resulting in (partial) 
loss of implant integrity without replacement by bone (Fig. 5.7J-L). 
3.5 Histomorphometry
The results of the morphometrical analysis of the PLGA/Ca-P cement composites 
are shown in ﬁgures 5.8 and 5.9. Comparison of non-implanted and subcutaneously 
implanted composites revealed no signiﬁcant differences in Ca-P cement surface 
area except for the 50/50 PLGA/Ca-P cement composites. As shown in Figure 5.8, 
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the 50/50 PLGA/Ca-P cement composites showed substantial degradation of the 
Ca-P cement after twelve weeks of subcutaneous implantation. Figure 5.9 represents 
the percentage of the cranial defect ﬁlled by cement and bone after twelve weeks of 
implantation. This ﬁgure shows a statistically signiﬁcant increase (p<0.05) compared to 
the Ca-P cement surface prior to implantation in the 15/85 as well as the 30/70 PLGA/
Ca-P cement composites. In contrast, the 50/50 PLGA/Ca-P cement composites did 
not show an increase in defect ﬁll due to degradation of the composite and limited bone 
formation. 
79
Control Ca-P (1:1) Ca-P (1:10) Ca-P (1:50) Ca-P (1:100)
0.00
0.20
0.40
0.60
0.80
1.00
1.20
N
or
m
al
iz
ed
 v
ia
bi
lit
y
Live Dead
4.5
0
10
20
30
40
50
C
om
pr
es
si
ve
 st
re
ng
th
 (M
Pa
)
Ca-P cement PLGA/Ca-P composite
*4.4
0 7 14 21 28
Time (days)
0.00
0.05
0.10
0.15
0.20
0.25
N
or
m
al
iz
ed
 c
um
ul
at
iv
e 
rh
B
M
P-
2 
re
le
as
e
2.7
Implantation period
0
10
20
30
40
50
60
70
80
90
100
Po
re
 fi
ll 
[%
 B
IC
/p
or
e 
su
rf
ac
e]
Ca-P cement Ca-P cement +rhBMP-2
2 weeks
*
10 weeks
2.6
Implantation period
0
10
20
30
40
50
To
ta
l b
on
e 
su
rf
ac
e 
[%
 b
on
e/
R
O
I]
Ca-P
[BIC]
Ca-P
[BOC]
Ca-P + rhBMP-2
[BIC]
Ca-P + rhBMP-2
[BOC]
*
*  *
10 weeks2 weeks
2.5
20 30 40 50 60 70 80 90 100 110 120 130 140 150 160
Microparticle diameter (µm)
0%
5%
10%
15%
20%
Fr
ac
ti
on
 o
f t
ot
al
Number distribution Volume distribution
6.1
0/100 15/85 30/70 50/50
PLGA/Ca-P (%wt/wt)
10
20
30
40
50
60
70
80
90
100
C
ra
ni
al
 d
ef
ec
t f
ill
 (%
 R
O
I)
Pre-operative 12 weeks post-operative
*
*
5.9
0/100 15/85 30/70 50/50
PLGA/Ca-P (%wt/wt)
10
20
30
40
50
60
70
80
90
100
C
a-
P 
ce
m
en
t s
ur
fa
ce
 a
re
a 
(%
 R
O
I)
Pre-operative 12 weeks post-operative
*
5.8
20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170
Diameter (µm)
0%
5%
10%
15%
20%
N
um
be
r 
 fr
ac
ti
on
PLGA microparticles Composite porosity
5.5
0 6 12 18 24 30 36 42 48
Hours
0.20
0.40
0.60
0.80
1.00
N
or
m
al
iz
ed
 r
et
en
ti
on
1.4
0 7 14 21 28
Time (days)
0.00
0.05
0.10
0.15
0.20
0.25
N
or
m
al
iz
ed
 c
um
ul
at
iv
e 
rh
B
M
P-
2
 r
el
ea
se
PLGA
pH 7.4
PLGA/Ca-P
pH 7.4
PLGA
pH 4.0
PLGA/Ca-P
pH 4.04.6
*  *
3 Days samples 7 Days samples
0.00
0.20
0.40
0.60
0.80
1.00
N
or
m
al
iz
ed
 f
ra
ct
io
n 
rh
B
M
P
-2
Porous Ca-P cement disc Capsule & surrounding tissue7.5
0 7 14 21 28
Days
0.20
0.40
0.60
0.80
1.00
N
or
m
al
iz
ed
 re
te
nt
io
n
Gamma counter Gamma counter
Non-pretreated Ca-P Albumin pretreated Ca-P
Gamma camera Gamma camera
One-phase exponential fit One-phase exponential fit
7.4
0 7 14 21
Days
0.20
0.40
0.60
0.80
1.00
N
or
m
al
iz
ed
 re
te
nt
io
n
Non-pretreated Ca-P Albumin pretreated Ca-P
PBS
Serum
PBS
Serum
7.2
4% LP 15% LP 4% HP 15% HP
0%
20%
40%
60%
80%
100%
D
en
si
ty
 (%
 o
f R
O
I)
Subcutaneous implants Cranial implants6.7
0 7 14 21 28
Days
0.40
0.60
0.80
1.00
N
or
m
al
iz
ed
 re
te
nt
io
n
HMW PLGA/Ca-P composite
Entrapped rhBMP-2
Adsorbed rhBMP-2
Entrapped rhBMP-2
Adsorbed rhBMP-2
LMW PLGA/Ca-P composite
8.3
* ***
***
Fig. 5.8: Results of histomorphometric 
analysis of subcutaneous PLGA/Ca-P  
cement composites. Ca-P cement surface  
area is expressed as a percentage of the 
region of interest (ROI). Ca-P cement 
surface area of the four formulations 
after twelve weeks of implantation 
are displayed against the Ca-P cement 
surface area prior to implantation. 
Error bars represent means ± standard 
deviation for n=8. * = p< 0.05.
Fig. 5.9: Results of histomorphometric 
analysis of PLGA/Ca-P cement 
composites in cranial defects. Defect ﬁll 
(surface area of new bone formation 
plus remaining Ca-P cement, expressed 
as a percentage of the region of interest) 
after twelve weeks of implantation 
is displayed against the Ca-P cement 
surface area prior to implantation. 
Error bars represent means ± standard 
deviation for n=8. * = p< 0.05.
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4. Discussion
In this study, we investigated the in vivo tissue response and degradation of PLGA/
Ca-P cement composites of varying PLGA to Ca-P cement ratios in a rat model. We 
hypothesized that incorporation of PLGA microparticles would result in a macroporous 
Ca-P structure after degradation of the PLGA, which would potentiate the ingrowth of 
bone and connective tissue and accelerate degradation of the Ca-P cement. 
The cranial defect used in this study was not a critical size defect.17,18 Moreover, tissue 
reaction was only evaluated after one time period. These limitations were no restrictions 
for the aim of this study, i.e. the ﬁrst investigation of tissue response and degradation 
of this novel composite. An implantation time of twelve weeks was appropriate, as it 
is known that PLGA microparticles of similar composition have degraded to a great 
extent within 12 weeks11 and that resorption of porous Ca-P cement could be observed 
after ten weeks.19 We have to emphasize, however, that for evaluation of regeneration 
capacity of this composite, the use of a critical-sized defect model will be required. 
Prior to implantation, the theoretical macroporosity of the various formulation in-
creased from 0 ± 0% in the control group (0/100 PLGA/Ca-P) to 30 ± 1% for the 15/85 
PLGA/Ca-P cement composites, 41 ± 3% for the 30/70 PLGA/Ca-P cement composites 
and 50 ± 6% for the 50/50 PLGA/Ca-P cement composites. Morphometrical analysis 
in this study detected macropores of 15 µm and more. Since the intrinsic microporosity 
(pore size < 1 µm) of this Ca-P cement is 39%4, total porosity (microporosity plus mac-
roporosity) of the various composites after complete hydrolysis of the PLGA reaches 
69%, 80% and 89% respectively. These values resemble porosities of various porous 
ceramics currently available for bone regeneration.20-23
A mild tissue response was observed to the various composites. Even in the com-
posites with the highest PLGA ratio (50 wt%), no signs of an adverse inﬂammatory re-
sponse were present after twelve weeks of implantation. Degradation of PLGA could 
not be quantiﬁed but was considered to be complete considering the ingrowth of tissue 
throughout macropores previously occupied by PLGA microparticles. Subcutaneous 
implantation did not reveal signiﬁcant degradation of the Ca-P cement scaffold in the 
0/100, 15/85 and 30/70 PLGA/Ca-P cement composites. This result is not surprising, 
as the Ca-P cement is being resorbed only by osteoclasts or eliminated by phagocytosis 
of small Ca-P particles by multinucleated inﬂammatory cells (e.g. macrophages and for-
eign body giant cells).3,24,25 Only the 50/50 PLGA/Ca-P cement composite showed ob-
vious degradation. Apparently, the amount of PLGA particles in this group was so high 
that the Ca-P cement lattice fragmented after hydrolysis of the PLGA, and remaining 
Ca-P cement particles were phagocytozed. This ﬁnding demonstrates that incorpora-
tion of PLGA microparticles can enhance degradation of the Ca-P cement.   
Incorporation of spherical microparticles does not guarantee an interconnected pore 
network. Nevertheless, histology revealed that ﬁbrous tissue and blood vessel ingrowth 
had proceeded into all macropores throughout the scaffold after twelve weeks of subcu-
taneous implantation. This remarkable observation suggests that the microporosity or 
even nanoporosity of the Ca-P cement also plays an important role in tissue ingrowth 
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over small distances. On the other hand, occasional air bubbles within the control scaf-
folds were not ﬁlled by ﬁbrous tissue, demonstrating that microporosity alone is not 
sufﬁcient to overcome larger distances. 
Pore size distribution was found similar as microparticle size distribution as shown 
in Figure 5.5. This implies that Ca-P cement pore size was determined by PLGA mic-
roparticle size prior to PLGA degradation, and suggests that variation of pore size can 
be engineered by selection of microparticle size fractions. For porous sintered ceram-
ics, optimal pore size for bone ingrowth has been suggested to be between 200-400 
µm.22,26,27 Average pore sizes of  the composites used in this study were much smaller 
than the postulated ideal requirements. Still, the ingrowth of bone and other tissue was 
impressive. This suggests, that for microporous osteoconductive materials such as Ca-P 
cements, the optimal pore sizes may be much smaller than for materials with less favor-
able biological interactions. It must be emphasized however, that studies with larger 
bone defects and various particle size fractions are required to come to conclusive an-
swers to this supposition. 
Unfortunately, the current histomorphometrical techniques do not allow to discern 
adequately between bone and cement due to similarities in mineral structure. There-
fore, bone formation and Ca-P cement are expressed together as defect ﬁll. Obviously, 
any increase in defect ﬁll after implantation is due to bone formation within the com-
posites. Simple subtraction of Ca-P cement surface area prior to implantation from the 
measured defect ﬁll after implantation, however, may result in an underestimation of 
bone formation, as it does not account for the supposed resorption of the implanted 
Ca-P material. No noteworthy difference could be observed between the increase in de-
fect ﬁll in the 15/85 composites and the 30/70 composites. Histological appearance, 
however, suggested that bone ingrowth in the latter was higher and more consistent. 
Additionally, the Ca-P cement scaffold appeared to have degraded to a greater extent 
after twelve weeks of implantation than the 15/85 composites, further suggesting a 
greater amount of bone formation within the defect borders. 
On the other hand, the decrease in defect ﬁll and the limited bone bridging in the 
50/50 composite suggests that 50wt% PLGA exceeds the optimal percentage of PLGA. 
Since only half of these defects in this non-critical size model were closed, it appears 
that bone formation is somehow hampered by this composite formulation. Although 
no severe inﬂammatory response could be observed after twelve weeks, we assume that 
the amount of PLGA in this composite was too high for favorable bone formation and/
or that the collapse of the Ca-P cement lattice further inhibited bone regeneration. 
To our knowledge, no previous studies have been published addressing the in vivo 
behavior of a Ca-P cement based PLGA/Ca-P cement composite material. In the recent 
years, two in vitro studies with similar materials have been reported, one by our group12 
and one by Simon et al.28 In our previous study, we demonstrated the feasibility of this 
composite material as vehicle for growth factor delivery. Simon et al. demonstrated 
the in vitro biocompatibility of a similar PLGA/Ca-P cement composite material. The 
current study emphasizes that this novel composite material shows excellent biological 
behavior. The results of this ﬁrst in vivo evaluation warrant further investigation of 
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material properties such as macropore formation, optimal pore size and regeneration 
capacity.  Taken into account the potentials of this composite for sustained growth 
factor delivery, PLGA/Ca-P cement composite may be an ideal scaffolding material for 
bone regeneration and bone tissue engineering.
5. Conclusions
From this study, it can be concluded that PLGA microparticles embedded in PLGA/
Ca-P cement composites form macropores within the Ca-P cement framework after 
PLGA degradation in vivo. An average pore size of 73 ± 27 µm is sufﬁcient to allow in-
growth of soft and hard tissues. PLGA/Ca-P cement composites show excellent osteo-
compatibility in weight ratios of 15/85 and 30/70 PLGA/Ca-P cement. Histological 
aspects suggests that 30/70 PLGA/Ca-P cement composites show the most favorable 
biologic response in this model.  
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1. Introduction 
Calcium phosphate (Ca-P) cements are injectable, self-setting ceramic pastes clini-
cally approved as ﬁller material for selected bone defects.1-3 Under investigation since 
the early 1980’s,4,5 Ca-P cements consist of a powder containing one or more solid com-
pounds of calcium phosphate salts and an aqueous cement liquid. Once mixed in an ap-
propriate ratio, the components combine to form a paste that sets at body temperature 
by entanglement of precipitating crystals. As an injectable, Ca-P cements can easily be 
shaped according to the defect dimension during the several minutes before complete 
setting in situ. The ability to set in situ provides clinical advantages compared to other 
allograft materials which are usually presented as prefabricated (porous) blocks and/ or 
granules. Prefabricated blocks are difﬁcult to shape, which can result in poor contour 
of the resulting bone or incomplete ﬁlling of the bone defect. Granules, on the other 
hand, do not provide dimensional stability and can easily migrate or disperse into the 
surrounding tissue.
Several Ca-P cements are currently available with slight differences in chemical 
composition, setting time, strength and resorbability.6 In a series of ongoing studies, 
our research group has focused on the tissue response to Ca-P cement consisting mainly 
of alpha tricalcium phosphate (α-TCP) and dicalcium phosphate anhydrous (DCPA).7-14 
In vivo resorption of this kind of Ca-P cement occurs mainly through cellular activi-
ty. Small particles are phagocytozed by multinucleated cells such as macrophages and 
foreign body giant cells15, while larger volumes are resorbed by osteoclasts at the bone-
cement surface.
 Currently marketed Ca-P cements do not possess a macroporous structure. Conse-
quently, the surface area to volume ratio is small, making the resorption rate of several 
Ca-P cements quite slow.10,16,17 Previous studies conducted in our laboratory have demon-
strated that increasing the surface area to volume ratio of Ca-P cements using a gas foam-
ing technique can accelerate its in vivo rate of resorption.8 
Although useful in small defects where bone formation would naturally occur, an 
osteoconductive implant will not sufﬁce in larger defects where induction of tissue is 
necessary. To augment the inductive capacity of a ceramic implant, growth factors such 
as bone morphogenetic protein 2 (rhBMP-2) can be adsorbed onto a macroporous Ca-P 
cement.9,14 On the other hand, controlled delivery of the growth factors can be achieved 
with degradable polymeric microparticles.18,19 Inclusion of rhBMP-2 loaded poly(DL- 
lactic-co-glycolic acid) (PLGA) microparticles within Ca-P cement enables a method for 
sustained delivery of rhBMP-2.20 
PLGA is a synthetic polymer that is known to degrade by non-enzymatic hydroly-
tic chain cleavage of its ester linkages.21 The in vivo rate of degradation of PLGA var-
ies from days to months depending on chemico-physical properties such as polymer 
molecular weight, copolymer ratio and particle size and structure. When the rate of 
degradation of the PLGA microparticles is faster than the surrounding Ca-P cement, 
the inclusion of PLGA microparticles results in increased macroporosity after degrada-
tion of the polymer. The resulting increase in macroporosity could allow for further 
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ingrowth of bone and other tissues and enhance bony substitution of the Ca-P cement. 
In composites that posses both CO2 induced macropores and PLGA microparticles, we 
assume that initial CO2 induced macroporosity will enable immediate ingrowth of tis-
sue, while PLGA degradation induced porosity will improve the ﬁnal osteoconductive 
efﬁcacy of the scaffold.
The experiments presented here focus on the in vivo biological response to porous 
PLGA/Ca-P cement composites. Four formulations which varied in CO2 induced mac-
roporosity and PLGA microparticle content were examined according to a 22 two-level 
full factorial design. Preset discs of each formulation were implanted subcutaneously and 
in cranial defects in rats for twelve weeks to investigate the tissue response and bone in-
growth. We hypothesized that PLGA microparticles can be integrated into porous Ca-P 
cement without negative effect on the favorable porous Ca-P cement tissue response. 
Also, we hypothesized that inclusion of PLGA microparticles into porous Ca-P cement 
can result in an increased scaffold porosity after PLGA degradation and can reduce the 
amount of CO2 induced porosity required to enable tissue ingrowth.
2. Materials and methods
2.1 Materials
Poly(DL-lactic-co-glycolic acid) (PLGA) with a 50:50 lactic to glycolic acid copoly-
mer ratio was obtained from Alkermes, Cincinnati, OH. The molecular weight (Mw) 
of PLGA was 47.6 kDa and the polydispersity index (PI) was 1.73 as determined by gel 
permeation chromatography. Ancillary chemicals for microparticle preparation were 
all of analytical grade and obtained as previously described.20 The Ca-P cement (Calci-
bon®, Biomet Merck, Darmstadt, Germany) consisted of a mixture of 62.5wt% trical-
cium phosphate (α-TCP), 26.8wt% dicalcium phosphate anhydrous (DCPA), 8.9wt% 
calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite (HA). Sodium bicarbonate 
(NaHCO3) was added to the cement powder for production of CO2 macroporosity in 
the cement.22 Sterile aqueous solutions of Na2HPO4 (2wt%) and NaH2PO4 (8wt%) were 
used as the liquid component. 
2.2 Preparation of PLGA microparticles 
PLGA microparticles were prepared by an established double-emulsion-solvent- 
extraction technique ([water-in-oil]-in-water) as previously described.18,20,23,24 The 
microparticles were produced by injecting 125 µl PBS/BSA[0.1%] into a ﬂint glass tube 
containing a solution of 250 mg PLGA in 1 ml dichloromethane. This mixture was emul-
siﬁed for 60 seconds on a vortexer (Vortex Genie 2, Scientiﬁc Industries, Bohemia, NY). 
Subsequently, 1.5 ml 0.3% aqueous poly(vinyl alcohol) (PVA) solution was added and 
emulsiﬁed for 60 sec on a vortexer to produce the second emulsion. This mixture was 
then added to 98.5 ml PVA solution and 100 ml of 0.2% aqueous isopropanol solution 
with rapid stirring for 1 hour. The formed microparticles were collected, centrifuged 
at 1000 rpm for 2 minutes, lyophilized, and sterilized under UV light for 24 hours. 
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The morphology of the microparticles was evaluated by scanning electron microscopy 
(SEM) (Jeol JSM-6310 Scanning Microscope, Tokyo, Japan). Microparticle size distri-
bution was assessed by morphometrical diameter analysis using a light microscope 
(Leica Microsystems AG, Wetzlar, Germany) and computer based image analysis tech-
niques (Leica® Qwin Pro-image analysis system, Wetzlar, Germany). Volume distribu-
tion was calculated from morphometrical diameter measurements assuming spherical 
microparticles.
2.3  Preparation of porous PLGA/Ca-P cement  
composites
Four formulations of porous PLGA/Ca-P cement composites were prepared under 
sterile conditions (Table 6.1). Prior to use, the Ca-P cement powder and the NaHCO3 were 
sterilized by ethylene oxide gas exposure (Anprolene Automatic Ventilated Sterilizer; 
Anderson Products, Chapel Hill, NC, USA). To fabricate composites, NaHCO3 was 
added to the Ca-P cement powder in weight ratio of 2.5% and 5%, which results in gas 
induced volumetric macroporosity of 10% and 20%, respectively, as was determined 
by histological and X-ray microcomputed tomographical analysis. Subsequently, sterile 
PLGA microparticles (4% or 15% by weight) were added to the Ca-P/NaHCO3 mixture. 
A 3 ml syringe (Becton Dickinson & Co, Franklin Lakes, NJ, USA) was closed at the tip 
with a plastic stopper and ﬁlled with 500 mg of PLGA/Ca-P/NaHCO3 mixture. Cement 
liquid was then added in a liquid/powder weight ratio of 0.5 and mixed thoroughly 
in a mixing apparatus (Silamat, Vivadent, Schaan, Lichtenstein). After mixing, the 
stopper was removed and the composite was injected into PTFE molds (3.5 mm Ø * 
2.0 mm). The discs were removed from the molds after setting of the cement at room 
temperature for one hour. In this way, 18 sterile discs of each formulation were made for 
cranial and subcutaneous implantation. Similarly, discs were prepared for SEM and X-
ray microcomputed tomography (µCT) (SkyScan 1072, SkyScan, Aartselaar, Belgium). 
CO2 porosity (vol%) PLGA  PLGA 
  4wt% 15wt%
LOW (10v%) 4%LP 15%LP
HIGH (20v%) 4%HP 15%HP
Table 1: Porous PLGA/Ca-P cement composite formulations used in this study.
2.4 Surgical procedure
Eighteen healthy skeletally mature male Wistar rats (Harlan, Indianapolis, IN, USA) 
with an approximate weight of 250 g were used as experimental animals. National 
Institutes of Health guidelines for the care and use of laboratory animals were respected. 
The implants were inserted into cranial defects in the parietal bone and subcutaneously 
in the back of the rats. Preoperatively, all animals received a subcutaneous injection of 
buprenorphine (50 µg/kg; Henry Schein, Melville, NY, USA) for analgesia. Surgery was 
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performed under general inhalation anaesthesia. The anaesthesia was induced with 4% 
isoﬂurane/O2 gas mixture and maintained with 2.5% isoﬂurane/O2 gas mixture by a 
non-rebreather mask. After induction, the incision sites and surrounding areas were 
shaved and disinfected with povidine iodine. 
2.4.1 Cranial implantation
For the insertion of the cranial implants, a longitudinal incision was made down 
to the periosteum from the nasal bone to the occipital protuberance. Subsequently, a 
midline incision was made in the periosteum. The periosteum was undermined and 
lifted off the parietal skull. One defect was drilled in each parietal calvarial bone with a 
dental trephine burr (ACE Dental Implant System, Brockton, MA, USA) with an outer 
diameter of 3.5 mm and continuous internal and external cooling with saline. Care was 
taken to make a full thickness defect without damaging the underlying dura. Following 
insertion of the implants, the periosteum and skin were closed in separate layers using 
resorbable Vicryl® 5-0 suture material (Ethicon, Somerville, NJ, USA). 
2.4.2 Subcutaneous implantation
One longitudinal incision was made vertebrally through the full thickness of the 
skin. At both lateral sides of the incision, a subcutaneous pocket was created by blunt 
dissection with scissors. Subsequently, one implant was inserted in each pocket. Finally, 
the skin was closed with Vicryl® 5-0 suture material.
In this way, a total of thirty-six cranial implants and thirty-six subcutaneous 
implants were placed according to a randomization scheme (n=9 for each formulation 
and implantation site). After twelve weeks, all rats were sacriﬁced by CO2 suffocation. 
2.5  Implant retrieval and histological  
preparations
Directly after euthanasia, implants with the surrounding tissues were retrieved 
and ﬁxed in 4% phosphate-buffered formaldehyde solution (pH=7.4). Subsequently, 
the tissue blocks were dehydrated in serial dilutions of ethanol and embedded in 
methylmethacrylate. Following polymerization, undecalciﬁed 10-µm-thick sections 
were prepared in a direction transverse to the implant’s axis using a modiﬁed sawing 
microtome technique.25 At least three sections from the central part of each implant 
were stained with methylene blue/basic fuchsin and examined. 
2.6  Histological and histomorphometrical  
evaluation
A light microscope was used for histological evaluation, consisting of a morpholog-
ical description of three sections per implant. In sections made from subcutaneous im-
plants, special attention was given to the soft tissue response, and soft tissue ingrowth 
into macropores formed by microparticle degradation. In sections made from cranial 
implants, bone-implant interface and bone ingrowth into macropores formed by 
microparticle degradation were analyzed. Also, cranial sections were assessed for 
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closure of the defect by new bone formation within the implant (bone bridging). 
Further, all sections were used for morphometrical evaluation using computer based 
image analysis techniques (Leica® Qwin Pro-image analysis system, Wetzlar, Germany). 
Digital analysis determined the following parameters for retrieved samples: 
1. The region of interest (ROI): the surface area (AROI) within the boundaries of the 
implanted composite. 
2. Pore area (AP): the surface area ﬁlled with CO2 macropores, PLGA microparticles, 
or ﬁbrous tissue. Used for calculation of the composite density (D), i.e. percentage 
of ROI occupied by Ca-P cement (subcutaneous composites [DSC]) or cement and 
bone (cranial composites [DCR]) and increase of mean composite density (∆ D) as 
estimation of bone ingrowth in cranial composites, using the equations:
(1)  D =      AROI - AP
       
            AROI
(2)  ∆ D = DCR - DSC
3. Pore size distribution (% of ROI): displays two dimensional size distribution as a 
function of each size-range’s area fraction of the ROI (subcutaneous composites). 
Pore areas of macropores larger than 15 µm in diameter were individually measured 
and distributed in ranges corresponding with areas of spherical pores per 100 µm 
diameter range. Accordingly, pore size descriptions concern pore diameter in µm. 
2.7 Statistical analysis
All measurements were statistically evaluated with GraphPad® Instat 3.05 software 
(GraphPad Software Inc, San Diego, CA), using an unpaired T-test with Welch correc-
tion for evaluation of composite density between subcutaneous and cranial composites, 
and one-way ANOVA with post test for evaluation of increase of composite density 
between groups. The Doornbos outlier test was used to calculate and exclude outlying 
data from the dataset. The progression of the errors of the different variables in equa-
tion two was determined by a multivariable method.26
3. Results
3.1  Preparation and characterization of  
PLGA microparticles 
PLGA microparticles were fabricated by a double-emulsion-solvent-extraction 
technique as previously described.18,23,24 The number average microparticle diameter 
was 66 ± 25 µm, and the volume average diameter was 75 µm (non-Gaussian distri-
bution) (Fig. 6.1). SEM analysis showed smooth, spherical shaped particles with occa-
sional pores (Fig. 6.2A).
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3.2  Preparation and characterization of  
PLGA/Ca-P cement composites
PLGA/Ca-P cement discs were prepared according to the described protocol. SEM 
of non-implanted discs showed intact PLGA microparticles embedded within the Ca-P 
cement (Fig. 6.2B). µCT analysis and histological sections could not visualize the PLGA 
microparticles, which appeared as empty spaces (macropores) in the Ca-P cement. 
Macropores induced by CO2 formation and microparticles were distributed homoge-
neously throughout the scaffolds in all formulations (Fig. 6.3). 
3.3 Implant retrieval
All eighteen rats in this experiment remained in good health and did not show any 
wound complications. After twelve weeks, a total of seventy-two implants were re-
trieved. At retrieval, the cranial implants were all covered by periosteum, whereas all 
Fig. 6.2: SEM image of PLGA microparticles (left) 
and the inner surface of a porous PLGA/Ca-P cement 
composite disc, revealing intact spherical PLGA micro-
particles embedded at the surface of CO2 induced 
macropores in the microporous Ca-P cement (right). 
Original magniﬁcation 1000x (A) and 500x (B),  
bar represents 10 µm.
Fig. 6.1: Size distribution of PLGA mic-
roparticles as a function of each size’s frac-
tion of the total microparticle number and 
volume. X-axis represents microparticle 
diameter per 10 µm range for micropar-
ticles larger than 15 µm. Y-axis represents 
the fraction of total microparticle number 
(n/ ∑n) or volume (v/ ∑v) for each size 
range. Microparticles demonstrate a num-
ber average diameter of 66 µm, and a vol-
ume average diameter of 75 µm.
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Fig. 6.3: Microcomputed tomography images of 
porous PLGA/Ca-P cement composites. PLGA 
microparticles appear as pores in the Ca-P cement. 
µCT reconstruction of segments of the various 
composites show a homogeneous distribution 
of microparticles and CO2 induced macropores 
throughout the scaffolds. Bar represents 1 mm.
Fig. 6.4: Subcutaneous implant (4%LP composite)  
after twelve weeks under low (A) and high magniﬁ-
cation (B, C). Connective tissue is present in the large 
CO2 pores, but not in all PLGA pores in the 4% PLGA 
formulations (B). Figure 6.4C shows the distinct 
mineralizations observed in PLGA pores in 67% of all 
subcutaneous implants. The smooth, dense mineralized 
matrix shows evident differences with the surrounding 
Ca-P cement and apparent similarity with bone matrix. 
Osteoid, osteoblasts or osteocytes were not observed. ��� ��
�
�
��� ��
�� �
�
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subcutaneous implants were surrounded by a thin ﬁbrous capsule. Macroscopically, all 
implants except one cranial 15%LP composite remained intact. No inﬂammatory signs or 
adverse tissue reaction were observed. 
3.4 Light microscopy
3.4.1 Subcutaneous implants
Light microscopic analysis of the subcutaneous sections revealed a thin ﬁbrous cap-
sule of 5-10 cell layers around the implants. Inﬂammatory cells, such as macrophages 
and foreign body giant cells, were observed occasionally in all formulations. Discrimi-
nation between macropores formed by CO2 (CO2 porosity) and macropores formed by 
PLGA degradation (PLGA porosity) was possible even though PLGA microparticles 
could not be observed histologically; PLGA porosity was characterized by the smooth, 
spherical shape of the cavities in the Ca-P lattice, whereas CO2 porosity typically ap-
peared as irregular, often channel-like spaces (Fig. 6.4 and 6.5). Frequently, the cross 
section surface area of CO2 macropores was much larger than PLGA macropore surface 
area, especially in the high CO2 porosity (HP) formulations (Fig. 6.5).
Ingrowth of connective tissue and blood vessels into macropores throughout the 
scaffolds was observed in all formulations. Fat cells were observed occasionally in large 
pores. In the 4% PLGA groups, PLGA pores in the vicinity of CO2 pores were consis-
tently ﬁlled with ﬁbrous tissue. However, more remote, solitary PLGA pores without 
ﬁbrous tissue ingrowth were also observed. In the 15% PLGA groups, all PLGA pores 
were ﬁlled with tissue, which conﬁrmed complete degradation of the PLGA. All im-
plants except one remained intact, though the boundaries of some of the HP composites 
appeared to have eroded slightly. The one broken implant (15%HP composite) showed 
evident cracks in the Ca-P cement lattice but was not fragmented. 
Remarkably, bone-like mineralizations were frequently observed in subcutaneous 
implants. In twenty-four subcutaneous implants (six 4%LP composites, eight 15%LP 
composites, ﬁve 4%HP composites and ﬁve 15%HP composites), distinct mineraliza-
tion was observed in spherical PLGA macropores near the implant surface. Under light 
microscopy this mineralized matrix appeared smoother and denser than its surround-
ing Ca-P cement surface and exceedingly similar to bone (Fig. 6.4C). However, oste-
oid, osteoblasts, osteocytes were not observed in the vicinity of these mineralizations. 
Also, the amount of mineralized matrix as well as the number of partially mineralized 
pores per section were very limited. The mineralizations were not observed in irregular 
shaped CO2 pores.
3.4.2 Cranial implants
Representative sections of the various formulations are depicted in Figure 6.6. One 
implant (15%LP composite) was completely fragmented. Based on the Doornbos out-
lier test, this composite was considered as outlier (p<0.001) and excluded from fur-
ther analysis. In all cranial sections, the original defect edge was still visible. Minimal 
quantities of inﬂammatory cells, such as macrophages and foreign body giant cells, were 
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observed. CO2 pores were ﬁlled with bone, blood vessels, ﬁbrous tissue or bone mar-
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<Fig. 6.5: Representative histological sections (left) and pore size distribution 
(right) of porous PLGA/Ca-P cement composites after twelve weeks of 
implantation. Pore size is displayed as relative frequency histogram showing 
the percentage of the region of interest (% of ROI) occupied by various sized 
pores after twelve weeks of subcutaneous implantation. Individual two 
dimensional pore areas are calculated from light microscopical cross sections 
of subcutaneous implants (n=9 for each formulation) and expressed as pore 
diameters of spherical pores. In the histogram, pore sizes are divided into 100 
micrometer diameter ranges. (Methylene blue/basic fuchsin staining)
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Fig. 6.6: Representative 
histological sections of 
cranial implants after 
twelve weeks of im-
plantation. A-B: 4%LP 
composite. Remote PLGA 
pores without ingrowth 
of tissue can be observed 
in this formulation (B) 
C-D: 15%LP composite. 
Extensive ingrowth of 
bone and connective tissue 
throughout all pores can 
be observed. E-F: 4%HP 
composite. Bone forma-
tion is clearly conducted 
by the Ca-P cement. 
Bone formation appears 
to be hampered by the 
absence of Ca-P cement 
in the large macropore 
cavity. G-H: 15%HP 
composite. As in E and 
F, bone formation ap-
pears to be hampered by 
the lack of Ca-P cement 
in the large macropore 
cavity. Bone marrow like 
tissue is observed in large 
macropores (F). (Methy-
lene blue/basic fuchsin 
staining)
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row like fat cells. In the 15% PLGA formulations, all PLGA pores were ﬁlled with bone, 
ﬁbrous tissue and blood vessels. In the 4% PLGA formulations, PLGA pores in the prox-
imity of larger CO2 pores showed tissue ingrowth, whereas part of the more remote 
PLGA pores remained empty. Direct apposition of bone at the Ca-P cement surface and 
ingrowth into the scaffold was present consistently in all implants. 
In the 4%LP implants, three out of nine implants exhibited complete closure of the 
defect (bone bridging) within the implant, while remaining implants showed ingrowth 
of bone at the edges of the implant. Most bone formation occurred in the irregular 
formed CO2 macropores. However, bone formation also proceeded into PLGA macro-
pores within close proximity to the CO2 macropores. No evidence of cement resorp-
tion was detectable. In the 15%LP implants, bone bridging occurred in six out of eight 
implants. Bone ingrowth appeared to be conducted through PLGA macropores as well 
as CO2 macropores. 
Similar to the subcutaneous composites, the HP formulations were characterized by 
large CO2 macropores. Bone ingrowth was present in all sections. Bridging was present 
in 6/9 of the 4%HP composites and 4/9 of the 15%HP composites. Bone formation 
appeared to be conducted along the cement surface of macropores in the composite. 
The lack of an osteoconducting Ca-P cement surface within the large cavities of the CO2 
macropores seemed to hamper bone formation in several sections. One composite in 
the 4%HP group showed cracks within the Ca-P cement lattice. All other HP composites 
had maintained their structural integrity during the implantation period. 
  (DSC) (DCR) (∆ D)
4% LP  81 ± 2% 86 ± 5% 5 ± 6%
15%LP  66 ± 3% 81 ± 5% 15 ± 6%
4%HP  62 ± 7% 78 ± 5% 16 ± 9%
15%HP 55 ± 5% 75 ± 7% 20 ± 9%
Table 2: Porous PLGA/Ca-P cement composite densities after 12 weeks of implantation. Mean subcutaneous 
density (DSC) represents the percentage of the region of interest (ROI) occupied by Ca-P cement. Mean cranial 
density (DCR) represents the percentage of the ROI occupied by Ca-P cement and bone. Increase of mean 
composite density (∆ D) and concomitant standard deviation26 provides an estimation of bone ingrowth in cranial 
composites.
3.5 Histomorphometry
Morphometry of subcutaneous cross sections revealed a two dimensional porosity 
of 19 ± 2% for the 4%LP composites, 34 ± 3% for the 15%LP composites, 38 ± 7% for the 
4%HP composites and 45 ± 5% for the 15%HP composites. Two dimensional pore size 
distributions of porous PLGA/Ca-P cement composites are shown in Figure 6.5.
The results of the morphometrical analysis of the PLGA/Ca-P cement composites 
are shown in Table 6.2 and Figure 6.7. This ﬁgure represents the two dimensional mean 
composite density of the cranial composites (percentage of ROI ﬁlled with cement and 
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bone [ DCR]) compared to the mean composite density of the subcutaneous compos-
ites (percentage of ROI ﬁlled with cement [ DsC]). A statistically signiﬁcant increase 
(p<0.05) between subcutaneous and cranial composites due to bone formation in cra-
nial composites is observed in all formulations (Fig. 6.2). Increase of mean composite 
density (∆ D ) in 4%LP composites was signiﬁcantly less (p<0.05) compared to the other 
formulations (Table 6.2).
4. Discussion
 
In this study, we investigated the biological response to porous PLGA/Ca-P cement 
composites. Macropores were induced in the Ca-P cement by a CO2 gas foaming method 
as well as by addition of degradable PLGA microparticles. Four formulations of varying 
CO2 and PLGA porosities were implanted subcutaneously and in cranial defects in the 
rat and the soft and hard tissue responses were examined. We hypothesized that PLGA 
microparticles can be integrated into porous Ca-P cement without negative effect on 
the favorable porous Ca-P cement tissue response and can reduce the amount of CO2 
induced porosity required to enable tissue ingrowth. 
For this study, the use of a non-critical sized cranial defect model27,28 was appro-
priate. We have to emphasize, however, that for ﬁnal evaluation of the regenerative 
capacity of these composites, a critical sized defect model will be required.
The formulations chosen in this study were based on previous studies with similar 
porous Ca-P cement.8,9,14,22 In these studies, CO2 gas foaming resulted in a macroporous 
Ca-P cement that showed abundant bone ingrowth and almost complete resorption in 
a goat model within ten weeks.8 In the current study, low (4wt%) and high (15wt%) 
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Fig. 6.7: Results of histomorphometric 
analysis of porous PLGA/Ca-P cement 
composites in cranial defects. Compos-
ite density of cranial implants (surface 
area of new bone formation plus 
remaining Ca-P cement, expressed as 
a percentage of the region of interest) 
after twelve weeks of implantation is 
displayed against the composite den-
sity of subcutaneous implants (surface 
area of Ca-P cement, expressed as a 
percentage of the region of interest) 
after twelve weeks of implantation. 
Error bars represent means ± standard 
deviation. * = p< 0.05; ** = p< 0.001; 
*** = p< 0.0001
amounts of PLGA microparticles were incorporated into porous Ca-P cement. The low 
volume of PLGA was used in order to minimize the potential negative tissue response 
to the acidic PLGA degradation products. The minimal quantity of microparticles in-
corporated in this group could serve as delivery vehicle for growth factors in a con-
trolled release system rather than to create additional macroporosity. The high quantity 
(15wt%) of PLGA microparticles was added primarily to induce additional macropo-
rosity after degradation of the PLGA. These particles, however, could also function as 
growth factor delivery vehicles. Initial macroporosity prior to PLGA degradation was 
provided by using CO2 induced macroporosity in two ratios. 
Morphometry of subcutaneous implants showed that after twelve weeks of implan-
tation, macroporosity of the composites reached 19 ± 2% and 34 ± 3% for the low CO2 
porosity formulations (4% PLGA and 15% PLGA, respectively), and 38 ± 7% and 45 ± 5 
for the high CO2 porosity formulations (4% PLGA and 15% PLGA, respectively). Previ-
ously published studies have demonstrated that the intrinsic microporosity (pore size 
< 1 µm) of this Ca-P cement is 39%.22 Total porosity (microporosity plus macroporos-
ity) of the various composites therefore range from 58% to 84%, values which fall with-
in the range of previously used porous Ca-P cements.8,9,14 
Cranial and subcutaneous implantation revealed that tissue ingrowth was facili-
tated by the addition of PLGA microparticles to the porous Ca-P cements. In both 4% 
PLGA groups, bone and ﬁbrous tissue ingrowth were frequently limited to CO2 pores 
and adjacent PLGA pores, whereas in both 15% PLGA groups tissue formation had pro-
ceeded throughout the entire composite. Given the abundant ingrowth of tissue in the 
15% PLGA composites, we presume that the amount of CO2 induced porosity can be 
reduced further or even can be abandoned. Moreover, no adverse tissue reaction to the 
PLGA was observed in any of the composites. Inﬂammatory cells were observed only 
occasionally and can be considered as a mild, resolvable tissue response.
In the cranial implants, a signiﬁcant amount of bone ingrowth was observed in all 
formulations. Unfortunately, limitations in the discriminating capacity of the current 
image analysis programs between colors of closely related gray levels do not allow to 
discern adequately between bone and cement. Therefore, bone formation and Ca-P ce-
ment are expressed together as composite density. In this model, any increase in cranial 
composite density compared to subcutaneous composite density is considered due to 
bone formation within the composites. Consequently, subtraction of mean densities 
as performed in equation (2) results in the parameter ∆ D, which estimates mean bone 
formation within cranial composites. It should be mentioned, however, that ∆ D will 
underestimate bone formation in groups with abundant bone ingrowth, as it does not 
account for Ca-P cement resorption by osteoclasts during orthotopic implantation13,17. 
Histological images of cranial sections in this study show that bone formation with-
in the composites occurs along the Ca-P cement pore surface. This observation is not 
surprising as Ca-P ceramics are generally known for their osteoconductive properties. 
However, the large CO2 macropores present in the HP composites appeared to ham-
per bone formation in many sections, due to the absence of bone guiding Ca-P cement 
within the large cavities. Moreover, morphometrical analysis revealed similar increases 
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in mean composite density (∆ D ) in 15%LP, 4%HP and 15%HP composites whereas 
∆ D in 4%LP composites was signiﬁcantly smaller. This indicates that additional initial 
CO2 macroporosity did not result in additional bone formation after twelve weeks and 
conﬁrms our hypothesis that CO2 porosity can be substituted by PLGA microparticles 
induced porosity. 
Histological sections showed extensive bone ingrowth in PLGA pores ranging from 
15-150 µm in diameter. For porous sintered ceramics, optimal pore size for bone in-
growth has been suggested to be between 200-400 µm.29-31 Morphometrical analysis 
and histological observations of the composites used in this study suggest that optimal 
pore size in Ca-P cement is much smaller than the postulated ideal requirements for sin-
tered porous ceramics. It must be emphasized however, that further investigations with 
larger bone defects are required to come to conclusive answers to this supposition.
The amount of PLGA microparticles incorporated in the Ca-P cement is crucial in 
order to provide an interconnected pore network after PLGA degradation. Incorpora-
tion of spherical microparticles does not guarantee an interconnected pore network, 
which was emphasized by the absence of tissue in a number of PLGA pores in the 4% 
PLGA formulations. Nevertheless, histology of 15% PLGA formulations revealed that 
ﬁbrous tissue and blood vessel ingrowth had proceeded into all macropores throughout 
the composite. We assume that the microporosity or even nanoporosity of Ca-P cement 
plays an important role for tissue to prevail over small non-interconnected pore to pore 
distances. 
Limited but distinct mineralized matrix was observed in spherical PLGA pores in 
67% of all subcutaneous implants. Although no characteristic bone features such as 
osteoid, osteoblasts or osteocytes were observed, the tissue’s smooth and dense ap-
pearance was remarkably similar to the appearance of bone. These results could con-
ﬁrm observations of others who have reported osteoinductive properties of Ca-P 
ceramics.32-34 Interestingly, Ripamonti et al. reported that concave macroporosity 
was the driving force for intrinsic osteoinduction in ceramics32,33, whereas Yuan et al. 
hypothesized that microporosity was of critical importance.34 The porous PLGA/Ca-P 
cement composite examined in this study exhibit both of these features. This ﬁnding 
strongly suggests that under appropriate conditions and architecture, porous PLGA/
Ca-P cement composites may possess intrinsic osteoinductive properties. 
To our knowledge, no previous studies have been published concerning the in vivo 
behavior of a porous Ca-P cement based PLGA/Ca-P cement composite material. In re-
cent years, two in vitro studies with PLGA/Ca-P cement composites without initial CO2 
induced porosity have been reported by our group20 and by Simon et al.35 In our previ-
ous study, we demonstrated the feasibility of PLGA/Ca-P cement composites as vehicle 
for growth factor delivery. Simon et al. demonstrated the in vitro biocompatibility of 
a similar PLGA/Ca-P cement composite material. The current study emphasizes that 
porous PLGA/Ca-P cement composites show excellent biological behavior. The tissue 
response to PLGA pores in Ca-P cement is even of such quality, that it is questionable 
whether any CO2 pore induction is needed for full tissue ingrowth. In a concomitant 
study in a similar animal model, we conﬁrmed that addition of 15% PLGA micropar-
99
ticles to Ca-P cement without CO2 porosity indeed enabled complete ingrowth of bone 
and other tissues.36 Taken into account the potentials for sustained growth factor deliv-
ery and even intrinsic osteoinduction, porous PLGA/Ca-P cement composites may be 
an ideal scaffolding material for bone regeneration and bone tissue engineering.
5. Conclusions
We conclude that PLGA microparticles can be incorporated into porous Ca-P 
cement and form macropores within the Ca-P cement framework after PLGA hydroly-
sis in vivo. No adverse tissue reaction to PLGA degradation products was observed in 
formulations of 4wt% and 15wt% PLGA. Initial CO2 induced porosity can be decreased 
or even abandoned with the incorporation of the PLGA microparticles. Bone-like min-
eralization present in subcutaneous implants strongly suggests that under appropriate 
conditions and architecture, porous PLGA/Ca-P cement composites possess intrinsic 
osteoinductive properties. This composite may be an ideal scaffolding material for bone 
regeneration and bone tissue engineering.
 
6. Acknowledgements
This study was ﬁnancially supported by the National Institutes of Health (R01-
AR42639), the Nanoscale Science and Engineering Initiative of the National Science 
Foundation (EEC-0118001) (AGM), the Netherlands Technology Foundation (STW) 
and the Van Walree Fund, Royal Netherlands Academy of Arts and Sciences. The 
authors would like to thank Ms. M.C.J. de With for her assistance with the Doornbos 
outlier test.
7. References
 1.  Friedman, C. D., Costantino, P. D., Takagi, S., and Chow, L. C. BoneSource hydroxyapatite cement: a novel bio-
material for craniofacial skeletal tissue engineering and reconstruction. J Biomed Mater Res, 43: 428-432, 1998.
 2.  Ladd, A. L. and Pliam, N. B. Use of bone-graft substitutes in distal radius fractures. J Am Acad Orthop Surg, 7: 
279-290, 1999.
 3.  Larsson, S. and Bauer, T. W. Use of injectable calcium phosphate cement for fracture ﬁxation: a review. Clin 
Orthop, 23-32, 2002.
 4.  Brown, W. E. and Chow, L. C. Dental restorative cement pastes. US. Patent (4,518,430). 1985. 
 5.  LeGeros, R. Z. Calcium phosphates in oral biology and medicine. Monogr Oral Sci, 15: 1-201, 1991.
 6.  Schmitz, J. P., Hollinger, J. O., and Milam, S. B. Reconstruction of bone using calcium phosphate bone cements: a 
critical review. J Oral Maxillofac Surg, 57: 1122-1126, 1999.
 7.  Comuzzi, L., Ooms, E., and Jansen, J. A. Injectable calcium phosphate cement as a ﬁller for bone defects around 
oral implants: an experimental study in goats. Clin Oral Implants Res, 13: 304-311, 2002.
100
Po
ro
u
s 
PL
G
A
/
C
a-
P 
C
em
en
t C
om
p
os
it
es
 fo
r 
R
ec
on
st
ru
ct
io
n
 o
f  
B
on
e 
D
ef
ec
ts
 8.  del Real, RP., Ooms, E., Wolke, J., Vallet-Regi, M., and Jansen, JA. In vivo bone response to porous calcium 
phosphate cement. J Biomed Mater Res, 65A: 30-36, 2003.
 9.  Kroese-Deutman, H. C., Ruhé, P. Q., Spauwen, P. H., and Jansen, J. A. Bone inductive properties of rhBMP-2 
loaded porous calcium phosphate cement implants inserted at an ectopic site in rabbits. Biomaterials, 26: 1131-
1138, 2005.
 10.  Ooms, E. M., Wolke, J. G., van der Waerden, J. P., and Jansen, J. A. Trabecular bone response to injectable calcium 
phosphate (Ca-P) cement. J Biomed Mater Res, 61: 9-18, 2002.
 11.  Ooms, E. M., Wolke, J. G., van der Waerden, J. P., and Jansen, J. A. Use of injectable calcium-phosphate cement for 
the ﬁxation of titanium implants: an experimental study in goats. J Biomed Mater Res, 66B: 447-456, 2003.
 12.  Ooms, E. M., Egglezos, E. A., Wolke, J. G., and Jansen, J. A. Soft-tissue response to injectable calcium phosphate 
cements. Biomaterials, 24: 749-757, 2003.
 13.  Ooms, E. M., Wolke, J. G., van de Heuvel, M. T., Jeschke, B., and Jansen, J. A. Histological evaluation of the bone 
response to calcium phosphate cement implanted in cortical bone. Biomaterials, 24: 989-1000, 2003.
 14.  Ruhé, P. Q., Kroese-Deutman, H. C., Wolke, J. G., Spauwen, P. H., and Jansen, J. A. Bone inductive properties of 
rhBMP-2 loaded porous calcium phosphate cement implants in cranial defects in rabbits. Biomaterials, 25: 
2123-2132, 2004.
 15.  Chow, L. C. Calcium phosphate cements. Monogr Oral Sci, 18: 148-163, 2001.
 16.  Clokie, C. M., Moghadam, H., Jackson, M. T., and Sandor, G. K. Closure of critical sized defects with allogenic and 
alloplastic bone substitutes. J Craniofac Surg, 13: 111-121, 2002.
 17.  Schliephake, H., Gruber, R., Dard, M., Wenz, R., and Scholz, S. Repair of calvarial defects in rats by prefabricated 
hydroxyapatite cement implants. J Biomed Mater Res, 69A: 382-390, 2004.
 18.  Lu, L., Stamatas, G. N., and Mikos, A. G. Controlled release of transforming growth factor beta1 from 
biodegradable polymer microparticles. J Biomed Mater Res, 50: 440-51, 2000.
 19.  Hedberg, E. L., Tang, A., Crowther, R. S., Carney, D. H., and Mikos, A. G. Controlled release of an osteogenic 
peptide from injectable biodegradable polymeric composites. J Control Release, 84: 137-50, 2002.
 20.  Ruhé, P. Q., Hedberg, E. L., Padron, N. T., Spauwen, P. H., Jansen, J. A., and Mikos, A. G. rhBMP-2 release from 
injectable poly(DL-lactic-co-glycolic acid)/calcium-phosphate cement composites. J Bone Joint Surg Am, 85-A 
Suppl 3: 75-81, 2003.
 21.  Shive, M. S. and Anderson, J. M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug 
Deliv Rev, 28: 5-24, 1997.
 22.  del Real, R. P., Wolke, J. G., Vallet-Regi, M., and Jansen, J. A. A new method to produce macropores in calcium 
phosphate cements. Biomaterials, 23: 3673-80, 2002.
 23.  Cleek, R. L., Rege, A. A., Denner, L. A., Eskin, S. G., and Mikos, A. G. Inhibition of smooth muscle cell growth in 
vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticles. J 
Biomed Mater Res, 35: 525-30, 1997.
 24.  Peter, S. J., Lu, L., Kim, D. J., Stamatas, G. N., Miller, M. J., Yaszemski, M. J., and Mikos, A. G. Effects of transforming 
growth factor beta1 released from biodegradable polymer microparticles on marrow stromal osteoblasts 
cultured on poly(propylene fumarate) substrates. J Biomed Mater Res, 50: 452-62, 2000.
 25.  van der Lubbe, H. B., Klein, C. P., and de Groot, K. A simple method for preparing thin (10 microM) histological 
sections of undecalciﬁed plastic embedded bone with implants. Stain Technol, 63: 171-6, 1988.
 26.  Squires, G. L. Further topics in statistical theory; Functions of several variables. In G. L. Squires (ed.), Practical 
physics, Third ed, pp. 33-46. Cambridge, UK: Cambridge University Press, 1985.
 
101
 27.  Sikavitsas, V. I., van den, D. J., Bancroft, G. N., Jansen, J. A., and Mikos, A. G. Inﬂuence of the in vitro culture 
period on the in vivo performance of cell/titanium bone tissue-engineered constructs using a rat cranial critical 
size defect model. J Biomed Mater Res, 67A: 944-951, 2003.
 28.  Blum, J. S., Barry, M. A., Mikos, A. G., and Jansen, J. A. In vivo evaluation of gene therapy vectors in ex vivo-
derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther, 
14: 1689-1701, 2003.
 29.  Kuboki, Y., Jin, Q., and Takita, H. Geometry of carriers controlling phenotypic expression in BMP-induced 
osteogenesis and chondrogenesis. J Bone Joint Surg Am, 83-A Suppl 1: 105-15, 2001.
 30.  Tsuruga, E., Takita, H., Itoh, H., Wakisaka, Y., and Kuboki, Y. Pore size of porous hydroxyapatite as the cell-
substratum controls BMP- induced osteogenesis. J Biochem (Tokyo), 121: 317-24, 1997.
 31.  LeGeros, R. Z. Properties of osteoconductive biomaterials: calcium phosphates. Clin Orthop, 81-98, 2002.
 32.  Ripamonti, U. Smart biomaterials with intrinsic osteoinductivity: Geometric control of bone differentiation. In J. 
E. Davies (ed.), Bone Engineering, pp. 215-222. Toronto: EM Squared Incorporated, 2000.
 33.  Ripamonti, U. and Crooks, J. a. K. A. N. Sintered porous hydroxyapatites with intrinsic osteoinductive activity: 
geometric induction of bone formation. S Afr J Sci, 95: 335-343, 1999.
 34.  Yuan, H., Kurashina, K., de Bruijn, J. D., Li, Y., de Groot, K., and Zhang, X. A preliminary study on osteoinduction 
of two kinds of calcium phosphate ceramics. Biomaterials, 20: 1799-1806, 1999.
 35.  Simon, C. G., Khatri, C. A., Wight, S. A., and Wang, F. W. Preliminary report on the biocompatibility of a 
moldable, resorbable, composite bone graft consisting of calcium phosphate cement and poly(lactide-co-
glycolide) microspheres. J Orthop Res, 20: 473-82, 2002.
 36.  Ruhé, P. Q., Hedberg, E. L., Padron, N. T., Spauwen, P. H., Jansen, J. A., and Mikos, A. G. Biocompatibility and 
degradation of poly(DL-lactic-co-glycolic acid)/calcium phosphate cement composites. J Biomed Mater Res, In 
press: 2005.
102
Po
ro
u
s 
PL
G
A
/
C
a-
P 
C
em
en
t C
om
p
os
it
es
 fo
r 
R
ec
on
st
ru
ct
io
n
 o
f  
B
on
e 
D
ef
ec
ts
7
In vivo Release of rhBMP-2 Loaded Porous Calcium
 Phosphate Cement Pretreated with Albumin.
 
P.Q. Ruhé1, O.C. Boerman2, F.G.M. Russel3, A.G. Mikos4, P.H.M. Spauwen5, J.A. Jansen1 
1   Department of Biomaterials, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
2   Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen,  
The Netherlands 
3   Department of Pharmacology and Toxicology, Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands 
4  Department of Bioengineering, Rice University, Houston, Texas, USA
5   Department of Plastic and Reconstructive Surgery, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands
In press: J Mater Sci Mater Med, 2005
103
1. Introduction
Calcium phosphate (Ca-P) ceramics form a distinct group among the diverse range 
of bone replacing biomaterials, and are generally known for their intrinsic osteophilic 
properties. Ca-P ceramics are commercially available in several chemico-physical forms 
and have also been used as scaffolding material for growth factor-based bone engineer-
ing.1-16 Most of these studies reported an osteoinductive effect of the BMP loaded con-
struct, but were not designed to investigate the relation between release kinetics and 
bioactivity of the loaded growth factor. For example, the biomaterial might potentiate 
the activity of BMP by binding the protein and presenting it to target cells in a “bound” 
form.17,18 On the other hand, the ceramic can also act as a delivery vehicle and released 
protein may provide a supra-physiological concentration of free protein in the vicinity 
of the implant, which may attract target cells to the implant-site by chemotaxis.19 Con-
sequently, protein binding to the biomaterial may play an important role in protein bio-
activity. Column chromatography separation techniques have shown that Ca-P ceram-
ics exhibit a high binding afﬁnity for proteins. Unfortunately, the exact binding mecha-
nism of rhBMP-2 to a Ca-P ceramic surface is not exactly known. Several adsorption 
mechanisms have been proposed for macromolecules with apatitic substrates,20 such as 
(1) physical adsorption that takes place in the electrical double layer,21 (2) chemisorp-
tion that involves direct bond formation between the adsorbing molecule and apatite,22 
(3) speciﬁc adsorption of calcium ions that may act as a bridge to bind anionic species to 
phosphate sites of the hydroxyapatite lattice,22 (4) H-bonding that enables interactions 
with phosphate, hydroxyl and/or ﬂuor groups of hydroxyapatite,22 and (5) formation of 
multilayers on the surface.23 Although elucidation of the precise binding mechanisms 
is hindered by the complexity of the structures and the diversity of functional groups in 
these macromolecules, maximum numbers of adsorption sites and afﬁnity constants to 
various Ca-P substrates have been described for several adsorbates.20 
Until now, a limited number of studies focused on the in vivo release kinetics of 
growth factors loaded onto Ca-P ceramics.2,3,8,16 The outcome of these studies varied 
considerably, most likely due to differences in surgical site, dose, adsorption procedures, 
material surface area and differences in chemico-physical interactions between material 
and growth factor. Overall, ceramics exhibited one or two phasic release kinetics with a 
certain retention for several weeks. Uludag et al. concluded that growth factor retention 
depended on carrier- as well as on protein characteristics.2,3 Carriers exhibiting higher 
retention of BMP yielded higher osteoinductive activity. However, chemico-physical 
differences between carriers confounded any correlation between protein pharmacoki-
netics and protein bioactivity. 
In view of the studies mentioned above, we carried out a study where rhBMP-2 was 
lyophilized on the surface of porous Ca-P cement discs. Ten weeks after subcutaneous 
implantation in rabbits, signiﬁcant osteoinduction was seen inside the disc porosity.7 
Nevertheless, in vitro analysis revealed a very limited release of rhBMP-2 from the Ca-P 
cement, which suggested an avid interaction between the Ca-P cement and the loaded 
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protein, but provided no answer to the question whether in this study optimal release 
kinetics and maximal bioactivity of the growth factor were obtained.10 Therefore, in the 
present study we focused on the in vivo release of rhBMP-2 loaded porous Ca-P cement 
and aimed for a method to enhance release kinetics without vital alterations in chemico-
physical material properties. We hypothesized, that in vivo rhBMP-2 release kinetics can 
be assessed reliably and longitudinally by scintigraphic imaging of radiolabeled rhBMP-2. 
We further hypothesized that the high afﬁnity adsorption sites of the Ca-P ceramic can be 
blocked by pretreatment of Ca-P with another protein prior to rhBMP-2 administration. 
Blocking of the high binding afﬁnity sites would result in a less avid protein binding of 
subsequently administered rhBMP-2. We assume that weaker interaction of rhBMP-2 
and Ca-P cement will cause an enhanced release of rhBMP-2. In this study, albumin was 
used for pretreatment as this is the most abundant body protein and known for its limited 
speciﬁc activity. Consequently, albumin pretreatment would result in enhanced growth 
factor release without changing the Ca-P material properties. 
2. Materials and methods
2.1 Materials
The Ca-P cement (Calcibon®, Biomet Merck, Darmstadt, Germany) consisted of 
a mixture of 62.5wt% tricalcium phosphate (α-TCP), 26.8wt% dicalcium phosphate 
anhydrous (DCPA), 8.9 wt% calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite 
(HA). NaHCO3 was added to the cement powder for production of CO2 macroporosity in 
the cement.24 Sterile aqueous solutions of Na2HPO4 (2wt%) and NaH2PO4 (8wt%) were 
used as the liquid component. Rat serum albumin (RSA), derived from Sprague Daw-
ley rats and bovine serum albumin were obtained from Sigma-Aldrich Co.(St. Louis, 
MO, USA). Human recombinant BMP-2 (rhBMP-2) was kindly provided by Wyeth Eu-
rope Ltd. (Berks, UK) and radiolabeled with 131I (Perkin Elmer, Milano, Italy).
2.2 Preparation of porous Ca-P cement discs
A 2 ml syringe was closed at the tip with a plastic stopper and ﬁlled with a mix-
ture of 500 mg Ca-P cement and 50 mg NaHCO3. After mixing for 15 seconds with 
Na2HPO4 (2%) in a mixing device (Silamat, Vivadent, Schaan, Liechtenstein), NaH2PO4 
(8%) was added and the syringe was shaken again for 2 seconds. The well-mixed Ca-P 
material was then injected into Teﬂon molds to ensure a standardized shape of the 
scaffolds (discs of 6.35 mm in diameter, 2.4 mm thickness and 75 mm3 volume). The 
discs were removed from the molds after setting of the cement and sterilized by auto-
claving at 121°C for 15 minutes. In this way, ﬁfty-eight sterile discs were prepared 
with an average weight of 63.2 ± 3.7 mg. To visualize the porous structure within the 
Ca-P cement, one disc was reconstructed by microcomputed tomography (µCT) (Sky-
Scan 1072, SkyScan, Aartselaar, Belgium) (Fig. 7.1).
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2.3 RSA pretreatment of porous Ca-P cement discs
A 10% solution of rat serum albumin (RSA) was prepared in double distilled water 
(ddH2O) and ﬁltered through a 0.2 µm cellulose acetate membrane ﬁlter (Omnilabo 
International BV, Breda, The Netherlands) to assure sterility. Under sterile conditions, 
twenty-nine Ca-P cement discs were soaked in 14.5 ml RSA solution and placed on an 
orbital shaker table at low rotational speed (40 rpm) at room temperature for 24 hours. 
Subsequently, the RSA solution was removed and the discs were carefully rinsed with 
29 ml ddH2O to remove free RSA. The discs were then lyophilized and stored dry at 
room temperature until use. Non-pretreated (control) Ca-P cement discs were prepared 
by incubation in ddH2O instead of RSA. 
2.4 Radioiodination of rhBMP-2
rhBMP-2 was labeled with 131I according to the iodogen method.25 Brieﬂy, 0.6 mg 
rhBMP-2 in 200 µl 500 mM phosphate buffer, pH 7.4 and 862 MBq 131I (862 MBq/
ml) were added to a glass vial pre-coated with 500 µg 1,3,4,6-tetrachloro-3α,6α-
diphenylglucouril (Pierce, Rockford, IL, USA). The reaction was allowed to proceed 
for 10 minutes at room temperature and then the reaction mixture was eluted on a 
disposable Sephadex G25M column (PD10; Pharmacia, Uppsala, Sweden) to separate 
labeled rhBMP-2 from free 131I. The void fractions were pooled and the 131I-rhBMP-2 
was concentrated to a ﬁnal concentration of 70 MBq/ml using a YM-10 ﬁlter device 
with a cut-off of 10,000 Da (Millipore, Bedford, MA, USA). 
The radiochemical purity of the 131I-labeled rhBMP-2 was determined by instant 
thin-layer chromatography (ITLC) on Gelman ITLC-SG strips (Gelman Laboratories, 
Ann Arbor, MI, USA) with 0.1 M citrate, pH 5.0 as the mobile phase. The radiochemi-
cal purity of the 131I-labeled rhBMP-2 preparation exceeded 99%, which indicates that 
more than 99% of the 131I-label was covalently linked to rhBMP-2. The radiolabeled 
product was further characterized on a TSK G3000SW gelﬁltration column (7.8 x 300 
mm) using a Bio-Rad BioLogic Duo-Flow FPLC system. The column was eluted with 
PBS at a ﬂow rate of 1.0 ml/min. FPLC analysis revealed a monomeric peak co-eluting 
with unlabeled rhBMP-2 at 22 minutes, demonstrating that the radioiodinated prepa-
ration did not contain rhBMP-2 aggregates or degradation products. 
The speciﬁc activity of the labeled protein was 10 µCi/µg. Hot/cold solutions were 
Fig 7.1: Microcomputed tomography 
image of preset porous Ca-P cement  
disc with irregular formed macropores.  
Bar represents 1 mm.
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prepared in ratios of 3:2 for the in vivo release study and 1:20 for the in vitro release study. 
The ﬁnal rhBMP-2 concentration was adjusted to 0.2 mg/ml in PBS/BSA[0.1%]. 
2.5 131I-rhBMP-2 implant loading 
131I-rhBMP-2 was administered to twenty-nine albumin pretreated and twenty-
nine control porous Ca-P cement discs. A volume of 12.5 µl 131I-rhBMP-2 solution was 
carefully loaded onto the surface of each side of the discs. In this way, all discs were 
loaded with 5 µg 131I-rhBMP-2. Thereafter, the discs were frozen and lyophilized. Sub-
sequent gamma emission of the samples was measured in a shielded well-type gamma 
counter (Wizard, Pharmacia-LKB, Sweden) simultaneously with aliquots of the admin-
istered dose (standards) to determine the initial dosage.
 
2.6 In vitro release assay
Twenty discs were placed in 10 ml glass vials for evaluation of in vitro rhBMP-2 
release kinetics. Samples were incubated in 2 ml PBS or 2 ml fetal calf serum (FCS) at 
37°C on an orbital shaker at low rotational speed (50 rpm) for 21 days (n=5 for each 
formulation and release medium). Both release media were supplemented with 120 
µg/ml gentamycin as antibiotic prophylaxis. At 1, 3, 7, 14, and 21 days, the samples 
were carefully transferred to new vials with fresh release medium. At each time point, 
activity in the discs was measured in a gamma counter prior to ongoing incubation at 
low rotational speed. Standards were counted simultaneously to correct for radioactive 
decay. The remaining activity in discs was expressed as percentage of the initial dose.
2.7 In vivo release assay
Fifteen healthy male Sprague Dawley rats (Harlan, Horst, The Netherlands) with an 
approximate weight of 250 g were used as experimental animals. National guidelines 
for the care and use of laboratory animals were respected. Anesthesia was induced and 
maintained using Isoﬂurane inhalation. The 131I-rhBMP-2 loaded discs were implanted 
subcutaneously in the back of the animals. For the insertion of the implants, the animals 
were immobilized and placed in a ventral position. The back of the animals was shaved 
and disinfected with povidone-iodine. Subcutaneous pockets were created by blunt dis-
section at each side of longitudinal dermal incisions at thoracic and lumbar vertebrae. In 
this way, each animal received two subcutaneous implants of both formulations placed 
according to a statistical randomization scheme. After insertion of the implants the skin 
was closed using agraven suture material. 
In total, forty-eight implants were placed in twelve rats. Three rats only received a 
paravertebral subcutaneous injection of 5 µg 131I-rhBMP-2 in 100 µl PBS/BSA[0.1%] at 
each side. These animals served as control to evaluate the clearance of a depot of rhBMP-2 
and did not receive implants to prevent the risk of adsorption of rhBMP-2 onto the Ca-P 
cement. 
A single-head gamma camera (Orbiter, Siemens Medical Systems Inc., Hoffman 
Estates, IL, USA) equipped with a parallel-hole high-energy collimator was used to 
measure longitudinal release in three rats (n=6 for each formulation) under general 
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inhalation anaesthesia at 0, 16 hours, 2, 3, 7, 9, 12, 14, 17, 21 and 28 days. Additionally, 
activity distribution in the three rats with subcutaneous rhBMP-2 depots (n=6) was 
imaged using the gamma camera after 0, 2, 6, 24 and 48 hours. Images (50,000–
300,000 counts per image) were obtained and digitally stored in 256 × 256 matrices. 
The scintigraphic images were analyzed quantitatively by drawing standardized regions 
of interest (ROI) over the implant. Activity measurements in the ROIs were corrected 
for radioactive decay, acquisition time and background radiation. The measured activity 
in implants was expressed as percentage of the initial dose. At the end of the study, all 
rats used for scintigraphy were euthanized by CO2/O2 suffocation.
After 3, 7 and 21 days, three rats were euthanized by CO2/O2 suffocation for re-
trieval of implants and their surrounding tissues. Subsequently, radioactivity was count-
ed in a shielded well-type gamma counter (Wizard, Pharmacia-LKB, Sweden). Eight 
implants retrieved after 3 and 7 days were separated carefully from their surrounding 
tissue by dissection of the thin ﬁbrous capsule. Both parts were counted independent-
ly to determine the amount of rhBMP-2 present in the surrounding tissue. Standards 
were counted simultaneously to correct for radioactive decay. The measured activity in 
implants and surrounding tissue were expressed as percentage of the initial dose.
Fig 7.3: In vivo retention of rhBMP-2 
injected as subcutaneous depot in the 
back of rats. Retention is expressed as the 
ratio of total mass of rhBMP-2 retained to 
total mass of rhBMP-2 loaded. Error bars 
represent the mean and standard deviation 
for six depots. 
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Fig 7.2: In vitro retention of rhBMP-2 
loaded porous Ca-P cement discs with or 
without albumin pretreatment in PBS or 
FCS under continuous shaking at 37°C. 
Retention is expressed as the ratio of total 
mass of rhBMP-2 retained at each time 
point to total mass of rhBMP-2 loaded. 
Error bars represent the mean and standard 
deviation for ﬁve samples.
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2.8 Statistical analysis
All measurements were statistically evaluated with GraphPad® Instat 3.05 software 
(GraphPad Software Inc., San Diego, CA), using an unpaired T-test with Welch correc-
tion. Pharmacokinetic analysis of rhBMP-2 release in vitro (gamma counter analysis) 
and in vivo (scintigraphic measurements) was done by nonlinear regression analysis 
using GraphPad® Prism 4.02 software (GraphPad Software Inc.). Data were weighted 
reciprocally and  ﬁtted according to a one phase exponential release model. From this 
model half-life (T½) and plateau (P) were calculated, in which T½ represents the average 
time required for a release of 50% of the total released dose and, P is the value to which 
the ﬁtted curve decays, representing the ﬁnally retained dose. 
3. Results
3.1 In vitro release assay
In vitro release kinetics of rhBMP-2 for rhBMP-2 loaded porous Ca-P cement discs 
with albumin pretreatment (initial loading 4.8 ± 0.2 µg rhBMP-2/scaffold) and control 
discs without albumin pretreatment (initial loading 4.8 ± 0.2 µg rhBMP-2/scaffold) were 
evaluated in PBS and serum over the course of 21 days (n=5 for each formulation). All 
discs maintained their integrity during this period. Pharmacokinetic analysis revealed 
that a single phase exponential release model could only be ﬁtted appropriately to the 
data between day 1 and day 21. Pharmacokinetics could not be analyzed separately 
for the rapid initial release during the ﬁrst day, due to the lack of data in this phase. 
Retention of the activity in the samples is depicted in Figure 7.2. Albumin pretreated 
Ca-P discs in serum showed an initial release of 30 ± 1% during the ﬁrst 24 hours, 
followed by a one phase exponential release (T½ = 6 ± 1 days, P = 46 ± 5%). Without 
albumin pretreatment, Ca-P cement discs in serum showed an initial release of 22 ± 
2% during the ﬁrst 24 hours, followed by a similar exponential release (T½ = 7 ± 1 days, 
P = 58 ± 2%). In PBS, initial release was slower for both formulations (11 ± 5% and 6 ± 
2% for pretreated and control discs, respectively). After the ﬁrst day, release was very 
limited compared to similar formulations in serum (T½ = 4 ± 2 days and 4 ± 1 days, 
P = 75 ± 8% and 86 ± 4% for pretreated and control discs, respectively). Calculated half-
lives after the ﬁrst day were not signiﬁcantly different among the various groups. Due 
to differences in initial release, plateaus were signiﬁcantly lower for albumin pretreated 
discs. (p < 0.05 for release in PBS, p < 0.005 for release in serum). 
3.2 In vivo release assay
In vivo release kinetics was assessed in the rat ectopic model by scintigraphic im-
aging of radiolabeled scaffolds in vivo and ex vivo gamma counting of retrieved scaf-
folds. All animals, except one, remained healthy during the experiment without any 
sign of complication in wound healing; one rat died after gamma camera imaging on 
day 21, probably due to an overdose of anaesthesia. All implants remained intact over 
the course of 28 days. 
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Scintigraphy of rhBMP-2 injected as subcutaneous depot in the back of the rats 
revealed one phase exponential release kinetics over a time course of 48 hours (T½ = 
0.3 day). Retention of subcutaneously injected 131I-rhBMP-2 was limited to 8 ± 12% 
after 24 hours (Fig. 7.3). Retention of rhBMP-2 in the porous Ca-P cement implants 
is shown in Figure 7.4. The scatter plots show the retention measured by longitudinal 
in vivo scintigraphic imaging and ex vivo gamma counting of retrieved implants. The 
line graph represents the kinetic release model ﬁtted on the scintigraphic imaging data. 
Scintigraphy determined an initial rhBMP-2 release from control and albumin pretreated 
discs of 19 ± 8% and 13 ± 10% after 16 hours, followed by sustained release phase. After 
28 days, 27 ± 5% of the initial activity in the control discs and 19 ± 5% of the initial 
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Fig 7.5: Distribution of rhBMP-2 
retained in porous Ca-P cement 
discs and rhBMP-2 present in 
capsules and surrounding tissues 
for samples retrieved after 3 and 7 
days of implantation, expressed as 
the ratio of rhBMP-2 mass to total 
cumulative rhBMP-2 mass of disc, 
capsule and surrounding tissue. 
Error bars represent the mean 
and standard deviation for eight 
samples. No signiﬁcant differences 
among groups are observed 
(p>0.05).
Fig 7.4: In vivo retention of rhBMP-2 
loaded porous Ca-P cement discs with or 
without albumin pretreatment implanted 
subcutaneously in the back of rats. The 
scatter plots show the results of longitudi-
nal in vivo scintigraphic imaging (closed 
markers) and ex vivo gamma counting of 
retrieved implants (open markers). The line 
graph represents the one-phase exponen-
tial release model ﬁtted on the scintigraphic 
imaging data. Retention is expressed as the 
ratio of total mass of rhBMP-2 retained to 
total mass of rhBMP-2 loaded. Error bars 
represent the mean and standard deviation 
for six samples. 
activity in the albumin pretreated discs was retained. Release kinetics revealed no 
signiﬁcant difference in half-lives between control and albumin pretreated discs (T½ = 
3 ± 1 days and 6 ± 3 days, p > 0.05). The extrapolated plateaus (P) at the terminal phase 
of the release proﬁle model were signiﬁcantly lower for pretreated discs than for control 
discs (P = 16 ± 10% and 31 ± 5%, p < 0.005). 
Gamma camera measurements were conﬁrmed by ex vivo gamma counting of 
retrieved samples with an average overestimation of gamma camera measurements of 8 
± 4% for each formulation and time period (Fig. 7.4). Further, ex vivo gamma counting 
showed that the capsule and surrounding tissues only contained a minor fraction 
rhBMP-2 compared to the implant (3 ± 1% for samples retrieved after 3 days, 3 ± 2% for 
samples retrieved after 7 days; no signiﬁcant difference among groups) (Fig. 7.5). 
4. Discussion
In this study, we investigated the in vitro and in vivo release kinetics of rhBMP-2 
loaded porous Ca-P cement. Release of growth factor depends on the protein binding 
afﬁnity of the biomaterial surface. We hypothesized that adsorption sites responsible 
for the high protein binding afﬁnity of Ca-P ceramics can be blocked by adsorption of an 
inactive protein as albumin prior to rhBMP-2 adsorption, resulting in a lower rhBMP-
2 binding afﬁnity and enhanced release. Furthermore, we hypothesized that in vivo 
rhBMP-2 release kinetics can be assessed in a reliable and longitudinal fashion using 
131I-labeled rhBMP-2 in combination with gamma-camera scintigraphy. 
Scintigraphy of 131I is generally used in nuclear medicine and allows accurate quan-
tiﬁcation of radiolabeled molecules. Radioiodination of rhBMP-2 is usually done with 
isotope 125I, but essentially identical as labeling with 131I, which has more appropriate 
physical characteristics for gamma camera measurements, mainly because the energy of 
the gamma emission is more suitable for scintigraphic imaging. A limitation of gamma 
camera measurements, however, is that the camera resolution is relatively low and that 
the activity in the implant and the surrounding tissue can not be distinguished. Conse-
quently, overestimation of the retained rhBMP-2 is a potential risk, as released protein 
in the vicinity of the implant is also counted and considered as retained protein. To in-
vestigate the residence time of rhBMP-2 in subcutaneous tissue, three animals received 
two subcutaneous depots of 131I-labeled rhBMP-2. Scintigraphy showed that only 
8 ± 12% of the injected free rhBMP-2 was retained at the injection site after 24 hours 
(T½ = 0.3 days). This indicates that released protein will only reside in the vicinity dur-
ing a short period before being cleared from the tissue. On the other hand, clearance 
within a capsule may be different from clearance from a subcutaneous injected depot. 
Therefore, additional rats were included in this study for separate ex vivo counting of 
the implant and the capsule with surrounding tissue. These measurements showed that 
the capsule and surrounding tissues contained 3.1 ± 1.6% of total rhBMP-2 present in 
implant and surrounding tissue, indicating that overestimation of scintigraphy due to 
released protein will be less than this percentage. 
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The retention of rhBMP-2 measured by scintigraphic imaging in the current study 
was 12 ± 4% higher for each formulation and time period than that determined by con-
ventional ex vivo counting. Most likely, scattering of radioactive sources in the vicinity 
of the measured object is responsible for this limited overestimation in the scinti- 
graphic analysis. Limitation of the number of implants per animal, and increase of 
distances between implants can reduce the effect of scattering and further enhance the 
accuracy of the measurements. Obviously, this will increase the number of animals re-
quired for sufﬁcient statistical power. Nevertheless, we conclude that scintigraphy of 
131I-labeled rhBMP-2 provides a reliable and straightforward method for longitudinal 
measurement of rhBMP-2 release kinetics. This longitudinal technique reduces the 
amount of experimental animals and growth factors required as compared to ex vivo 
counting of retrieved specimens. 
Albumin can be considered as a relatively inert protein, which expresses its principle 
functions as carrier protein and regulator of osmotic blood pressure rather by its quantity 
than by its speciﬁcity.26 Moreover, any implanted biomaterial is directly covered with a 
layer of extracellular proteins, of which albumin is the most abundant.27-30 Therefore, we 
assumed that adsorption of serum albumin prior to implantation would not dramatically 
alter the tissue response compared to control material covered by albumin after implanta-
tion. Meanwhile, we assumed that the interaction between rhBMP-2 and the Ca-P cement 
would be weaker after albumin pretreatment, leading to enhanced release of rhBMP-2. 
In previous studies, we carried out in vitro release assays in protein-free buffer solu-
tions (e.g. PBS) as frequently done in investigations of release kinetics. Based on the re-
sults of those studies, we assumed that Ca-P cement showed a high retention of growth 
factors. The current in vitro release study appeared to support this aforementioned sug-
gestion. In PBS, a limited release of rhBMP-2 from porous Ca-P cement was observed, 
comparable with our earlier experiment. On the other hand, substitution of the incu-
bation medium with FCS resulted in a signiﬁcantly higher release pattern. This ﬁnd-
ing corroborates with observations of Lind et al.31 and Laffargue et al.32 who observed 
similar differences investigating release of various growth factors from Ca-P ceramic 
surfaces, and suggested that serum proteins could enhance desorption of growth fac-
tors. Further, the in vitro release of rhBMP-2 was somewhat accelerated by pretreatment 
of the porous Ca-P cement surface with serum albumin, which seemed to prove our 
initial hypothesis. On the other hand, we also investigated the in vivo release of rhBMP-
2 and compared the results with the in vitro data. Striking differences in release kinet-
ics were observed. Evidently, in vitro release in serum still underestimated the release 
rate occurring in vivo. In addition, differences observed among pretreated and control 
scaffolds were not found in vivo. This underlines that in vitro release studies of growth 
factors from Ca-P ceramics only represent the in vivo release kinetics to a limited degree. 
Similar observations were reported by Li et al., who investigated release of rhBMP-2 
mixed through α-BSM, a highly resorbable Ca-P cement16 After a period of 21 days, 
they found an in vitro release in serum/DMEM of less than 10% and an in vivo release of 
more than 90% in a rabbit ulnar defect model. Based on the results of the current study, 
we strongly recommend that in vitro release studies with Ca-P ceramic materials should 
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be performed in a protein-rich buffer solution similar to body ﬂuids and that one should 
be reluctant when extrapolating the data to the in vivo situation. 
Furthermore, we have to emphasize that not all the observations in the present in 
vivo study correspond with observations by others who carried out in vivo release stud-
ies with rhBMP-2 loaded Ca-P ceramics. For example, Louis-Ugbo et al.8 observed an 
initial release of only 10% after 1 day from rhBMP-2 loaded biphasic calcium phosphate 
granules in a spinal fusion model in rabbits. On the other hand, Li et al. determined a 
burst release of rhBMP-2 loaded α-BSM of approximately 40% within 1 day in a rab-
bit ulnar defect16, while Uludag et al.2 even observed a burst release of more than 70% 
within 3 hours from various rhBMP-2 loaded Ca-P ceramics implanted subcutaneously 
in rats. Also, the subsequent release phase observed in the present in vivo study was 
different from that reported in other in vivo studies. We observed a retention of 20-
30% after 28 days, whereas the investigators mentioned above found retention of less 
than 10% within that time period. Moreover, pharmacokinetics were described by a 
two phase exponential release model by Uludag et al., whereas a one-phase exponential 
release model ﬁtted the data best in the current study. This illustrates that growth factor 
release kinetics are complex and may be inﬂuenced by many variables. A deﬁnite expla-
nation for the discrepancy in results is difﬁcult to give, because the current study was 
not designed to elucidate the protein-Ca-P binding mechanism. Moreover, the phar-
macokinetic model used in this study does not describe the mechanism responsible for 
the rhBMP-2 release. Therefore, we can only hypothesize that competition of protein 
binding to the adsorption sites in combination with complex Ca-P dissolution and pre-
cipitation processes occurring in vivo can cause differences in protein release charac-
teristics.33,34 The biological relevance of these differences in release proﬁle is difﬁcult 
to predict due to the diversity in chemico-physical properties of the used carriers, but 
should be a topic of future research.
The clinical importance of long term retention as observed in the current study 
remains unclear and can be studied in future investigation. Currently, we assume that 
the life cycle of rhBMP-2 does not exceed four weeks and that no additional bioactivity 
should be expected of proteins retaining for a longer time period. For that reason, we do 
not consider the differences in extrapolated plateaus between control Ca-P cement discs 
(P = 31 ± 5%) and albumin pretreated discs (P = 16 ± 10%) as biologically relevant.
5. Conclusions
Scintigraphy of 131I-labeled rhBMP-2 provides a reliable and straightforward method 
for longitudinal measurement of rhBMP-2 release kinetics in vivo. Although albumin 
pretreatment of porous Ca-P cement results in increased initial release of rhBMP-2 
in vitro, in vivo release kinetics are similar compared to non-pretreated porous Ca-P 
cement. Preset rhBMP-2 loaded porous Ca-P cement discs exhibit one phase exponen-
tial release kinetics in the rat ectopic model, characterized by a retention of 20-30% 
after 28 days. 
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1. Introduction
Injectable calcium phosphate (Ca-P) materials have been in development since the 
early 1980’s1,2 to overcome disadvantages of prefabricated Ca-P materials. Injectable Ca-P 
cements consist of a powder containing one or more solid compounds of calcium phosphate 
salts and an aqueous cement liquid. Mixed in an appropriate ratio, a paste is formed which 
sets at body temperature by entanglement of the crystals precipitating within the paste. 
Therefore, Ca-P cements can be shaped according to the defect dimensions and set in situ. 
After setting, the Ca-P crystals typically form a microporous structure with pores smaller 
than 1 µm.3,4 
Ca-P cements in general are known for their biocompatibility and osteoconductive 
properties.3 Currently, several injectable Ca-P cements are commercially available with 
slight differences in chemical composition, setting time, strength and resorbability.5-7 
However, these Ca-P cements do not possess a macroporous structure which allows 
ingrowth of bone and ﬁbrous tissue. Consequently, the ratio of cement-bone surface 
area to cement volume is low and osteoclastic resorption rate is slow.8,9 Moreover, an 
osteoconductive implant alone will not sufﬁce in critical sized defects where induction 
of tissue is necessary. 
The aim of our research is the development of an injectable osteoinductive biomaterial 
based on Ca-P cement, in which a macroporous structure develops in time to allow bone 
ingrowth and to enhance resorption, but which also stimulates bone regeneration and 
repair. Bone healing is a complex physiological process that is initiated and controlled by 
growth factors, like bone morphogenetic protein-2 (BMP-2), BMP-7 and transforming 
growth factor-ß1 (TGF-ß1). The importance of growth factors for bone healing has 
instigated the development of new treatment strategies, which consist of the local delivery 
of growth factors to the defect site with help of a so-called carrier material. In view of 
this, we have recently shown the feasibility of a composite material of Ca-P cement with 
incorporated growth factor loaded poly(DL-lactic-co-glycolic acid) (PLGA) microparticles 
for delivery of recombinant human BMP-2 (rhBMP-2).10 We have also demonstrated that 
PLGA/Ca-P cement composite showed excellent biocompatibility in heterotopic and 
orthotopic implantation sites.11 The composite maintained its integrity in weight ratios 
of 15% and 30% PLGA, developed a macroporous structure after PLGA degradation and 
showed complete penetration of bone, ﬁbrous tissue and blood vessels after twelve weeks 
of implantation in rats. 
PLGA is a synthetic polymer that is known to degrade by non-enzymatic hydrolysis of 
its ester linkages. Eventually, the polymer decreases in molecular weight to the point where 
the integrity of the microparticles can no longer be maintained  and the microparticles 
break down into particulate which undergo macrophage phagocytosis and complete 
degradation.12 Therefore, initial molecular weight is one of the factors that determine 
the time required for complete polymer degradation; for example, PLGA microparticles 
with a molecular weight of 10,000 degraded approximately twice as fast as microparticles 
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with a molecular weight of 20,000 when inserted subcutaneously in the back of rats.12 
These diverse degradation proﬁles of PLGA of different molecular weights can be used to 
inﬂuence and optimize the tissue ingrowth and degradation rate of PLGA/Ca-P cement 
composites. Moreover, the PLGA degradation properties will have an effect on the release 
of incorporated growth factors incorporated. For example, it can be supposed that PLGA 
microparticles with a lower molecular weight will exhibit a faster degradation and a faster 
release of incorporated proteins than PLGA microparticles of higher molecular weight 
PLGA.
In previous studies, we have investigated release kinetics of rhBMP-2 loaded PLGA/
Ca-P cement composites with growth factor entrapped in the PLGA microparticles during 
microparticles fabrication as is done frequently in bone tissue engineering research.13-16 
Entrapment of proteins allows control over release kinetics. On the other hand, entrapment 
is inevitably accompanied by a certain loss of protein due to entrapment inefﬁciency and 
has the potential risk of protein damage. Alternatively, growth factor can be adsorbed 
onto the PLGA surface after microparticle fabrication.17-20 Regardless possibilities for 
control over release, it is most likely that release of protein adsorbed onto the surface of 
PLGA microparticles will be faster than entrapped protein. 
In view of the considerations mentioned above, the aim of this study was to 
investigate the in vivo release of rhBMP-2 loaded PLGA/Ca-P cement composites 
and development of composites with different release rates for future investigation 
of rhBMP-2 bioactivity. We hypothesized that incorporation of low molecular weight 
PLGA microparticles in rhBMP-2 loaded PLGA/Ca-P cement composites would result 
in faster release of rhBMP-2 than incorporation of high molecular weight PLGA. 
Further, we hypothesized that adsorption of rhBMP-2 onto the surface of PLGA 
microparticles would also result in faster release from rhBMP-2 loaded PLGA/Ca-P 
cement composites compared to entrapment within PLGA microparticles.
2. Materials and methods
2.1 Materials
The Ca-P cement (Calcibon®, Biomet Merck, Darmstadt, Germany) consisted of 
a mixture of 62.5wt% tricalcium phosphate (α-TCP), 26.8wt% dicalcium phosphate 
anhydrous (DCPA), 8.9wt% calcium carbonate (CaCO3) and 1.8wt% hydroxyapatite 
(HA). Sterile aqueous solutions of Na2HPO4 (2wt%) were used as the liquid component. 
High molecular weight (HMW) and low molecular weight (LMW) poly(DL-lactic-co-
glycolic acid) (PLGA) with a 53:47 lactic to glycolic acid copolymer ratio were obtained 
from Purac Biochem BV (Gorinchem, The Netherlands). Weight average molecular 
weight (Mw) was 49,100 ± 1,700 for the HMW PLGA (polydispersity index [PI]: 
2.01 ± 0.01), and 5,900 ± 300 for the LMW PLGA (PI: 2.66 ± 0.00) as determined 
by gel permeation chromatography. The PI is equal to the ratio of the weight average 
molecular weight to number average molecular weight (Mw /Mn). Ancillary chemicals 
for microparticle preparation were all of analytical grade and obtained as previously 
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described.10 Human recombinant BMP-2 (rhBMP-2) was kindly provided by Wyeth 
Europe Ltd., Berks, UK and radiolabeled with 131I (Perkin Elmer, Boston, MA) as 
described below. 
2.2 Radioiodination of rhBMP-2
rhBMP-2 was labeled with 131I according to the iodogen method.21 Brieﬂy, 0.6 mg 
rhBMP-2 in 200 µl 500 mM phosphate buffer, pH 7.4 and 862 MBq 131I (862 MBq/
ml) were added to a glass vial pre-coated with 500 µg 1,3,4,6-tetrachloro-3α,6α-
diphenylglucouril (Pierce, Rockford, IL, USA). The reaction was allowed to proceed 
for 10 minutes at room temperature and then the reaction mixture was eluted on a 
disposable Sephadex G25M column (PD10; Pharmacia, Uppsala, Sweden) to separate 
labeled rhBMP-2 from free 131I. The void fractions were pooled and the 131I-rhBMP-2 
was concentrated to a ﬁnal concentration of 70 MBq/ml using a YM-10 ﬁlter device 
with a cut off of 10,000 Da (Millipore, Bedford, MA, USA)). 
The radiochemical purity of the 131I-labeled rhBMP-2 was determined by instant 
thin-layer chromatography (ITLC) on Gelman ITLC-SG strips (Gelman Laboratories, 
Ann Arbor, MI, USA) with 0.1 M citrate, pH 5.0 as the mobile phase, The radiochemical 
purity of the 131I-labeled rhBMP-2 preparation exceeded 99%, which indicates that 
more than 99% of the 131I-label was covalently linked to rhBMP-2. The radiolabeled 
product was further characterized on a TSK G3000SW gelﬁltration column (7.8 x 300 
mm) using a Bio-Rad BioLogic Duo-Flow FPLC system. The column was eluted with 
PBS at a ﬂow rate of 1.0 ml/minute. FPLC revealed a monomeric peak co-eluting with 
unlabeled rhBMP-2 at 22 minutes, demonstrating that the radioiodinated preparation 
did not contain signiﬁcant amounts of rhBMP-2 aggregates or degradation products. 
The speciﬁc activity of the labeled protein was 10 µCi/µg. A 3:2 hot/cold solution 
was prepared, and the ﬁnal rhBMP-2 concentration was adjusted to 0.65 mg/ml 
(rhBMP-2 adsorption) and 1.33 mg/ml (rhBMP-2 entrapment) in PBS/BSA[0.1%]. 
2.3  Preparation of unloaded- and entrapped  
rhBMP-2 loaded microparticles 
PLGA microparticles were prepared by an established double-emulsion-solvent-
extraction technique ([water-in-oil]-in-water) as previously described.10,13,16,22 High 
molecular weight (HMW) microparticles were produced by injecting 125 µl PBS/
BSA[0.1%] (unloaded microparticles) or 125 µl 131I-rhBMP-2 solution (1.33 mg 
rhBMP-2/ml PBS/BSA[0.1%]) (entrapped rhBMP-2 microparticles) as ﬁrst aqueous 
phase into a ﬂint glass tube containing a solution of 250 mg HMW PLGA in 1 ml 
dichloromethane. 
Accordingly, low molecular weight (LMW) microparticles were produced in a flint 
glass tube containing a solution of 350 mg LMW PLGA in 0.5 ml dichloromethane 
to obtain microparticles of similar sizes. The mixtures were emulsified for 60 
seconds on a vortexer (Vortex Genie 2, Scientific Industries, Bohemia, NY, USA). 
Subsequently, 1.5 ml 0.3% aqueous poly(vinyl alcohol) (PVA) solution was added 
as second aqueous phase and emulsified for 60 seconds on a vortexer to produce the 
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second emulsion. This mixture was then added to 98.5 ml PVA solution and 100 ml 
of 0.2% aqueous isopropanol solution with rapid stirring for 1 hour. The extraction 
of the dichloromethane into the external aqueous phase resulted in the precipitation 
of the dissolved polymer and subsequent microparticle formation. The formed 
microparticles were collected, centrifuged at 1000 rpm for 2 minutes, lyophilized, 
weighed and stored at -20°C until use. 
The entrapment efﬁciency of rhBMP-2 during microparticle preparation was 
calculated by measuring of 131I activity of the 131I-rhBMP-2 added during the fabrication 
process and the 131I activity in the formed microparticles in a shielded well-type 
gamma counter (Wizard, Pharmacia-LKB, Sweden). Aliquots of the administered dose 
(standards) were measured simultaneously to correct for radioactive decay of 131I. The 
morphology of unloaded microparticles was evaluated by scanning electron microscopy 
(SEM) (Jeol JSM-6310 Scanning Microscope, Tokyo, Japan). Microparticle size 
distribution was assessed by morphometrical analysis using a light microscope (Leica 
Microsystems AG, Wetzlar, Germany) and computer based image analysis techniques 
(Leica® Qwin Pro-image analysis system, Wetzlar, Germany).
2.4  Preparation of adsorbed rhBMP-2 microparticles
After lyophilization of unloaded HMW and LMW PLGA microparticles, 131I-rhBMP-
2 solution (0.65 mg rhBMP-2/ml PBS/BSA[0.1%]) was adsorbed onto unloaded PLGA 
microparticles in a ﬂuid/particle ratio of 0.8 µl/mg. This ratio provided complete wetting 
of the PLGA microparticles without ﬂuid surplus. After 30 minutes adsorption time, 
microparticles were frozen at -20°C and lyophilized. Thereafter, microparticles were 
transferred into a new vial. Subsequent gamma counting determined the adsorption 
efﬁciency of rhBMP-2 onto the microparticles. 
2.5  Preparation of 131I-rhBMP-2 loaded PLGA/ 
Ca-P cement composites
PLGA/Ca-P cement composites were prepared under aseptic conditions. Four 
formulations of rhBMP-2 loaded microparticles were incorporated in Ca-P cement, i.e. 
(1.) rhBMP-2 entrapped in HWM PLGA microparticles, (2.) rhBMP-2 adsorbed onto 
HWM PLGA microparticles, (3.) rhBMP-2 entrapped in LWM PLGA microparticles, and 
(4.) rhBMP-2 adsorbed onto LWM PLGA microparticles. Unloaded PLGA microparticles 
(either HMW or LMW) were mixed with rhBMP-2 loaded microparticles to achieve 
identical doses of rhBMP-2 for all formulations (0.3 µg rhBMP-2/mg). Subsequently, 
microparticles were added to the Ca-P cement powder in a 30/70 PLGA/Ca-P weight 
ratio. A 2 ml syringe was closed at the tip with a plastic stopper and ﬁlled with 500 mg 
of this PLGA/Ca-P mixture. Then, cement liquid (2 wt% aqueous solution of Na2HPO4) 
was added in a liquid/powder weight ratio of 0.5. Subsequently, the syringe was closed 
with the injection plunger and placed in a mixing device (Silamat, Vivadent, Schaan, 
Lichtenstein). After mixing for 15 seconds, the stopper was removed and the composite 
was injected into Teﬂon molds to ensure a standardized shape of the composites (discs 
of 6.35 mm in diameter, 2.4 mm thickness and 75 mm3 volume). The discs were 
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removed from the molds after setting of the cement at room temperature for one hour. 
In this way, twenty-four discs of each formulation were produced for subcutaneous 
implantation. The initial rhBMP-2 dosage in the composites was determined by activity 
measurements in a gamma counter. Composites prepared similarly with unloaded 
microparticles were imaged by scanning electron microscopy.
2.6 In vivo release assay
Twenty-four healthy male Sprague Dawley rats (Harlan, Horst, The Netherlands) 
with an approximate weight of 250 g were used as experimental animals. National 
guidelines for the care and use of laboratory animals were respected. Anesthesia was 
induced and maintained using Isoﬂurane inhalation. The 131I-rhBMP-2 loaded composite 
discs were implanted subcutaneously in the back of the animals. For the insertion of the 
implants, the animals were immobilized and placed in a ventral position. The back of the 
animals was shaved and disinfected with povidone-iodine. Subcutaneous pockets were 
created by blunt dissection at each side of longitudinal dermal incisions at thoracic and 
lumbar vertebrae. In this way, each animal received one subcutaneous implant of each 
formulation placed according to a statistical randomization scheme. After placement 
of the implants the skin was closed using Agraven suture material. In total, ninety-six 
implants were placed in twenty-four rats. 
A single-head gamma camera (Orbiter, Siemens Medical Systems Inc., Hoffman 
Estates, IL, USA) equipped with a parallel-hole high-energy collimator was used to 
measure release of 131I-rhBMP-2 from the composites longitudinally in six rats (n=6 
for each formulation) under general inhalation anaesthesia at 0, 16 hours, and 2, 3, 7, 9, 
12, 14, 17, 21 and 28 days. Images (50,000–300,000 counts per image) were acquired 
and digitally stored in 256 × 256 matrices. The scintigraphic images were analyzed 
quantitatively by drawing standardized regions of interest (ROI) over the implants. 
Activity measurements in the ROIs were corrected for radioactive decay, acquisition 
time and background activity. The measured activity in implants was expressed as 
percentage of the initial dose. At the end of the study, all rats used for scintigraphy were 
euthanized by CO2/O2 suffocation.
After 3, 7 and 21 days, six rats were euthanized by CO2/O2 suffocation, and the 
implants and their surrounding tissues were dissected. Subsequently, radioactivity in 
the retrieved samples was counted in a shielded well-type gamma counter. Standards 
were counted simultaneously to correct for radioactive decay. The measured activity 
in implants and surrounding tissue were expressed as percentage of the initial dose. 
Twenty-one implants were separated carefully from their surrounding tissue by 
dissection of the thin ﬁbrous capsule, and counted independently to determine the 
amount of rhBMP-2 present in the surrounding tissue. 
2.7 Statistical analysis
RhBMP-2 release rates (expressed as percentage of loaded dose per day) were 
calculated by linear regression analysis from the slopes of scintigraphic data from 3 to 
28 days using GraphPad® Prism 4.02 software (GraphPad Software Inc., San Diego, 
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CA, USA). All measurements were statistically evaluated with GraphPad® Instat 3.05 
software (GraphPad Software Inc.), using an one-way analysis of variance (ANOVA) 
with Tukey post test. Differences were considered signiﬁcant if p < 0.05. 
3. Results
3.1  Preparation and characterization of  
PLGA microparticles 
PLGA microparticles were prepared by a double-emulsion-solvent-extraction 
technique as previously described.10,13,16,22 The mean microparticle size was 44 ± 
16 µm for LMW microparticles and 45 ± 16 µm for HMW microparticles (Fig. 8.1). 
Scanning electron microscopy revealed a spherical shape and occasional pores in 
HMW microparticles and more frequently in LMW microparticles (Fig. 8.2). Gamma 
counting revealed an entrapment efﬁciency of 65% for rhBMP-2 loaded in the LMW 
microparticles and 77% for rhBMP-2 loaded in the HMW microparticles. Adsorption 
efﬁciency was 93% for LMW as well as HMW microparticles. 
3.2  Preparation and characterization of  
PLGA/Ca-P cement composites
PLGA/Ca-P cement composites were prepared according to the described protocol. 
Unloaded PLGA microparticles (either HMW or LMW) were mixed with rhBMP-2 
loaded microparticles to achieve identical doses of rhBMP-2 for all formulations (0.3 
µg rhBMP-2/mg). Depending on differences in loading efﬁciencies, the fraction of 
rhBMP-2 loaded microparticles in this mixture was 54 ± 6%. Twenty-four discs of each 
formulation were prepared for subcutaneous implantation. Gamma counting prior 
to implantation revealed initial doses of 6.9 ± 0.3 µg rhBMP-2 for HMW entrapped 
rhBMP-2 composites, 6.3 ± 0.6 µg rhBMP-2 for HMW adsorbed rhBMP-2 composites, 
6.5 ± 0.6 µg rhBMP-2 for LMW entrapped rhBMP-2 composites, and 7.1 ± 1.8 µg 
rhBMP-2 for LMW adsorbed rhBMP-2 composites. SEM imaging revealed intact PLGA 
microparticles embedded in the Ca-P cement (Fig. 8.3).
3.3 In vivo release assay
In vivo release kinetics were assessed in the rat ectopic model by in vivo scintigraphy 
and ex vivo gamma counting of retrieved scaffolds. All animals, except two, remained 
healthy during the experiment without any sign of complication in wound healing; Two 
rats died during gamma camera imaging on day 17, most likely due to an overdose of 
anaesthetics. All implants remained intact over the course of 28 days. 
Retention of rhBMP-2 in the composites measured by longitudinal scintigraphic 
imaging is shown in Figure 8.4 and Table 8.1. None of the formulations demonstrated a 
burst release of rhBMP-2. On the contrary, all formulations appeared to be slow release 
vehicles and revealed an almost linear release from day 3 to day 28 (HMW adsorbed 
rhBMP-2 composites) or during the complete period (other formulations). Linear 
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regression showed that the release of LMW entrapped rhBMP-2 composites (Table 8.1) 
was signiﬁcantly faster than release from LMW adsorbed rhBMP-2 composites (p < 
0.001), HMW entrapped rhBMP-2 composites (p < 0.01), and HMW adsorbed rhBMP-
2 composites (p < 0.001). 
Ex vivo counting of retrieved samples revealed comparable proﬁles as scintigraphic 
imaging, although retention measured by scintigraphy was 16 ± 4% higher than retention 
measured by ex vivo gamma counting. Further, separate ex vivo activity measurements 
of twenty-one implants and their surrounding tissues retrieved at day 3 and 7 showed 
that the capsule and surrounding tissues contained 2 ± 2% of the total rhBMP-2 present 
in the implant and surrounding tissue (no signiﬁcant difference among groups).
Fig 8.1: Size distribution of HMW 
and LMW PLGA microparticles as a 
function of each size range’s fraction 
of the total microparticle number.
Fig 8.2: SEM image of the PLGA microparticles. High molecular weight 
microparticles (right) show a smooth spherical surface with occasional 
small pores, whereas low molecular weight microparticles (left) display 
larger pores more frequently. Original magniﬁcation 1000x,  
bar represents 10 µm.
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4. Discussion
In this study, we investigated the in vivo release kinetics of rhBMP-2 loaded 
PLGA/Ca-P cement composites prepared with different rhBMP-2 loading techniques 
and different molecular weights (MW) PLGA. We hypothesized that entrapment of 
rhBMP-2 in low molecular weight (LMW) PLGA/Ca-P cement composites would 
result in faster release of rhBMP-2 than entrapment of rhBMP-2 in high molecular 
weight (HMW) PLGA/Ca-P cement composites, due to more rapid degradation of the 
LMW polymer. Further, we hypothesized that adsorption of rhBMP-2 onto the surface 
of PLGA microparticles would result in faster release from rhBMP-2 loaded PLGA/Ca-
P cement composites than entrapment within PLGA microparticles. 
In this study, the in vivo release was monitored by scintigraphic imaging of 131I-la-
Fig 8.3: SEM image of the surface of HMW (right) and LMW (left) PLGA/
Ca-P cement composites, revealing intact spherical PLGA microparticles 
embedded in the microporous Ca-P cement. Original magniﬁcation 
1000x, bar represents 10 µm.
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Fig 8.4: Longitudinal scintigraphic 
assessment of rhBMP-2 retention 
of rhBMP-2 loaded PLGA/Ca-P 
cement composites discs implanted 
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Retention is expressed as the ratio 
of total mass of rhBMP-2 retained 
to total mass of rhBMP-2 loaded. 
Error bars represent the mean and 
standard deviation for six samples.
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beled rhBMP-2 in the rat ectopic model. Due to the relatively low resolution of a gam-
ma camera (spatial resolution ± 3 mm), scintigraphic imaging can not discern between 
radioactive protein retained in the implant and released protein in the vicinity of the 
implant. In a recent study, we concluded that scintigraphy of 131I-labeled rhBMP-2 pro-
vides a reliable and straightforward method for longitudinal measurement of rhBMP-2 
release kinetics.23 The current study was carried out accordingly to conﬁrm these con-
clusions. Additional scaffolds were implanted for three discrete time periods and re-
trieved for conventional ex vivo gamma counting. Separate ex vivo counting of retrieved 
implants and capsules with surrounding tissues showed that the capsule and surround-
ing tissues contained 2 ± 2% of total rhBMP-2 present in implant and surrounding tis-
sue. Consequently, the overestimation of scintigraphy due to measurement of released 
protein is limited. However, the retention of rhBMP-2 measured by scintigraphic imag-
ing was 16 ± 4% higher for each formulation and time period than measurements by 
conventional ex vivo counting. As described in our previous publication,23 scattering of 
radioactive sources in the vicinity of the measured object is probably responsible for an 
overestimation in the scintigraphic measurement. Reduction of the number of implants 
per animal, and enhancement of the distance between implants can reduce the scatter 
and further enhance the accuracy of the measurements. Nevertheless, the current ex-
periment conﬁrmed again that scintigraphy of 131I-labeled rhBMP-2 provides a reliable 
and straightforward method for longitudinal assessment of rhBMP-2 release kinetics.
The pathway of growth factor bioactivity is not completely clear. Released protein 
may provide a supra-physiological concentration of free protein in the vicinity of the 
implant, which may attract target cells to the implant-site by chemotaxis.24 Released 
protein, however, was found to be cleared from the delivery site within hours, which 
supposedly terminates its local effect.23,25 On the other hand, the protein may also 
express its bioactivity in a “bound” form.26,27 In this context, Uludag et al. suggested 
that biomaterials exhibiting higher retention of BMP yielded higher osteoinductive 
activity.28,29 Unfortunately, chemico-physical differences between carriers confound a 
general correlation between protein pharmacokinetics and protein bioactivity. 
In the present study, rhBMP-2 release was found substantially faster than in a 
previous in vitro release study with similar composites.10 On the other hand, release was 
  Retention Retention Release rate
  day 3 day 28  rhBMP-2/day
HMW entrapped rhBMP-2 composites 94 ± 4% 65 ± 5% 1.2 ± 0.2%
HMW adsorbed rhBMP-2 composites 94 ± 4% 75 ± 4% 1.0 ± 0.1%
LMW entrapped rhBMP-2 composites 98 ± 5% 50 ± 4% 1.7 ± 0.3%
LMW adsorbed rhBMP-2 composites 97 ± 3% 70 ± 6% 0.9 ± 0.3%
Table 8.1: Longitudinal rhBMP-2 release from four different formulations of rhBMP-2 loaded PLGA/Ca-P 
cement composites. Release rates are calculated by linear regression of release proﬁles of individual composite discs 
from 3 to 28 days.  
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substantially slower than in vivo release of rhBMP-2 adsorbed onto the surface of Ca-P 
cement, which demonstrated a one-phase exponential release characterized by a half-
life of 3 ± 1 days and a plateau of 30 ± 5%.23 In the current study, PLGA/Ca-P cement 
composites demonstrated slow, but linear release during four weeks, with signiﬁcant 
differences between release rates of LMW entrapped rhBMP-2 composites and the 
other formulations (p < 0.01). This indicates that PLGA/Ca-P cement composites can 
be considered as sustained slow release vehicles and that the release rate can be tailored 
according to the desired proﬁle to a limited extent. 
The hypothesis that entrapment of rhBMP-2 in fast degrading (LMW) PLGA 
microparticles enhances rhBMP-2 release from PLGA/Ca-P cement composites 
compared to composites prepared from slower degrading (HMW) PLGA/Ca-P cement 
composites is conﬁrmed by the signiﬁcantly higher release rate of LMW entrapped 
rhBMP-2 composites (p < 0.01). However, the difference observed was much smaller 
than expected on basis of the large difference in PLGA degradation kinetics. Although 
degradation of the PLGA has not been investigated in this study, we presume that LMW 
PLGA microparticles have been degraded completely after 28 days in vivo.12 Release of 
rhBMP-2 from the composites, however, was far from complete. A shortcoming of this 
study is that release from PLGA microparticles not-embedded in Ca-P cement has not 
been monitored. Therefore, we can only speculate that release from and degradation 
of the LMW microparticles were complete within 28 days. This suggests that at least 
part of the rhBMP-2 interacted with the Ca-P cement directly after delivery from 
the microparticles. Ca-P cement is known to exhibit a high protein binding afﬁnity. 
Interaction of rhBMP-2 and Ca-P cement after release from the PLGA microparticles can 
explain the limited differences observed in the current study between release proﬁles 
from different composites with quite different PLGA formulations. Whether or not the 
protein bound onto the Ca-P cement maintains its bioactivity will be a topic in a future 
investigation. 
Surprisingly, adsorption of rhBMP-2 onto the surface of the PLGA microparticles 
did not result in increased release from the composites compared to rhBMP-2 entrapped 
in the microparticles. On the contrary, release of LMW adsorbed rhBMP-2 composites 
was signiﬁcantly slower than LMW entrapped rhBMP-2 composites. Possibly, the 
rhBMP-2 adsorbed at the surface of LMW microparticles underwent an avid interaction 
with the Ca-P cement upon mixing and setting of the composite. This ﬁnding rejects 
the second hypothesis of this study and shows, that rhBMP-2 release from PLGA/Ca-P 
cement composites is complex and can be opposite to expectations based on individual 
materials. 
 
5. Conclusions
We conclude that PLGA/Ca-P cement composites are sustained, slow release 
vehicles for rhBMP-2 delivery in vivo. Release proﬁles of rhBMP-2 loaded PLGA/Ca-P 
cement composites can be inﬂuenced to a limited extent by variation of molecular 
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weight of the PLGA used for microparticle preparation and administration method of 
the rhBMP-2. Most likely, release of rhBMP-2 from the composite is slowed down by 
an avid interaction of rhBMP-2 and Ca-P cement after rhBMP-2 release from PLGA 
microparticles. 
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1. Summary and address to the aims 
Calcium phosphate ceramics are clinically used for various dental and surgical 
applications due to their favorable bone behavior. Ca-P compounds exhibit a variety in 
crystallinities and Ca/P ratios, of which tricalcium phosphate (TCP) and hydroxyapatite 
(HA) are most frequently used for biomedical applications. TCP is more soluble in water 
than HA and subject to cellular resorption, whereas HA is stronger but virtually non-
resorbable. Caused by an inherent lack of ductility, all Ca-P ceramics are brittle, which 
make these materials less suitable for application under weight-bearing conditions. 
Generation of porosity further deteriorates the mechanical properties of Ca-P ceramics, 
but is essential for bone- and soft tissue ingrowth, and according to some researchers, 
porosity could even establish an intrinsic osteoinductive capacity. Numerous porous Ca-
P products, either synthetic or naturally derived, are commercially available as granules, 
prefabricated blocks or injectable cements. In the last decade, numerous studies have 
investigated the potential of porous Ca-P ceramics as a scaffold material for bone tissue 
engineering. It was shown, that cultured bone marrow stromal cells loaded into porous 
Ca-P ceramics enabled bone formation even in large animal models. Administration 
of osteoinductive growth factors can also result in ample bone formation in porous 
Ca-P ceramics. However, many variables such as factor dosage, release and retention, 
efﬁcacy, and potentials of multicomponent constructs need to be investigated to reach a 
successful tissue engineered bone graft substitute. 
The overall aim of the Bone Tissue Engineering research group is the development 
of an osteogenic and/or osteoinductive bone graft substitute (BGS) for reconstruction 
of osseous defects. In this thesis, we focused on the potentials of osteoconductive Ca-P 
cement based materials for bone tissue engineering and aimed for the development of a 
porous Ca-P cement suitable for delivery of growth factors and applicable as injectable 
or as preset structure.  
1. Investigation of suitability of preset porous calcium phosphate (Ca-P) 
cement as carrier material for recombinant human bone morphogenetic 
protein-2 (rhBMP-2) at orthotopic and ectopic locations.
In chapter two and three, the osteoinductive properties of preset porous calcium 
phosphate cement loaded with osteoinductive growth factor bone morphogenetic 
protein 2 (rhBMP-2) were evaluated at an orthotopic and ectopic site. Porosity in 
the Ca-P cement was created during the setting of the cement using a CO2 foaming 
technique, which was developed recently by our research group. Porous preset discs 
with a diameter of 8 mm (volume: 150 mm3) were loaded with 10 µg rhBMP-2. After 
lyophilization, discs were inserted in rabbits in 8 mm full thickness cranial defects 
(chapter two) or in subcutaneous pockets in the back of the rabbits (chapter three). 
Implants were retrieved after two and ten weeks and prepared for histological and 
histomorphometrical assessment. The material revealed excellent osteoconductive 
properties and maintained its shape and stability during the implantation time, but 
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showed no objective degradation. In chapter two, orthotopic bone formation was 
increased signiﬁcantly by administration of rhBMP-2 (ten weeks pore ﬁll: 53.0 ± 5.4%), 
but also reached a reasonable amount without rhBMP-2 (43.1 ± 10.4%). Remarkably, 
callus-like bone formation outside the implant was observed frequently in the two 
weeks rhBMP-2 loaded implants, suggesting a correlation with the presence of growth 
factor in the surrounding tissue. However, in vitro analysis in phosphate buffered saline 
(PBS) revealed an accumulative release of no more than 9.7 ± 0.9% after four weeks. 
In chapter three, retrieved samples revealed evident ectopic bone formation in all 
rhBMP-2 loaded Ca-P cement discs (pore ﬁll: 18 ± 6%) after ten weeks of implantation. 
Bone induction occurred only in rhBMP-2 loaded porous Ca-P cement discs. Based on 
the results of chapter two and three, we concluded that: 1. Porous Ca-P cement is an 
appropriate candidate scaffold material for bone engineering. 2. Bone formation can 
be enhanced orthotopically and induced ectopically by lyophilization of rhBMP-2 on 
the cement. 3. Degradation of porous Ca-P cement is species-, implantation site- and 
implant dimension-speciﬁc. However, lyophilization of rhBMP-2 onto the porous Ca-P 
cement did not provide control over rhBMP-2 delivery, which is supposed to play a key 
role in growth factor bioactivity.
2. Investigation of the feasibility of a composite material based on 
Ca-P cement and embedded poly(DL-lactic-co-glycolic acid) (PLGA) 
microparticles for delivery of rhBMP-2.
In close collaboration with the department of Bioengineering, Rice University, 
Houston, Texas, USA, we developed a composite material of Ca-P cement and embedded 
poly(DL-lactic-co-glycolic acid) (PLGA) microparticles. This institute is well known 
for their polymer based tissue engineering research and has ample experience with 
PLGA microparticles as delivery vehicle for bioactive molecules. In chapter four, the 
feasibility of rhBMP-2 loaded PLGA/Ca-P cement composite for delivery of rhBMP-2 
was investigated. PLGA/Ca-P cement composites were prepared in a 30:70 wt% ratio. 
Material properties were evaluated by SEM, µCT and mechanical testing. Radiolabeled 
125I rhBMP-2 was incorporated in PLGA microparticles and release kinetics of rhBMP-
2 from PLGA/Ca-P cement discs and PLGA microparticles alone were determined in 
vitro in two buffer solutions (pH 7.4 and pH 4.0) for up to 28 days. Analysis showed 
spherical PLGA microparticles (average size of 66 ± 25 µm) distributed homogeneously 
throughout the microporous discs. The compressive strength was signiﬁcantly lower 
for PLGA/Ca-P cement composite scaffolds than for Ca-P scaffolds alone (6.4 ± 0.6 
MPa vs. 38.6 ± 2.6 MPa, respectively). The entrapment yield of rhBMP-2 in PLGA 
microparticles was 79 ± 8%. Average rhBMP-2 loading was 5.0 ± 0.4 µg per 75 mm3 
disc. Release of rhBMP-2 was limited for all formulations. At pH 7.4, 3.1 ± 0.1% of the 
rhBMP-2 was released from the PLGA/Ca-P cement discs and 18.0 ± 1.9% from the 
PLGA microparticles alone after 28 days. At pH 4.0, PLGA/Ca-P discs revealed more 
release of rhBMP-2 than PLGA microparticles alone (14.5 ± 6.3% vs. 5.4 ± 0.7%) by 
day 28. The results of chapter four indicated that preparation of PLGA/Ca-P cement 
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composite for the delivery of rhBMP-2 is feasible and that the release of rhBMP-2 is 
dependent on the composite composition and microstructure as well as the pH of the 
release medium. 
3. Investigation of the in vivo tissue response to PLGA/Ca-P cement 
composites.
In chapters ﬁve and six, the in vivo response to PLGA/Ca-P cement composite was 
evaluated. In chapter ﬁve, preset PLGA/Ca-P cement composite discs of various weight 
ratios (0/100; 15/85; 30/70 and 50/50) were implanted subcutaneously and in cranial 
defects in rats for twelve weeks. Porosity was supposed to develop after degradation 
of incorporated PLGA microparticles, which would enable ingrowth of tissue and 
resorption of the cement. Histological analysis revealed that all macropores in the PLGA 
containing composites (average pore size 73 ± 27 µm) were ﬁlled with ﬁbrous tissue and 
blood vessels (subcutaneous implants) and/or bone (cranial implants). Histologically, 
bone formation appeared most abundant and most consistent in the 30/70 PLGA/
Ca-P cement composites. Histomorphometrical evaluation revealed a signiﬁcant 
increase in defect ﬁll in the 15/85 and 30/70 PLGA/Ca-P cement composites. Finally, 
subcutaneous and cranial 50/50 PLGA/Ca-P cement composites had degraded to a 
large extent, without adequate replacement by bone in the cranial implants. Therefore, 
we concluded that PLGA/Ca-P cement composites enabled tissue ingrowth and showed 
excellent osteocompatibility in weight ratios of 15/85 and 30/70 PLGA/Ca-P cement. 
In this model, 30/70 PLGA/Ca-P cement composites showed the most favorable 
biological response. 
4. Investigation of the in vivo tissue response to porous PLGA/Ca-P 
cement composites with CO2 induced porosity.
In chapter six, in vivo tissue response to PLGA/Ca-P composites with initial CO2 
induced porosity was investigated in an identical animal model as used in chapter 
ﬁve. Initial porosity was induced by CO2 foaming to enable direct ingrowth of tissue. 
Secondary porosity was supposed to develop after degradation of incorporated 
PLGA microparticles, which would enable further ingrowth of tissue and resorption 
of the cement. Preset composite discs of four formulations (4wt% or 15wt% PLGA 
microparticles and low or high CO2 induced porosity) were implanted subcutaneously 
and in cranial defects in rats for twelve weeks. Histological analysis of the explanted 
composites revealed that bone and ﬁbrous tissue ingrowth was facilitated by addition of 
PLGA microparticles (diameter of 66 ± 25 µm). No adverse tissue reaction was observed 
in any of the composites. Signiﬁcant increases in composite density due to bone 
ingrowth in cranial implants were found in all formulations. The results suggest that 
the PLGA pores are suitable for bone ingrowth and may be sufﬁcient to enable complete 
tissue ingrowth without initial CO2 induced porosity. Finally, bone-like mineralization 
in subcutaneous implants suggests that under appropriate conditions and architecture 
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porous PLGA/Ca-P cement composites can exhibit osteoinductive properties. Based 
on the results of chapters ﬁve and six, we concluded that PLGA/Ca-P composites are a 
promising scaffolding material for bone regeneration and bone tissue engineering.
In chapters seven and eight, the in vivo release kinetics of rhBMP-2 from materials 
used in the previous chapters was investigated in a rat ectopic model. Delivery of the 
loaded growth factor is supposed to play a key role for factor bioactivity. However, it has 
not been elucidated which proﬁle of release or retention results in optimal growth factor 
bioactivity. The biomaterial might potentiate the activity of BMP by binding the protein 
and presenting it to target cells in a “bound” form. On the other hand, the ceramic can 
also act as a delivery vehicle and released protein may provide a supra-physiological 
concentration of free protein in the vicinity of the implant, which may attract target 
cells to the implant-site by chemotaxis. It has been reported that carriers exhibiting 
higher retention of BMP yielded higher osteoinductive activity. However, chemico-
physical differences between these carriers confound any correlation between protein 
pharmacokinetics and protein bioactivity. 
5. Investigation of the in vivo release of rhBMP-2 from porous Ca-
P cement and development of a method to influence release kinetics 
without vital alterations in chemico-physical material properties.
In chapter seven, we focused on the in vivo release of rhBMP-2 loaded porous Ca-P 
cement and aimed for a method to inﬂuence release kinetics without vital alterations in 
chemico-physical material properties. We hypothesized that adsorption sites of Ca-P 
ceramic with high afﬁnity for rhBMP-2 can be blocked by pretreatment of the ceramic 
with albumin prior to rhBMP-2 administration, which would result in a less speciﬁc, 
weaker rhBMP-2 binding and enhanced release of rhBMP-2. Preset porous Ca-P cement 
discs with a diameter of 6.35 mm (volume: 75 mm3) were pretreated by incubation in 
a solution of 10% rat serum albumin for 24 hours or in ddH2O (control group) prior 
to administration of 4.8 ± 0.2 µg radiolabeled 131I rhBMP-2. Release was assessed in 
vitro in phosphate buffered saline (PBS) and fetal calf serum and in vivo by longitudinal 
scintigraphic imaging of radiolabeled 131I-rhBMP-2 and gamma counting of dissected 
implants. In vitro release from pretreated discs was higher during the ﬁrst day. For both 
formulations, release in PBS was limited compared to release in serum. In vivo release 
considerably exceeded in vitro release. In vivo release kinetics showed no signiﬁcant 
difference of half-lives between pretreated and control discs. Both formulations 
showed sustained release during at least 4 weeks. Ex vivo gamma counting of retrieved 
samples conﬁrmed scintigraphic results and showed that the capsule and surrounding 
tissues only contained a minor fraction rhBMP-2. We conclude that 1. scintigraphy of 
131I-labeled rhBMP-2 provides a reliable method for longitudinal measurement of 
rhBMP-2 release kinetics in vivo. 2. Albumin pretreatment of porous Ca-P cement 
does not result in a relevant increase of initial release of rhBMP-2 in vivo, and 3. Preset 
rhBMP-2 loaded porous Ca-P cement discs exhibit one phase exponential release kinetics 
in the rat ectopic model, characterized by a retention of 20-30% after four weeks.
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6. Investigation of the in vivo release of rhBMP-2 from PLGA/Ca-P 
cement composites and development of composites with different release 
kinetics.
In chapter eight, in vivo release of 131I-radiolabeled rhBMP-2 loaded PLGA/Ca-P 
cement composites was assessed in a similar model. We aimed to inﬂuence release 
kinetics by entrapment of rhBMP-2 in slow resorbable high molecular weight (HMW) 
PLGA microparticles (49.1 ± 1.7 kDa) and fast resorbable low molecular weight (LMW) 
PLGA microparticles (5.9 ± 0.3 kDa). Moreover, we aimed to enhance release by 
adsorption of 131I-rhBMP-2 onto the surface of the microparticles besides entrapment 
within the microparticles. Release of 131I-rhBMP-2 loaded composites was assessed by 
scintigraphic imaging according to a 22 two-level full factorial design in the rat ectopic 
model during four weeks. In vivo release kinetics varied among formulations. All 
formulations showed slow release without initial burst, and displayed a linear release 
from 3 to 28 days. Release of LMW entrapment rhBMP-2 composites (1.7 ± 0.3%/day) 
was signiﬁcantly faster than release from other formulations (p < 0.01). After 28 days, 
retention within the composites was 65 ± 5%, 75 ± 4%, 50 ± 4% and 70 ± 6% of the 
initial rhBMP-2 for HMW entrapment, HMW adsorbed, LMW entrapment and LMW 
adsorbed rhBMP-2 composites, respectively. The differences in release of rhBMP-2 
between formulations were smaller and different than expected. Release from the 
composite was probably slowed down by an interaction of rhBMP-2 and Ca-P cement 
after rhBMP-2 release from PLGA microparticles. We conclude that PLGA/Ca-P cement 
composites can be considered as sustained slow release vehicles and that the release 
and retention of rhBMP-2 can be tailored according to the desired proﬁle to a limited 
extent.
2. Closing remarks 
The ﬁrst studies in this thesis described the investigation of porous Ca-P cement for 
bone tissue engineering applications. This porous, injectable material was developed 
in our laboratory in the recent years and showed excellent biocompatibility and 
degradation characteristics in the ﬁrst evaluations. We demonstrated that preset porous 
Ca-P cement is a suitable carrier material for bone tissue engineering in orthotopic and 
ectopic locations. However, the question raised whether the used method resulted in 
optimal growth factor bioactivity. We concluded that the lack of control over growth 
factor release kinetics caused drawbacks for optimization of the bone inductive 
properties. Moreover, the CO2 foaming technique was applicable for preparation of 
preset porous Ca-P cement, but appeared to impede cement setting after injection into 
a bone defect. 
Therefore, an alternative carrier was developed using the ample knowledge of 
polymer biotechnology from our collaborating research group in Houston, USA. The 
result of this collaboration was the development of a composite material of Ca-P cement 
136
Su
m
m
ar
y,
 a
d
d
re
ss
 to
 th
e 
ai
m
s 
an
d
 f
u
tu
re
 p
er
sp
ec
ti
ve
s
and embedded PLGA microparticles, which can be used for (controlled) delivery of 
rhBMP-2. 
Subsequently, the in vivo response to PLGA/Ca-P cement composite without rhBMP-
2 was investigated. The results of these in vivo evaluations exceeded our expectations 
by far; As expected, degradation of the PLGA microparticles created macropores in 
the composite which enabled ingrowth of tissues. However, complete ingrowth of 
tissue was observed in formulations containing 15% microparticles by weight or 
more, regardless the relatively small microparticle size and the absence of complete 
pore interconnectivity. In addition, the spherical porosity resulting from microparticle 
degradation revealed bone-like mineralizations after twelve weeks of subcutaneous 
implantation, which suggests that, under appropriate conditions and architecture, 
porous PLGA/Ca-P cement composites can exhibit osteoinductive properties without 
administration of growth factors. This remarkable observation was done in chapter six; 
reviewing the histological sections described in chapter ﬁve showed that these subtle 
mineralizations were also present in that study. This excellent in vivo response to 
PLGA/Ca-P cement composite underlines its potency as bone graft substitute-with or 
without rhBMP-2. 
In the last two studies described in this thesis, we started with a series of experiments 
to elucidate some questions raised in the previous studies, i.e. the correlation between 
growth factor bioactivity and factor release and retention. In chapter seven and eight, 
we investigated the in vivo release and retention of rhBMP-2 in close cooperation with 
the department of Nuclear Medicine of the Radboud University Nijmegen Medical 
Centre. Although longitudinal scintigraphy of radiolabeled macromolecules is a well 
established technique in nuclear medicine, it is hardly used in the ﬁeld of growth factor 
based tissue engineering. Therefore, we also intended to validate this technique for 
assessment of rhBMP-2 release. We demonstrated that scintigraphy of 131I-rhBMP-
2 indeed provides a reliable method for longitudinal evaluation of rhBMP-2 release 
and retention. This ﬁnding justiﬁes future evaluation of growth factor release with 
scintigraphic imaging, which will reduce the required amount of experimental animals 
and growth factors compared to conventional methods. We also demonstrated that Ca-
P cement displayed a one-phase exponential release of rhBMP-2 in vivo, despite quite 
limited release observed in vitro. However, control over release kinetics by pretreatment 
of the Ca-P cement could not be established. It was shown that PLGA/Ca-P cement 
composites were more appropriate vehicles for controlled delivery of rhBMP-2. These 
composites showed slow sustained release for at least four weeks with variable release 
rates depending on the formulation. With this knowledge, the biological relevance of 
different release proﬁles can now be investigated. 
3. Future perspectives
The work described in this thesis, reports the development and ﬁrst in vivo evaluation 
of a novel composite material for reconstruction of bone defects. An impressive in 
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vivo response indicates that this composite is a promising biomaterial for bone graft 
substitution. Whereas the administration of growth factors remains essential for 
reconstruction of critical sized bone defects, PLGA/Ca-P cement composite without 
growth factors could become a sturdy completion of the available assortment of 
(currently non-porous) injectable bone ﬁller biomaterials. As PLGA and Ca-P cement 
products are already approved for several clinical applications, the pathway of clinical 
approval could be relatively short for this composite. However, several aspects of 
PLGA/Ca-P cement composites require further investigation: 
1. Optimization of injectability and clinical handling, regarding setting time, 
moldability and strength. 
2. Optimization of PLGA microparticle size and resulting pore sizes, especially with 
respect to regenerative capacity in critical sized defects and potential intrinsic 
osteoinduction.
3. Optimization of molecular weight of PLGA microparticles, which determines PLGA 
degradation rate and macropore formation and requires concomitance with tissue 
ingrowth.
For achievement of our ﬁnal aims, near future investigations should also focus on 
further development of a tissue engineered, growth factor based composite:  
1. Proof of osteoinduction of rhBMP-2 loaded PLGA/Ca-P cement composites. 
2. Optimization of growth factor bioactivity: Further elucidation of correlation 
between factor release and retention and factor bioactivity.
3. Optimization of growth factor kind, dosage and synergism between various growth 
factors.
Clinical use of rhBMP-2 and rhBMP-7 has been approved for speciﬁc applications 
in traumatology in the recent years. This will probably facilitate the approval of new 
applications in near future. Nevertheless, approval of a growth factor based PLGA/Ca-P 
cement composite for ectopic and/or orthotopic bone reconstruction, will require 
extensive additional pre-clinical studies in appropriate higher animal models and 
humans to prove efﬁcacy and safety.
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1. Samenvatting 
Transplantatie van autoloog (eigen) bot is de gouden standaard voor reconstructie 
van botdefecten. Deze techniek heeft echter een aantal nadelen zoals de beperkte 
beschikbaarheid en pijnklachten op de donorplaats, waardoor er alternatieve, 
synthetische botvervangers ontwikkeld zijn. Calciumfosfaat (Ca-P) keramieken 
worden in de chirurgie en tandheelkunde als botvervanger gebruikt en staan bekend 
om een bijzonder goede botrespons en de chemische gelijkenis met de minerale fase van 
bot. Door de kenmerkende kristalstructuur zijn alle Ca-P keramieken bros en daardoor 
minder geschikt voor gewicht dragende toepassingen. Van de diverse Ca-P keramieken 
worden vooral tricalciumfosfaat (TCP) en hydroxyapatiet (HA) biomedisch toegepast. 
TCP is oplosbaar in water en kan door het lichaam worden geresorbeerd, terwijl HA 
sterker is maar vrijwel onoplosbaar. Beide materialen zijn commercieel verkrijgbaar 
als korrels, geprefabriceerde blokken of injecteerbaar cement. Het aanbrengen van 
porositeit verslechtert de mechanische eigenschappen nog verder, maar is essentieel 
voor de ingroei van bot en andere weefsels. Hoewel deze biomaterialen goede 
resultaten geven voor het vullen van kleine botdefecten, bieden de materialen alleen 
geen oplossing voor reconstructie van grote defecten. Een mogelijke oplossing hiervoor 
wordt gevonden in de relatief jonge wetenschap “tissue engineering”, waarbij in een 
geschikt dragermateriaal nieuw autoloog weefsel gegenereerd wordt met behulp van 
groeifactoren en/of opgekweekte beenmergstamcellen. In de afgelopen tien jaar zijn in 
diverse studies de potenties van poreuze Ca-P keramieken als dragermateriaal voor bot 
tissue engineering aangetoond. Veel variabelen echter moeten nog onderzocht en/of 
geoptimaliseerd worden voordat het concept tot een klinische toepassing kan komen. 
 Het doel van de Bone Tissue Engineering onderzoeksgroep is de ontwikkeling van 
een osteogeen en/of osteoinductief botsubstituut voor reconstructie van botdefecten. 
In dit proefschrift werden de mogelijkheden van injecteerbaar Ca-P cement voor 
op groeifactor gebaseerde bot tissue engineering onderzocht. Doelstelling was de 
ontwikkeling van een osteoinductief poreus Ca-P cement met gereguleerde afgifte van 
een van de meest osteoinductieve eiwitten, recombinant humaan “bone morphogenetic 
protein-2” (rhBMP-2). 
Het eerste hoofdstuk in dit proefschrift is een inleiding over Ca-P keramieken en 
een review van literatuur over Ca-P keramieken en bot tissue engineering. De daarop 
volgende hoofdstukken zijn afzonderlijke studies die vraagstellingen zoals hierna 
geformuleerd uitwerken en beantwoorden.  
1. Is voorgevormd poreus Ca-P cement geschikt als drager materiaal voor 
rhBMP-2 op orthotopische en ectopische locaties?
In de hoofdstukken twee en drie werden de osteoinductieve eigenschappen van 
voorgevormd poreus Ca-P cement geladen met rhBMP-2 onderzocht in een bot-
omgeving (orthotopisch) en in een omgeving waar van nature geen bot voorkomt 
(ectopisch). Door gebruik te maken van een recentelijk in ons laboratorium ontwik-
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kelde CO2 gasvorming methode werd porositeit gecreëerd in het Ca-P cement. Voor-
gevormde poreuze schijfjes met een doorsnede van 8 mm (volume: 150 mm3) werden 
geladen met 0 of 10 µg rhBMP-2. Na vriesdrogen werden de schijfjes geïmplanteerd in 
8 mm schedeldakdefecten bij konijnen (hoofdstuk twee) of onderhuids in de rug van 
konijnen (hoofdstuk drie). De implantaten werden verwijderd na twee of tien weken 
en bewerkt voor histologische analyse. Het materiaal behield vorm en stabiliteit en 
vertoonde uitstekende botgeleiding, maar liet geen degradatie zien. In hoofdstuk twee 
werd aangetoond dat orthotopische botvorming signiﬁcant toenam door toevoeging 
van rhBMP-2 (porievulling na tien weken 53 ± 5%), maar dat ook zonder toevoeging 
van rhBMP-2 een aanzienlijke botingroei werd verkregen (porievulling na tien weken 
43 ± 10%). Opvallend was de botvorming rondom de rhBMP-2 geladen implantaten 
na twee weken. Dit suggereerde de aanwezigheid van groeifactoren in het omliggende 
weefsel. In vitro analyse liet evenwel slechts een cumulatieve afgifte van 9.7 ±0.9% na 
vier weken zien. In hoofdstuk drie werd evidente ectopische botvorming aangetoond in 
alle onderhuidse implantaten na tien weken (porievulling 18 ± 6%). Botinductie werd 
alleen waargenomen in de rhBMP-2 geladen implantaten. 
Gebaseerd op de resultaten van hoofdstukkken twee en drie konden de volgende 
conclusies worden getrokken: 1. Poreus Ca-P cement is een geschikt dragermateriaal 
voor bot tissue engineering. 2. Toevoeging van rhBMP-2 aan het cement kan botvorming 
in een botomgeving versnellen en in een botvrije omgeving induceren. 3. Degradatie 
van het poreuze Ca-P cement is afhankelijk van species, locatie van implantatie en 
dimensies van het implantaat. 
Ondanks de goede resultaten verschafte deze techniek geen controle over de 
rhBMP-2 afgifte, hetgeen verondersteld werd een sleutelrol te spelen in groeifactor 
bioactiviteit. 
2. Is het haalbaar een composiet materiaal gebaseerd op Ca-P cement met 
poly(DL-lactic-co-glycolic acid) (PLGA) micropartikels te maken voor 
afgifte van rhBMP-2?
In nauwe samenwerking met de afdeling Bioengineering, Rice University, Houston 
Texas, USA, werd een composiet materiaal ontwikkeld van Ca-P cement en poly(DL-
lactic-co-glycolic acid) (PLGA) micropartikels. In hoofdstuk vier werd de haalbaarheid 
van een rhBMP-2 geladen PLGA/Ca-P cement composiet onderzocht. PLGA/Ca-P 
cement composieten werden gemaakt in een 30:70 gewicht verhouding. De 
materiaaleigenschappen werden onderzocht met behulp van elektronenmicroscopie, 
microCT scan en mechanische testen. Radioactief gelabeld 125I rhBMP-2 werd 
geïntegreerd in de PLGA micropartikels en de afgifte kinetiek van rhBMP-2 van 
PLGA micropartikels en PLGA/Ca-P cement composiet schijfjes werd gedurende 28 
dagen in twee buffer oplossingen (pH 7.4 and pH 4.0) in vitro bepaald. De resultaten 
toonden bolvormige PLGA micropartikels (gemiddelde grootte 66 ± 25 µm) en een 
homogene verdeling in het Ca-P cement. De druksterkte was signiﬁcant lager voor de 
composieten dan voor het Ca-P cement (6.4 ± 0.6 MPa versus 38.6 ± 2.6 MPa). Van het 
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toegevoegde rhBMP-2 werd het merendeel na het productieproces in de micropartikels 
teruggevonden (ladingsefﬁciëntie 79 ± 8%). Per schijfje van 75 mm3 was de gemiddelde 
rhBMP-2 dosis 5.0 ± 0.4 µg. De afgifte van rhBMP-2 was beperkt voor alle groepen. Bij 
neutrale pH kwam na 28 dagen totaal 3.1 ± 0.1% van het rhBMP-2 vrij uit de PLGA/
Ca-P cement schijfjes en 18.0 ± 1.9% uit de groep met alleen PLGA micropartikels. In 
een zuur milieu (pH 4.0) vertoonden de PLGA/Ca-P schijfjes na 28 dagen een hogere 
cumulatieve afgifte dan de groep PLGA micropartikels (14.5 ± 6.3% vs. 5.4 ± 0.7%). 
De resultaten van hoofdstuk vier toonden aan dat het mogelijk is een PLGA/Ca-P 
cement composiet te maken met afgifte van rhBMP-2 en dat de afgifte van rhBMP-2 
afhankelijk is van de samenstelling en structuur van de composiet en de pH van de 
bufferoplossing.  
3. Wat is de weefselreactie op PLGA/Ca-P cement composieten?
In de hoofdstukken vijf en zes werd de in vivo respons op PLGA/Ca-P cement 
composieten onderzocht. In hoofdstuk vijf werden voorgevormde PLGA/Ca-P cement 
schijfjes van verschillende gewichtsverhoudingen (0/100; 15/85; 30/70 and 50/50) 
in schedeldakdefecten en onderhuids bij ratten geïmplanteerd gedurende twaalf weken. 
Er werd verondersteld dat door degradatie van de PLGA micropartikels een poreuze 
Ca-P cement structuur zou ontstaan, waardoor weefselingroei en resorptie van het 
cement zou plaatsvinden. Histologische analyse toonde aan dat inderdaad alle poriën van 
de PLGA bevattende composieten (gemiddelde poriegrootte 73 ± 27 µm) ﬁbreus weefsel 
en bloedvaten (onderhuidse implantaten) en/of bot (craniale implantaten) bevatten. 
Botvorming leek het meest uitgebreid en het meest consistent in de 30/70 PLGA/Ca-P 
cement composieten. Histomorfometrische analyse vertoonde een signiﬁcante toename 
van de implantaat dichtheid in zowel de 15/85 als de 30/70 composieten. De 50/50 
PLGA/Ca-P cement composieten daarentegen waren voor een groot deel gedegradeerd 
zonder adequate vervanging door bot in de craniale implantaten. Derhalve kon worden 
geconcludeerd dat ingroei van weefsel in PLGA/Ca-P cement composieten mogelijk is 
en dat de 15/85 en 30/70 composieten een uitstekende osteocompatibiliteit vertonen. 
In dit model leek de 30/70 PLGA/Ca-P cement composiet de meest gunstige biologische 
respons te geven. 
4.  Hoe is de weefselreactie op poreuze PLGA/Ca-P cement composieten 
met CO2 geïnduceerde porositeit?
In hoofdstuk zes werd de weefselrespons op PLGA/Ca-P cement composieten 
met CO2 geïnduceerde porositeit onderzocht in een identiek diermodel als gebruikt in 
hoofdstuk vijf. Initiële porositeit werd geïnduceerd met behulp van de eerder beschre-
ven CO2 gasvorming methode om directe ingroei van weefsel mogelijk te maken. Er 
werd verondersteld dat door degradatie van de PLGA micropartikels ook een secundaire 
porositeit in de Ca-P cement structuur zou ontstaan, waardoor weefselingroei en re-
sorptie van het cement verder zou toenemen. Voorgevormde composiet schijfjes van 
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vier verschillende samenstellingen (4% of 15% PLGA micropartikels [diameter 66 ± 25 
µm] en lage of hoge CO2 geïnduceerde porositeit) werden gedurende twaalf weken in 
schedeldakdefecten of onderhuids bij ratten geïmplanteerd. Histologische analyse toon-
de aan dat ingroei van bot en ﬁbreus weefsel vergemakkelijkt werd door het toevoegen 
van PLGA micropartikels. In geen van de groepen werd een negatieve weefselreactie 
gezien. Alle groepen PLGA/Ca-P cement vertoonden door botingroei een signiﬁcante 
toename van implantaat dichtheid in de schedeldakdefecten. De resultaten suggereer-
den dat de poriën ontstaan door PLGA degradatie in het bijzonder geschikt zijn voor 
botingroei en afdoende zijn voor volledige ingroei van weefsel in de composiet zonder 
initiële CO2 porositeit. Tenslotte werden bot-achtige mineralisaties waargenomen in 
PLGA micropartikel poriën van de subcutane implantaten. Deze opvallende bevinding 
suggereert dat PLGA/Ca-P cement composiet onder de juiste omstandigheden en met 
de juiste geometrie een osteoinductief karakter zou kunnen hebben zonder toevoeging 
van groeifactoren. Op basis van de resultaten van hoofdstukken vijf en zes kan worden 
geconcludeerd dat PLGA/Ca-P cement composiet een veelbelovend dragermateriaal is 
voor bot tissue engineering. 
In de hoofdstukken zeven en acht werd de in vivo afgifte van rhBMP-2 uit materialen 
zoals beschreven in de voorgaande hoofdstukken onderzocht in een ectopisch model bij 
de rat. Het afgifte patroon van de groeifactor wordt verondersteld een sleutelrol te spelen 
in de bioactiviteit van het eiwit. Het is evenwel nog niet duidelijk welk proﬁel van afgifte 
of retentie resulteert in de grootste bioactiviteit. Enerzijds zou aan het biomateriaal 
gebonden eiwit actief kunnen zijn door zich in gebonden vorm aan doelwit-cellen te 
presenteren, anderzijds zou vrijgekomen eiwit een boven fysiologische concentratie 
van vrij eiwit in de nabije omgeving van het implantaat kunnen veroorzaken, hetgeen 
doelwit-cellen zou kunnen aantrekken door middel van chemotaxis. Het is in de 
literatuur beschreven dat dragermaterialen met een hoge mate van groeifactor retentie 
een hogere mate van osteoinductie vertoonden. Chemisch-fysische verschillen tussen 
de onderzochte dragermaterialen verhinderden echter een duidelijke correlatie tussen 
de groeifactor farmacokinetiek en de groeifactor bioactiviteit.   
5. Hoe is de in vivo afgifte van rhBMP-2 geladen op poreus Ca-P cement 
en kan de afgifte kinetiek veranderd worden  zonder de chemisch-
fysische eigenschappen van het materiaal ernstig te veranderen? 
In hoofdstuk zeven werd de in vivo afgifte van rhBMP-2 geladen op poreus Ca-P 
cement onderzocht en werd gestreefd naar het ontwikkelen van een methode om de 
afgifte van het eiwit te veranderen zonder de chemisch-fysische eigenschappen van 
het cement ernstig te veranderen. Met verschillende afgiftepatronen zou vervolgens 
de relatie tussen afgifte kinetiek en bioactiviteit van de goeifactor kunnen worden 
geëvalueerd. Er werd verondersteld dat de adsorptieplekken op het Ca-P cement met 
een hoge bindingsafﬁniteit voor rhBMP-2 kunnen worden geblokkeerd door een 
voorbehandeling van het cement met een relatief inactief eiwit als serum albumine. Dit 
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zou vervolgens kunnen leiden tot een minder speciﬁeke, zwakkere binding met rhBMP-
2 en dientengevolge tot een hogere afgifte van de groeifactor. Voorgevormde, met behulp 
van CO2 gasvorming poreus gemaakte Ca-P cement schijfjes met een diameter van 6.35 
mm (volume: 75 mm3) werden gedurende 24 uur voorbehandeld met een oplossing 
van 0% (controlegroep) of 10% ratten serum albumine in gedemineraliseerd water 
voordat een dosis van 4.8 ± 0.2 µg radioactief gelabeld 131I rhBMP-2 werd aangebracht. 
Afgifte van rhBMP-2 werd in vitro bepaald in fosfaat gebufferde zoutoplossing (PBS) 
en in foetaal kalverserum (FCS); in vivo afgifte werd bepaald in het ectopische model 
bij de rat met behulp van longitudinale scintigraﬁsche beeldvorming en met separate 
gamma-telling van geëxplanteerde implantaten. In vitro afgifte van met albumine 
voorbehandelde schijfjes was hoger gedurende de eerste dag. De afgifte van rhBMP-2 
in PBS was beperkt ten opzichte van de afgifte in serum voor zowel de voorbehandelde 
als de controle schijfjes. In vivo afgifte was aanzienlijk hoger dan in vitro afgifte. Er was 
geen signiﬁcant verschil in vivo tussen afgifte kinetiek van voorbehandelde en controle 
schijfjes; beide groepen vertoonden een aanhoudende afgifte gedurende vier weken. 
Ex vivo gamma telling van geëxplanteerde implantaten bevestigde deze resultaten en 
liet zien dat het kapsel en omliggende weefsel slechts een kleine hoeveelheid rhBMP-
2 bevatten ten opzichte van het implantaat. De volgende conclusies konden worden 
getrokken: 1. Scintigraﬁe van 131I-gelabeld rhBMP-2 is een betrouwbare methode om in 
vivo rhBMP-2 afgifte longitudinaal te meten. 2. Voorbehandeling van Ca-P cement met 
albumine resulteert niet in een toename van rhBMP-2 afgifte in vivo. 3. Voorgevormde 
rhBMP-2 geladen poreuze Ca-P cement schijfjes vertonen een éénfase exponentiële 
afgifte kinetiek in het ectopische model bij de rat met een retentie van 20-30% na vier 
weken.
6. Hoe is de in vivo afgifte van rhBMP-2 van PLGA/Ca-P cement 
composiet en kunnen composieten met verschillende afgifte kinetieken 
ontwikkeld worden? 
In hoofdstuk acht werd de in vivo afgifte van 131I rhBMP-2 geladen PLGA/Ca-P 
cement composiet onderzocht in een soortgelijk model. Doelstelling was om de 
afgifte kinetiek te beïnvloeden door integratie van rhBMP-2 in langzaam resorbeerbare 
PLGA micropartikels (hoog moleculair gewicht [HMW], 49.1 ± 1.7 kDa) dan wel snel 
resorbeerbare PLGA micropartikels (laag moleculair gewicht [LMW], 5.9 ± 0.3 kDa). 
Daarnaast werd verondersteld dat afgifte kon worden verhoogd door het adsorberen 
van de groeifactor aan het oppervlak van de PLGA micropartikels in plaats van  het 
integreren ervan in de micropartikels. De combinatie van deze twee variabelen leverde 
vier onderzoeksgroepen op. De afgifte van 131I-rhBMP-2 geladen composieten werd 
met behulp van scintigraﬁsche beeldvorming gedurende vier weken bepaald in het 
ectopische model bij de rat. In vivo afgifte verschilde tussen de diverse groepen. Alle 
groepen vertoonden een langzame afgifte zonder initiële piek met een lineaire afgifte 
van tussen de 3e en 28e dag. Afgifte van rhBMP-2 van LMW geïntegreerd rhBMP-2 
composiet (1.7 ± 0.3%/dag) was signiﬁcant hoger dan afgifte van de andere groepen (p < 
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0.01). Na 28 dagen was de rhBMP-2 retentie in HMW geïntegreerd rhBMP-2 composiet 
65 ± 5%, HMW geadsorbeerd rhBMP-2 composiet 75 ± 4%, LMW geïntegreerd rhBMP-
2 composiet 50 ± 4% en LMW geadsorbeerd rhBMP-2 composiet 70 ± 6% van de 
initiële hoeveelheid rhBMP-2. De verschillen in afgifte tussen de verschillende groepen 
waren kleiner dan verwacht. Afgifte uit de composieten werd waarschijnlijk vertraagd 
door een interactie tussen rhBMP-2 en het Ca-P cement na afgifte van de rhBMP-
2 uit de micropartikels. Op basis van de resultaten van hoofdstuk acht kan worden 
geconcludeerd dat PLGA/Ca-P cement composieten een trage, voortdurende rhBMP-2 
afgifte vertonen en dat de afgifte van rhBMP-2 in beperkte mate kan worden aangepast 
aan het gewenste afgifte proﬁel. 
2. Afsluitende opmerkingen 
De eerste hoofdstukken van dit proefschrift beschreven de geschiktheid van poreus 
Ca-P cement voor bot tissue engineering. Dit poreuze, injecteerbare materiaal was in 
de afgelopen jaren op de afdeling Biomaterialen ontwikkeld en vertoonde uitstekende 
biocompatibiliteit en degradatie karakteristieken in de eerste evaluaties. Wij toonden 
aan dat het ook een geschikt dragermateriaal is voor bot tissue engineering in een 
orthotopische en ectopische omgeving. Het was echter de vraag of de gebruikte methode 
ook resulteerde in optimale efﬁciëntie van de groeifactoren. Wij concludeerden dat 
het ontbreken van controle over de groeifactor afgifte kinetiek een belemmering was 
bij het optimaliseren van de bot inducerende eigenschappen. Bovendien bleek de CO2 
gasvorming techniek weliswaar goed te werken voor voorgevormde implantaten, maar 
bij injectie in botdefecten toch problemen op te leveren wat betreft uitharding van het 
cement. 
Daarom werd besloten om een nieuw dragermateriaal te ontwikkelen in samen-
werking met de afdeling Bioengineering, Rice University. Deze onderzoeksgroep staat 
bekend om hun tissue engineering onderzoek met polymeer dragermaterialen en heeft 
ruime ervaring met PLGA micropartikels voor gereguleerde afgifte van groeifactoren. 
De samenwerking resulteerde in de ontwikkeling van een composiet materiaal van Ca-P 
cement en PLGA micropartikels, dat kan worden gebruikt voor de (gecontroleerde) 
afgifte van rhBMP-2. 
Daarna werd de weefselrespons op deze composiet onderzocht zonder toevoeging 
van rhBMP-2. De resultaten van deze studie waren indrukwekkend. Zoals verwacht 
resulteerde de degradatie van de micropartikels in poriën in het Ca-P cement waardoor 
weefselingroei mogelijk werd. Complete doorgroei van weefsel werd echter zelfs al in 
groepen met 15 gewicht % micropartikels gezien, ondanks de relatief kleine poriegrootte 
en de afwezigheid van een onderling compleet verbonden poriestructuur. Bovendien 
bleek in de sferische, door micropartikel degradatie ontstane poriën bot-achtinge 
mineralisatie voor te komen na twaalf weken onderhuidse implantatie. Dit suggereert 
dat PLGA/Ca-P cement composiet onder geschikte omstandigheden osteoinductief kan 
zijn zonder toevoeging van groeifactoren. Deze opmerkelijke ontdekking werd gedaan 
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in hoofdstuk zes; achteraf werden deze subtiele mineralisaties ook in hoofdstuk vijf 
waargenomen. Deze buitengewone weefselrespons benadrukt de potentie van PLGA/
Ca-P cement composiet als synthetisch botvervanger met of zonder rhBMP-2. 
In de laatste twee studies werd begonnen met een serie experimenten om enkele 
vragen te beantwoorden die gerezen waren in de eerdere studies, zoals de correlatie 
tussen groeifactor bioactiviteit en factor afgifte en retentie. In hoofdstuk zeven en 
acht werd de in vivo afgifte van rhBMP-2 onderzocht in nauwe samenwerking met 
de afdeling Nucleaire Geneeskunde. Hoewel longitudinale scintigraﬁe van radioactief 
gelabelde macromoleculen een gangbare techniek is binnen de nucleaire geneeskunde, 
wordt het nog nauwelijks gebruikt in de op groeifactoren gebaseerde bot tissue 
engineering. Daarom werd deze techniek gevalideerd voor het vervolgen van rhBMP-2 
afgifte. Wij toonden aan dat scintigraﬁe van 131I-rhBMP-2 een betrouwbare methode 
is om de afgifte en retentie van rhBMP-2 longitudinaal te vervolgen, waardoor in de 
toekomst het aantal proefdieren en groeifactoren kan worden beperkt ten opzichte van 
evaluatie met conventionele technieken. Er werd ook aangetoond dat Ca-P cement in 
vivo een éénfase exponentiële afgifte van rhBMP-2 laat zien, ondanks de zeer beperkte 
afgifte die in vitro wordt gemeten. Het is echter niet gelukt om controle te krijgen over 
de afgifte van de groeifactor van het Ca-P cement. Er werd aangetoond dat PLGA/Ca-P 
cement composiet een meer geschikte drager is voor gecontroleerde afgifte van rhBMP-
2. Afhankelijk van de composiet samenstelling werden verschillende afgifte snelheden 
van een geleidelijke, voortdurende afgifte bewerkstelligd voor tenminste vier weken. 
Met deze kennis kan in de toekomst de biologische relevantie van verschillende afgifte 
proﬁelen worden bepaald. 
3. Toekomst perspectieven
Het werk beschreven in dit proefschrift beschrijft de ontwikkeling en eerste in vivo 
evaluatie van een nieuw composiet materiaal voor reconstructie van bot defecten. Een 
indrukwekkende in vivo weefselrespons benadrukt dat dit biomateriaal veelbelovend 
is als synthetische botvervanger. Hoewel toediening van groeifactoren noodzakelijk 
zal blijven voor de reconstructie van kritisch grote botdefecten, kan PLGA/Ca-P 
cement composiet een belangrijke aanvulling worden op het beschikbare assortiment 
van (thans niet poreuze) injecteerbare botvullers. Aangezien PLGA en Ca-P cement 
nu al goedgekeurd zijn voor diverse klinische toepassingen, kan de weg naar klinische 
goedkeuring relatief kort zijn. Desalniettemin moeten diverse aspecten van PLGA/Ca-P 
cement composiet nog nader worden onderzocht: 
1. Optimalisatie van injecteerbaarheid en klinische hanteerbaarheid wat betreft 
uitharding, vormbaarheid en sterkte. 
2. Optimalisatie van PLGA micropartikel grootte en resulterende poriegrootte, met 
name wat betreft regeneratieve capaciteit in kritisch grote defecten en eventuele 
intrinsieke osteoinductie. 
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3. Optimalisatie van het moleculaire gewicht van de PLGA micropartikels, dat de 
PLGA degradatie en porievorming bepaalt en moet samenvallen met de ingroei van 
weefsel. 
Om ons uiteindelijke doel van een osteoinductief botsubstituut te verwezenlijken, 
zal toekomstig onderzoek eveneens gericht moeten zijn op verdere ontwikkeling van 
een met groeifactoren geladen PLGA/Ca-P cement composiet: 
1. Bewijzen van de osteoinductiviteit van met rhBMP-2 geladen PLGA/Ca-P cement 
composiet. 
2. Optimalisatie van groeifactor bioactiviteit: Verheldering van de samenhang tussen 
groeifactor bioactiviteit en groeifactor afgifte en retentie. 
3. Optimalisatie van groeifactor soort, dosis en synergisme tussen verschillende 
groeifactoren. 
Klinisch gebruik van rhBMP-2 and rhBMP-7 is recentelijk toegestaan voor een 
aantal toepassingen binnen de traumatologie. Waarschijnlijk zal dit goedkeuring voor 
nieuwe toepassingen in de toekomst vereenvoudigen. Desalniettemin zal klinische 
goedkeuring van een op groeifactoren gebaseerde PLGA/Ca-P cement composiet voor 
ectopische en/of orthotopische bot reconstructie uitvoerige preklinische studies in 
geschikte hogere diermodellen en mensen vereisen, om efﬁciëntie en veiligheid te 
bewijzen. 
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Het is hartverwarmend om te zien dat zoveel mensen zoveel hebben bijgedragen aan het tot stand komen van dit proefschrift. Ik wil iedereen heel hartelijk danken 
voor hun inzet; ook de mensen die hier niet met name genoemd worden. Het is een 
geweldige tijd geweest en dat was zonder alle hulp heel anders geweest. 
Miriam, jij komt met recht op de eerste plaats. Wij promoveren samen; het eerste 
deel is nu klaar, de betere helft zal spoedig volgen. Dank je voor alles. Als geen ander 
weet jij dat onderzoek niet altijd over rozen gaat. Mijn waardering voor jou als partner, 
wetenschapper en chirurg laat zich niet in woorden vatten. Ik ben je ontzettend dankbaar 
voor je hulp, geduld en alles wat je bent. 
Prof. Jansen, beste John. Als directe supervisor ben jij bepalend geweest wat betreft 
onze koers. Dat ging zoals het hoort; in het begin sturend, verder in het traject met steeds 
meer vrijheid. Daar ben ik je erg dankbaar om, ook al ging dat niet vaak zonder slag of 
stoot, maar wel geregeld met een ‘levendige’ discussie. Mijns inziens hebben wij een 
uitstekende samenwerking gehad. Ik heb veel waardering voor wat je met de afdeling 
Biomaterialen hebt bereikt, in het bijzonder dat wetenschap, kwaliteit en eerlijkheid 
voor jou op de eerste plaats blijven staan.
Prof. Spauwen. U houdt de grote lijnen in de gaten en vervult daarmee een onmisbare 
rol in de samenwerking tussen de afdelingen Biomaterialen en Plastische Chirurgie. 
De periodieke promotiebesprekingen waren altijd waardevol, evenals uw punctuele 
correcties van manuscripten. Ik ben u zeer dankbaar voor uw vertrouwen om mij op te 
leiden tot plastisch chirurg. Uw discretie en integriteit zijn een inspirerend voorbeeld 
voor mij.
Dr. Mikos. My stay in Houston has been very valuable. Not only it resulted in three 
papers and a promising composite material, it also was an unforgettable experience to 
work and live in Houston for three months and to get acquainted with the American 
way of life and perception of the world. Unfortunately you could not be present for the 
thesis defense. Thanks for your share. 
Dr. Wolke, beste Joop. To the point, recht door zee en oprecht. Dank je daarvoor en 
voor alle onmisbare uitleg over keramieken. 
Dr. Hartman en dr. Vehof, beste Ed en Johan. Jullie beide ben ik in het bijzonder 
veel dank verschuldigd. Jullie hebben de basis gelegd voor de vruchtbare samenwerking 
tussen beide afdelingen en daarmee de Engineered Bone trein op gang gebracht. Als 
begeleiders van mijn wetenschappelijke stage waren jullie kennelijk zo goed dat ik 
verder mocht gaan met een promotieonderzoek. Ed veel dank voor de klinische lessen 
en de mogelijkheid om veel microchirurgische ervaring op te doen in het CDL. Johan 
dank voor je introductie in onderzoeksland en alle do’s en don’t’s. Ik hoop dat het er nog 
eens van komt om samen een stuk te schrijven, wie weet in een aanstaande klinische 
bone engineering trial. 
Dr. Boerman, beste Otto. Een uur nadat ik je voor het eerst belde, zaten we rond 
de tafel en waren de plannen gesmeed. Dat bleek kenmerkend voor een efﬁciënte en 
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prettige samenwerking. Dat we met succes de scintigraﬁe in de bot Tissue Engineering 
hebben geïntroduceerd, blijkt wel uit het feit dat bijna al mijn onderzoekscollega’s nu 
bij jou over de vloer komen. Sorry daarvoor.
Alle andere co-auteurs van artikelen in dit proefschrift: prof. Russel, Henriëtte, 
Elizabeth en Nestor, dank voor jullie geweldige bijdrage. 
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en plezier op de afdeling en daarbuiten. Also many thanks to the Rice University 
Bioengineering crew in Houston for assisting me at the lab and around, especially to 
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van de afdeling Nucleaire Geneeskunde, met name Peter en Huub, voor alle hulp en een 
hoop pret met isotopen. 
Alle staﬂeden en (voormalig) assistenten van de plastische chirurgie, waaronder dr. 
Kappel, Ed, David, Stijn, Ildemar, Maarten, Herm, Ghita, Esther, Xander, Michiel en 
Pieter wil ik graag bedanken voor de klinische ochtenden, gezelligheid en wijze lessen 
over plastische chirurgie. 
Dit proefschrift zou niet mogelijk zijn geweest zonder de deskundige assistentie 
van alle biotechnici op het dierenlaboratorium; Alex, Debby, Fred, Geert, Gerry, Ilona, 
Jeroen, en Ton. Jullie toewijding en bekwaamheid heeft tot het eind toe bijzonder veel 
indruk op mij gemaakt. 
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vrienden zijn gelukkig niet noodzakelijkerwijs tot twee beperkt en in dat verband wil ik 
ook Ben, Joris en Mark bedanken. Jullie zijn een baken in mijn leven en zorgen, sportend 
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Tenslotte wil ik mijn lieve ouders, broers en schoonzussen bedanken voor hun 
onvoorwaardelijke steun gedurende al die jaren. Een goed voorbeeld doet volgen; jullie 
deden het eerste, ik probeer het laatste. Met de komst van Laura, Merle, Finn en Luka is 
het familieleven helemaal een feest!
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Quinten Ruhé werd op 25 februari 1974 geboren te Amsterdam. In 1992 werd het eindexamen behaald op het Gymnasium 
Haganum te Den Haag. In datzelfde jaar werd hij nageplaatst voor de 
studie Geneeskunde aan de Katholieke Universiteit Nijmegen. In 1997 
werd het doctoraalexamen behaald, waarna de studie onderbroken 
werd voor een jaar reizen door Azië. Tijdens de daarop volgende co-
schappen werd zes maanden onderzoek gedaan op de afdelingen 
Plastische Chirurgie en Biomaterialen van het Universitair Medisch 
Centrum St Radboud te Nijmegen. In 2001 werd het artsexamen 
behaald na een afsluitend co-schap op de afdeling Plastische Chirurgie, 
Diakonessenhuis te Paramaribo, Suriname. 
Van 2001 tot en met 2004 werd promotieonderzoek verricht op de afdeling 
Biomaterialen (hoofd prof. dr. J.A. Jansen) in samenwerking met de afdeling Plastische 
en Reconstructieve Chirurgie (hoofd prof. dr. P.H.M. Spauwen) van het Universitair 
Medisch Centrum St Radboud te Nijmegen. In 2002 werd in dit kader een drie maanden 
durend bezoek gebracht aan de afdeling Bioengineering, Rice University, Houston, USA 
(hoofd prof. dr. A.G. Mikos). De resultaten van dit promotieonderzoek zijn beschreven 
in dit proefschrift. 
In januari 2005 werd gestart met de chirurgische vooropleiding op de afdeling 
Algemene Chirurgie van het Meander Medisch Centrum te Amersfoort (opleider dr. 
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